[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"GE Medical Systems SCS\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":298},{"warningLetters":4,"total":297},[5,31,48,68,86,103,125,147,165,186,204,222,241,258,278],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},520,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025\">Contec Medical Systems Co., Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kun “James” Hu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Contec Medical Systems Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 112 Qinhuang West Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Economic and Technical Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Qinhuangdao Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hebei Sheng\u003C\u002Fspan>, \u003Cspan>066004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>Dear Kun “James” Hu:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\u003Cp>A. The cause of nonconformities identified are not adequately investigated.\u003C\u002Fp>\u003Cp>B. Corrective actions taken are not documented per your firm’s CAPA procedure.\u003C\u002Fp>\u003Cp>C. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\u003C\u002Fp>\u003Cp>D. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>A. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\u003C\u002Fp>\u003Cp>B. Test reports do not confirm that design outputs meet design inputs. For example,\u003C\u002Fp>\u003Cp>i. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\u003C\u002Fp>\u003Cp>ii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\u003C\u002Fp>\u003Cp>C. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\u003C\u002Fp>\u003Cp>D. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\u003C\u002Fp>\u003Cp>The adequacy of the response dated July 1, 2025, cannot be determined at this time.\u003C\u002Fp>\u003Cp>While your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\u003C\u002Fp>\u003Cp>The adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\u003C\u002Fp>\u003Cp>Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003Cbr>Bram Zuckerman&nbsp;&nbsp;\u003Cbr>Director Office of Cardiovascular Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Marco Mu\u003Cbr>MID-LINK INTERNATIONAL CO., Ltd\u003Cbr>2219 Rimlang Drive, Suite 301\u003Cbr>Bellingham, Washington, US 98226\u003Cbr>Phone: 702-209-5185\u003Cbr>Fax: 360-925-3199\u003Cbr>Email: us.agent@mid-link.net\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKun “James” Hu\n\nRecipient Title\n\nCEO\n\nContec Medical Systems Co., Ltd.\n\nNo. 112 Qinhuang West Street\n\nEconomic and Technical Development Zone\n\nQinhuangdao Shi\n\nHebei Sheng, 066004\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nOctober 2, 2025\nDear Kun “James” Hu:\nDuring an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\nA. The cause of nonconformities identified are not adequately investigated.\nB. Corrective actions taken are not documented per your firm’s CAPA procedure.\nC. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\nD. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\nThe response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\n2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\nA. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\nB. Test reports do not confirm that design outputs meet design inputs. For example,\ni. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\nii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\nC. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\nD. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\nThe adequacy of the response dated July 1, 2025, cannot be determined at this time.\nWhile your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\nThe response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\n4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\nThe adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\nGiven the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\nYour firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBram Zuckerman\nDirector Office of Cardiovascular Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nMarco Mu\nMID-LINK INTERNATIONAL CO., Ltd\n2219 Rimlang Drive, Suite 301\nBellingham, Washington, US 98226\nPhone: 702-209-5185\nFax: 360-925-3199\nEmail: us.agent@mid-link.net","Contec Medical Systems Co., Ltd.","contec-medical-systems-co-ltd-717941-10022025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025","2026-10-26T08:08:17.623451+00:00","Warning Letter","Issued","2025-10-28","717941","Medical Devices","Kun “James” Hu","2026-08-19T16:12:22.676+00:00","VIA Electronic Mail","2025-10-02",{"id":32,"raw":33,"subject":12,"body_html":37,"body_text":38,"firm_name":39,"letter_id":40,"created_at":41,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":46,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":47,"medical_device_id":19,"response_letter_date":19},21920,[34,35,36,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-07T04:00:00Z\">10\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-729208-10072026\">Olympus Medical Systems Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Olympus Medical Systems Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2951 Ishikawa-machi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hachioji-shi\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>192-8507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@olympus.com\"> (b)(6)@olympus.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #729208\u003C\u002Fp>\u003Cp>October 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. White:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\u003C\u002Fp>\u003Cul>\u003Cli>Olympus Medical Systems Corporation, located at 2951 Ishikawa-Cho, Hachioji-Shi, Tokyo, JP 192-8507, FEI 3002807795, November 17, 2025, to November 21, 2025 (“Hachioji”)\u003C\u002Fli>\u003Cli>Aomori Olympus Co., Ltd., located at 2-248-1 Okkonoki, Kuroishi-shi, Aomori, JP, 036-0357, FEI 3003995201, from November 4, 2025, to November 7, 2025 (“Aomori”)\u003C\u002Fli>\u003Cli>Olympus Medical Systems Corp. Hinode Plant, located at 34-3 Hirai, Hinode-Machi, Nishitama-Gun, Tokyo, JP, 190-0182, FEI 3003637092, from November 17, 2025, to November 21, 2025 (“Hinode”)\u003C\u002Fli>\u003Cli>Shirakawa Olympus Co., Ltd., located at 3-1 Okamiyama, Odakura, Nishigo-Mura, Nishishirakawa-Gun, Fukushima, JP 961-8061, FEI 3002808148, November 10, 2025, to November 14, 2025 (“Shirakawa”)\u003C\u002Fli>\u003Cli>Olympus Winter &amp; IBE Gmbh, located at Kuehnstrasse 61, Hamburg, DE 22045, FEI 3002807798, from November 10, 2025, to November 21, 2025 (“Hamburg”)\u003C\u002Fli>\u003Cli>Gyrus ACMI, Inc. [dba Olympus Surgical Technologies (OSTA)], located at 9600 Louisiana Ave North, Brooklyn Park, MN 55445, FEI 3011050570, from October 6, 2025, to November 12, 2025 (“Brooklyn Park”)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During these inspections, our investigators determined that your firm manufactures a variety of surgical and endotherapy devices, including but not limited to, hemostatic metal clips, sphincterotomes, cystoscopes, bronchoscopes, endoscopic distal covers, valves, and insufflators. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The above-referenced inspections revealed that the devices manufactured at the Hachioji, Aomori, Hinode, Shirakawa, Hamburg, and Brooklyn Park facilities are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. This nonconformity includes issues across the referenced inspected facilities, resulting in the distribution of nonconforming devices and significant risks to patients.\u003C\u002Fp>\u003Cp>A Form FDA 483 (FDA 483), List of Inspectional Observations, was issued to the Aomori facility on November 7, 2025, the Brooklyn Park facility on November 12, 2025, the Shirakawa facility on November 14, 2025, the Hachioji facility on November 21, 2025, the Hinode facility on November 21, 2025, and the Hamburg facility on November 21, 2025. We received responses concerning our investigator’s observations noted on these FDA 483s from Robert A. Fryc, Director, Global Quality Compliance, External Regulatory Communications, Olympus Corporation of the Americas, dated December 22, 2025, February 13, 2026, March 30, 2026, May 28, 2026, and July 31, 2026. We address these responses (collectively referred to as “your firm’s response”) below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Design Control Violations – Shirakawa, Aomori, Hamburg, and Hachioji facilities\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). For example,\u003C\u002Fp>\u003Cp>a. At the Shirakawa facility, your firm failed to identify and control known catastrophic hazards in your risk management documentation and failed to validate the device design under actual or simulated use conditions for the UHI-4 insufflator. Catastrophic hazards, including air embolism, arrhythmia, and patient death, were identified through Health Hazard Assessments and complaint investigations associated with CAPA-201353; however, your \u003Cem>Risk Management Report\u003C\u002Fem> (DC00067142, dated November 6, 2025) did not reflect these hazards or ensure implementation of appropriate risk control measures, even after a confirmed patient death and Class I recall of UHI-4 units in 2023. Further, your design validation did not simulate actual or worst-case use conditions related to pressure sensor failure or inaccurate pressure measurements to ensure that the device would operate safely. As a result, devices distributed had design deficiencies that contributed to overpressure events during clinical use.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that design-related deficiencies are being addressed through global CAPAs, including CAPA-204150 (design control) and CAPA-203525 (risk management), and that a traceability matrix for the UHI-4 will be developed to evaluate design requirements, verification, and validation. You also indicate that additional design verification and\u002For validation testing will be performed as needed and that potential design changes will be assessed by the design owner (Olympus Hachioji). However, these activities remain ongoing, and you have not provided objective evidence demonstrating that design validation deficiencies have been corrected or that revised validation activities adequately address identified risks, including overpressure conditions. Additionally, corrective actions have been deferred to global CAPAs and another facility, and no documentation has been provided demonstrating completion or effectiveness of these actions.\u003C\u002Fp>\u003Cp>b. At the Aomori facility, your firm failed to identify and assess known hazards in the risk management documentation and failed to establish risk control measures for manufacturing processes for the Sphincterotome. In your risk management report (E_V-KD_\u003Cem>Risk Management Report\u003C\u002Fem>_Rev.27), the corresponding risk line ID (KD-G158-00) identifies the potential patient harm as “Delay in Treatment” for complaints of deformed wires but fails to include the higher risk identified through analysis of Medical Device Reports of unintended cutting of blood vessels leading to patient bleeding. It also fails to identify any risk control measures for the manufacture of the wire for the Sphincterotome. Additionally, the risk management report (DC00609260_20250910) does not include the known hazard of failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes and does not include risk control measures for this hazard, which can lead to tissue damage and procedural complications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm has not provided an updated \u003Cem>Risk Management Report\u003C\u002Fem> (DC00609260_20250910) to address the hazard and implement risk control measures for failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes. Additionally, your firm has not provided an updated risk management report (E_V-KD_\u003Cem>Risk Management Report\u003C\u002Fem>) to address the risk of unintended cutting of blood vessels leading to patient bleeding and risk control measures for manufacture of the wire.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm distributed the Continuous Flow Cystoscope (model WA22810A) with instructions for use (IFU) that claimed compatibility with the GreenLight PV ADDstat laser fiber component without conducting design validation testing to ensure compatibility under use conditions. This resulted in two recalls, RES 95584 and RES 98300, due to a risk of damage and\u002For overheating to the tip of the sheath when used together. Unrecognized sheath damage can result in tissue injury or parts of the sheath breaking off into the patient.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response should include a retrospective review of similar devices with IFU compatibility claims to ensure that they are supported by design validation activities to ensure compatibility under use conditions.\u003C\u002Fp>\u003Cp>d. At the Hachioji facility:\u003C\u002Fp>\u003Cp>i. Your firm distributed the BF-1TH190 bronchoscope with instructions for use (IFU) claiming compatibility with CO\u003Csub>2\u003C\u002Fsub> lasers without conducting design validation testing to ensure compatibility under use conditions. This resulted in a class I recall (RES 93052), due to a risk of endobronchial combustion if high-frequency cauterization is performed while supplying oxygen and\u002For the electrode section of the electrosurgical accessory is too close to the distal end of the endoscope. If endobronchial combustion occurs, the patient may suffer adverse events, including internal burns in their airway or lungs. The related CAPA did not evaluate compatibility claims for all endoscopes and lasers.\u003C\u002Fp>\u003Cp>ii. Design validation activities were not conducted with an understanding of the actual operating conditions for the Evis Exera Video Imaging System, used with your firm’s endoscopes for processing images. For example, design validation did not consider the conductivity of the electrolyte when it contained dust and moisture, nor did it consider the impact over time of water entering the scope during cleaning. This caused signal transmission problems and resulted in a significant number of complaints and MDRs for image erasure, image transition problems, and poor-quality images.\u003C\u002Fp>\u003Cp>iii. Your firm failed to complete design verification testing after implementing a change to the 0.2 μm Water Filter (Part MAJ-2318) to demonstrate that the device meets established design requirements and acceptance criteria. This water filter is used in your OER-Elite and OER-Mini Reprocessors for cleaning and high-level disinfection of your flexible endoscopes, their accessories, and endoscope reprocessor accessories. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, requires design verification or validation for all changes. However, ECR ER00006389 (dated December 11, 2024) shows verification testing was incomplete. Document MAJ-318_DC00429244 establishes the requirements and acceptance criteria for the product, including a filter service life of at least one month; however, design verification and validation records did not demonstrate that the filter has a service life of at least one month.\u003C\u002Fp>\u003Cp>iv. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, and \u003Cem>Traceability Activities\u003C\u002Fem> (OMBS W_7.3.3_03_002) require documentation of design traceability matrices. However, you have not implemented design traceability matrices for the following products: Evis Exera III Bronchovideoscopes, Evis Exera III Video System Center, Evis X1 Video System Center, Single Use Reloadable Clip Applicator, Endoscope Reprocessor, Evis Exera III Duodenovideoscopes. Without design traceability matrices there is no documentation demonstrating that all design requirements, including safety requirements, were properly verified and validated.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response for (i) through (iv) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Nonconforming Product Violations – Brooklyn Park and Hinode facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm reworked and distributed nonconforming Vizishot 2 FLEX (19G) devices without adequate justification that the rework addressed the cause of the nonconformance. NCR-00038111 was opened on July 30, 2025, to disposition nonconforming material subject to recall (RES 97303) for the detachment of the Vizishot 2 Flex 19G needle [laser cut hypotube (LCH)] after reported complaints and MDRs, including where the device may have contributed to a patient death during explant surgery to recover the detached needle. Your firm reworked product under NCR-00038111 and dispositioned passing products using an automated vision system for release, stating this minimized impact on any product safety, efficacy, or performance of the product\u002Fmaterial. However, the primary CAPA for the LCH ejection issues had not identified a root cause, and there were two additional CAPAs open related to the observed complaints (pebax material degradation and sheath snap lock not engaging), indicating other potential contributing factors to nonconformances. Additionally, your firm circumvented the ship hold in place under the NCR by changing the manufacturing date during rework, which allowed the release of those units.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203864 was opened and determined that the issue was linked to global processes GSOP‑00022 \u003Cem>Global NC Management\u003C\u002Fem> and GSOP‑00023 \u003Cem>Global CAPA Management\u003C\u002Fem>. The process related aspects of this observation are being addressed separately under Global CAPAs, CAPA-203799 and CAPA-204047. Your response acknowledged in CAPA 203864 that the eleven lots of product noted in NCR-00038111 underwent rework outside of your procedures. You reinstated the ship hold and quarantined all Vizishot 2 FLEX product. You executed product removal activities separately for Vizishot 2 FLEX (19G) devices, including a global removal decision made on December 11, 2025, with a corresponding 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203864, CAPA-203799 and CAPA-204047.\u003C\u002Fp>\u003Cp>ii. Your firm failed to control all nonconforming Shockpulse Lithotripsy generators that were subject to recall due to a miswired component (RES 98360). NCR-00000670 was opened on June 1, 2022, to scope the units affected under recall FY23-OSTA-05, for the miswiring of the Shockpulse generator. This NCR did not include a scope of all affected devices, including 2 lots containing 21 and 25 sub-assemblies, 9 finished units, and 2 service units. NCR-00046008 was opened to address the scoping nonconformance.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203777 was opened and the root cause identified the need to evaluate process gaps in \u003Cem>Global Nonconformance Management\u003C\u002Fem> GSOP-00022, specifically related to scoping methodology, alignment with HHA\u002FFCA teams, and decision-making during NCR and Stop Ship activities. A Global Ship Hold for miswired ShockPulse generator units was initiated on November 12, 2025, and the recall scope was expanded on December 9, 2025, with an 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203777 and CAPA-204047.\u003C\u002Fp>\u003Cp>b. At the Hinode facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to control nonconforming MAJ 210 single-use biopsy valves when devices failed durability testing during the investigation of CAPA 203270. This CAPA was initiated after receiving multiple complaints reporting fractures of the device, including MDR reportable events. Although devices failed testing during the complaint investigation, your firm did not initiate a nonconformance for these out-of-specification device failures. Your firm eventually initiated NCR-00030581 for the complaint trend, but not for the identified testing failures.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm has initiated actions to address the MAJ-210 failures, including a shipping hold on the device, a plan to modify the device design, and an investigation into the complaint trend. Your response does not address why a nonconformance was not initiated when testing showed the product\u002Ffailed the durability specification per GSOP-00029 \u003Cem>Global Complaint Investigation\u003C\u002Fem> and was only later opened for the complaint trend. It is unclear if you plan to evaluate whether similar issues occurred for other devices and how you will ensure that complaint investigations result in CAPAs when appropriate.\u003C\u002Fp>\u003Cp>ii. Your firm failed to control nonconforming devices with sterile barrier seal overlap defects that were found to impact seal integrity. A nonconformance (NCR-00025684) was initiated in March 2025 in response to observed defects in sterile seals from September 2024- January 2025. NCR-00025684 identified overlaps as a novel defect that was not included in your visual inspection procedures. CAPA-202690 concluded that because seal overlaps are a large wrinkle, inspectors trained to visually identify wrinkles would identify seal overlap defects. However, wrinkles and seal overlaps represent distinct sterile barrier defects. CAPA-203907 included a retrospective evaluation to demonstrate that existing visual inspection procedures were likely to identify seal overlaps, based on a blind test of engineers. However, this evaluation does not demonstrate that overlaps were identified at the time of the nonconformances.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. You state that you are conducting an investigation and root cause analysis as part of your CAPA; however, this is in progress and the details of this investigation and corrective actions are not clear, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Production and Process Controls Violations – Brooklyn Park, Hinode, Aomori, and Shirakawa facilities\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to validate the heat sealing process for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer (P4001467-001 Gyrus ACMI SN:01) Operational Qualification using Universal tray sealing nests, documented in \u003Cem>Operational Qualification (OQ) Report\u003C\u002Fem> D8201348-002 Rev AB, does not contain passing results for the challenge conditions at the high and low setpoints. The validation was intended to cover low setpoints of 200°F, 100 PSI, and 2.0 seconds and high setpoints of 265°F, 125 PSI, and 7.0 seconds. However, visual results showed all failures at the lower setpoints and all failures at the high setpoints for the Universal and PKS Omni products. Only the nominal settings (232°F, 115 PSI, 4.5 seconds) showed passing results, which do not match your current production setpoints (253°F, 118 PSI, 4 seconds).\u003C\u002Fp>\u003Cp>During the inspection, you re-executed the validation (D8201348-002, Revision AC). While this validation passed seal integrity and seal strength requirements at high and low challenge conditions, the deviation section notes that trays sealed at low settings had spottiness in the seal and trays from high settings had warp that would cause rejection during 100% visual inspection, demonstrating that the process is not capable of consistently producing conforming product throughout the acceptable setpoint ranges.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203841 to address the root cause of inadequate process for assessing procedure revisions that resulted in earlier validations (Operational Qualifications) not being updated to meet regulatory requirements. Specifically, you plan to transition from \u003Cem>Process Validation\u003C\u002Fem> GSOP-7.5-1 to \u003Cem>Global Process Validation\u003C\u002Fem> GSOP-00002. Your response indicates that the retrospective re-validation of the heat sealers is complete except for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer for the Universal Tray products and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer for the Powerseal vessel sealing product line. You are currently assessing the risks associated with products manufactured and distributed using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer, which failed the retrospective re-validation. Regarding the retrospective revalidation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat sealer used for the Powerseal product line you have noted the OQ failed to meet seal width acceptance criteria as detailed in the protocol, however, the OQ\u002FPQ testing will not be repeated at the current process settings (temperature, time, pressure). You have indicated that you will communicate with FDA regarding any actions taken based on the outcome of the completed HHA for distributed product and failed retrospective revalidation.\u003C\u002Fp>\u003Cp>ii. Your firm failed to validate the heat sealing process for tray material PN0003356 (45cm PETG Tray line) on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer SN01. The \u003Cem>OQ Report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> BM3025-E2W2 for 45cm packaging\u003C\u002Fem> (DN0010012) and \u003Cem>PQ Report for BP \u003Cstrong>(b)(4)\u003C\u002Fstrong> BM3025-E2W2 for 45cm packaging\u003C\u002Fem> (DN0010301) for this material and setpoints is for sealer \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was decommissioned and removed from use in 2023. Your firm did not provide documentation showing this material was validated on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer or justification for equipment equivalency.\u003C\u002Fp>\u003Cp>In addition, your procedure \u003Cem>Process Confirmation for Sterile Barrier Sealing\u003C\u002Fem> GWI-0704-07 Rev AE dated April 4, 2024, allows for abbreviated validation runs for \"equivalent or duplicate equipment.\" This procedure allows for equipment with the same manufacturer and model number to be considered equivalent, regardless of the year purchased or any other modifications made to the sealers. There is no additional justification or testing required to establish equivalency of the equipment.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203842 to address GWI-0704-07 REV AE, \u003Cem>Process Confirmation for Sterile Barrier Sealing\u003C\u002Fem>, and FM-7.4-3 REV AC, \u003Cem>Sterile Barrier Sealing Confirmation\u003C\u002Fem>, not aligning with GSOP-00002 REV AD, \u003Cem>Validation Program\u003C\u002Fem>, nor GSOP-7.5-1 REV BA, Process Validation. In addition, your response confirmed that the work instructions and form lacked objective evidence to justify equipment equivalency. You are in the process of completing a Health Hazard Assessment (HHA- FY26-071-A) to evaluate any risks associated with sterile barriers for distributed products.\u003C\u002Fp>\u003Cp>iii. Your firm failed to operate your heat sealers at the validated setpoints used for the Powerseal vessel sealing products. Heat sealer numbers 19-11821 and 23-70915 are only calibrated for time at 5 seconds and 10 seconds, but the nominal setpoint is 3 seconds according to your procedure \u003Cem>POWERSEAL MP: Tray Sealer Setup and Peel Test\u003C\u002Fem> DN0044870 Rev AE. There is no documented justification on why this calibration is acceptable to demonstrate accuracy at the validated setpoint, or potential impact on packaging seal quality and sterile barrier integrity for the Powerseal products.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. For example, GSOP-7.18-1 REV AT, \u003Cem>Control of Inspection, Measuring, and Test Equipment\u003C\u002Fem>, does not ensure consistent implementation of calibration across the intended use range. Additionally, the supporting work instruction, GWI-0718-03 Rev AB \u003Cem>Completing a Calibration Request Form\u003C\u002Fem>, lacked sufficient clarity to implement the requirements of GSOP-7.18-1. Your firm plans to revise GWI-0718-03 to improve clarity, include a requirement to notify external calibration vendors of specification changes, and ensure calibration point selection is documented with clear rationale. The calibration request form (FM 7.18-1) will also be updated to provide traceability, reference the revised work instruction, and ensure alignment with validated set points. GSOP-7.18-1 will be updated to explicitly require calibration points to cover validated set points, document rationale for selected calibration points, and mandate re-evaluation of calibration points when validation parameters or process conditions change.\u003C\u002Fp>\u003Cp>b. At the Hinode facility, your firm failed to adequately validate critical process parameters of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the heat sealing process. An Operational Qualification (OQ) for the heat sealing process for the MAJ-210 Single Use Biopsy valve was conducted in July 2024, after \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the heat sealing packaging process to address seal wrinkle defects; however, the process parameters and validation are inadequate. The process parameter range shown in the Operational Qualification lists a lower set value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> liters\u002Fminute and a higher set value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> liters\u002Fminute, which is flawed because the \"lower\" limit exceeds the \"higher\" limit. The OQ documentation does not detail how the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm completed an investigation and root cause analysis under CAPA-203908, and as a result, updated GSOP-00002 to provide instruction for how to identify process parameters that require control in a validated process. Your firm is also planning to conduct a review of all validated manufacturing processes in place at the facility to confirm that process parameters are adequately controlled.\u003C\u002Fp>\u003Cp>c. At the Aomori facility, your firm failed to validate the cleaning process for metal components used in the production of the HX-610 EZ Clip (hemostasis clip) made according to procedure DC00736661 to remove dirt or other particles. For example, the procedure doesn’t include defining and validating all critical process parameters with acceptable ranges including cleaning solution (type, concentration, temperature), immersion time, drying parameters, and visual inspection criteria.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm initiated a Global Ship Hold (ID.530) and CAPA 203781 as part of your corrective actions.\u003C\u002Fp>\u003Cp>d. At the Shirakawa facility, your firm did not adequately validate the testing process used in the production of UHI-4 Insufflation Unit where the results could not be fully verified by subsequent inspection and testing. For example, the software-driven functional testing process used to evaluate device performance was not adequately validated to ensure that it consistently produced devices meeting specifications in that it did not include appropriate test cases to demonstrate user requirements met acceptance criteria.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that process validation deficiencies are being addressed through ongoing remediation activities and global CAPA efforts, and that validation activities are planned or underway to ensure processes consistently produce conforming devices. You have not provided objective evidence demonstrating that process validation activities have been completed or that affected processes have been validated, including validation protocols, reports, or data demonstrating that processes consistently produce conforming devices.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm failed to establish adequate process monitoring to ensure validated sealing processes for the heat sealers used for the Powerseal vessel sealing and Miscellaneous Urology products continue to meet specifications throughout production. Per procedure \u003Cem>Peel Strength Test Method for Trays and Pouches\u003C\u002Fem> D5100327-001 Rev AL, the heat sealer for Powerseal products requires peel strength testing to be completed at the beginning and the end of a lot. The process monitoring does not demonstrate that the heat sealing meets specification throughout the manufacturing operations, nor does the process monitoring demonstrate the machine was fully set up and operational when heat sealing process for a lot occurs over multiple days. The DHR for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> notes that the sealing took place over two days. However, the process monitoring was conducted according to the procedure and only had a single tray sealing sample for testing at the start of the lot on June 20, 2025, and at shutdown on June 23, 2025. Your firm’s procedure for set-up, “\u003Cem>POWERSEAL MP: Tray Sealer Setup and Peel Test\u003C\u002Fem>” DN0044870 Rev AE states in \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the temperature to stabilize prior to use; however, there is no indication that this was done at the start of the second production day. This step is identified as critical, according to your firm’s Symbol Index in DN0044870. Additionally, the sealing procedure, D5100327-001, is also used for the Miscellaneous Urology line and the Cutting Forceps line and requires the pull strength testing be performed at the beginning and end of every day. Your firm has not assessed whether critical parameters remain in control during all production activities, including after equipment set up on subsequent production days and when processing multiple products with different configurations on the same day. Finally, your procedure \u003Cem>Process Monitoring - Packaging Data Review\u003C\u002Fem> D0300188-001 Rev AK states in section 4, step 2 that a process control analysis should include an evaluation of lower and upper control limits. However, these limits are not currently calculated by your firm, and the upper and lower bound specifications are used instead. There is no documented statistical rationale for this decision.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203867 to capture corrective actions such as the retraining of employees on process monitoring requirements to include peel testing at the beginning and end of each lot for the affected product lines. You note that you will revise FM-7.5-10, Control Plan requirements with risk assessments to define and align appropriate sample sizes and frequency monitoring. Ongoing actions as part of CAPA-203867 include defining, establishing, and implementing risk-based requirements in Process Controls, GSOP-7.5-4, for ongoing validated process monitoring. You have not performed an assessment of potentially affected units in the field and any ongoing post market monitoring to assess any risks of commercially distributed product. Your firm plans to review all process monitoring plans subject to D0300188-001 Rev AK, to ensure that such plans include justified control limits as well as specification limits. Your firm has not implemented calculated control limits.\u003C\u002Fp>\u003Cp>5. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example,\u003C\u002Fp>\u003Cp>a. At the Hinode facility, your firm failed to revalidate the heat sealing process after implementing process changes in response to seal defects in the MAJ-1555. CAPA-202690 identified the cause of the overlap defects as a misalignment of the bag surfaces when the bag enters the sealing operation to create the sterile barrier. To address this issue, your firm added a sensor to control opening and closing of the extraction arm and receiving arm, which impacts bag surface alignment during sealing. Operational qualification or performance qualification was not performed after these changes to validate that the modified process continued to meet specifications and quality attributes.\u003C\u002Fp>\u003Cp>This is a repeat violation from our 2023 Warning Letter issued to the Hinode facility.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Following an investigation and root cause analysis under CAPA-203919, your firm revised GSOP-00002 to provide additional instruction on how to assess whether a manufacturing change triggers revalidation of the manufacturing process, and your firm established the guidance document GREF-00197 to provide revalidation guidelines. The verification of effectiveness of these actions is not yet complete, and it is unclear whether concerns with process validation have been adequately addressed for other products subject to sealing at your facility. Your response stated that all seals are subject to visual inspection and, therefore, any nonconforming seals would be detected prior to release; however, visual inspection is not a substitute for adequate process validation.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Corrective and Preventive Action Violations – Brooklyn Park, Shirakawa, Hinode, Hachioji, Hamburg, and Aomori facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>6. Failure to identify the action(s) needed to correct and prevent the recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to identify corrective actions that address the full scope of multiple Line Clearance Control nonconformances on the Miscellaneous Urology Production Line. CAPA-201354 was opened on August 31, 2023, and included automated verification steps and automated inspections on the lines. However, the CAPA only included implementing the automated verifications for the Soltive laser fibers and did not address corrections for any of the other products made on the Miscellaneous Urology production line, including nonconformances associated with missing syringes in the Irri-Flow line or incorrectly labeled RB Electrodes, as listed in the CAPA Initiation Information.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened and is developing an action plan for CAPA-203705, which revealed that the Miscellaneous Urology product line lacks sufficient process controls and robust automation and further noted that this technical gap creates a potential for the recurrence of nonconformances. While a quality plan was developed per GSOP-5.5-1 Rev AB \u003Cem>Quality Plans\u003C\u002Fem> to address the remaining implementation requirements for this line, the execution of these corrective actions occurred outside of the formal CAPA framework and did not include verification of effectiveness.\u003C\u002Fp>\u003Cp>ii. Your firm failed to identify corrective actions to address ongoing Supplier Quality Performance rate failures for Vizishot endoscopic aspiration needle slider components. CAPA-202086 was opened on August 15, 2024, to address the Supplier Quality Performance rate (SQ3) not meeting the KPI objective for more than three months in a row. The investigation identified root causes related to supplier capability gaps, including inadequate manufacturing processes, insufficient purchase order review, and delayed drawing revisions. A separate NCR-00028865 due to a SQ2 KPI signal (Part Failure Rate) was escalated to CAPA-202086 on May 20, 2025. CAPA-202086 was closed on October 16, 2025, with no corrective or preventive actions taken, and the SQ3 KPI was eliminated without addressing the underlying quality problems or providing a rationale for no action taken.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203869 confirmed that the early closure of CAPA-202086 occurred because GSOP-00023, Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> and GWI-00014, Rev AB \u003Cem>CAPA Management Work Instruction\u003C\u002Fem> – Agile did not clearly define requirements for early closure rationale or verification of linked records. An action plan is being developed but has not yet been implemented for CAPA-203869.\u003C\u002Fp>\u003Cp>iii. Your firm identified a root cause for the blue ring on the Powerseal vessel sealing device detaching from the rotation knob during use (operator error during assembly) but failed to implement corrective actions consistent with that root cause. CAPA-200547 was opened on July 22, 2022, for the detachment, which resulted in a recall (RES 90788). The CAPA found the root cause was an operator error during assembly and not the out of specification supplier component originally documented in the HHA FY23-OSTA-07. However, the scope of corrections for the recall were based on supplier component lots and the scope was not expanded to include all devices assembled during the period when the operator error occurred, allowing potentially defective devices to remain in distribution.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203868 and noted that the Health Hazard Assessment (HHA) and Field Corrective Action (FCA) for CAPA-200547 were not reassessed after the identified root cause changed, as procedure GSOP-00023 Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> did not define requirements for re-evaluation when new investigation findings modify the identified failure mode. Your firm indicated that since the process is shared among sites, the process related aspects of this observation are being addressed separately under Global CAPA-203799. An action plan is being developed but has not yet been implemented for CAPA-203868.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to identify corrective actions needed to correct and prevent the recurrence of known quality problems associated with the UHI-4 insufflation system. CAPA-200872 identified pressure sensor failures as the root cause of front panel display issues; however, you relied on prior corrective actions (SCAR-Shirakawa-152-06) and concluded that the risk remained acceptable despite 325 complaints. Your firm failed to implement adequate corrective actions to address supplier control failures, complaint trending deficiencies, and design and risk management process gaps that allowed these repeated failures. As a result, your supplier control processes failed to prevent defective components from entering production and your quality system failed to detect and escalate recurring defects.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response noted planned corrective actions, including reliance on global CAPA procedures (GSOP00023) and proposed improvements to complaint trending, supplier controls, and risk management processes. You indicated that CAPA deficiencies continue to be addressed through ongoing local and global CAPAs and that you have initiated additional CAPAs (e.g., CAPA-203879, CAPA-203856, CAPA-203877).\u003C\u002Fp>\u003Cp>c. At the Hinode facility, your firm’s CAPA procedures failed to ensure that corrective actions addressed the root causes and prevented recurrence. Between October 2022 and September 2025, three CAPAs (CAPA-200736, CAPA-201399, CAPA-203398) were opened for wrinkle defects in sterile barrier seals across five products (MAJ-2315, MAJ-1555, MAJ-209, MAJ-210, MAJ-287). Each CAPA identified inadequate process validation as a contributing factor, yet none implemented corrective actions to address the underlying validation methodology deficiency that allowed critical process parameters to be missed. For example, CAPA-203398 identified the root cause as \"Method Inadequate validation\" but did not implement corrective actions to address the validation failure. CAPA-201399 identified wrinkles across multiple products but concluded that inspection would remove nonconforming product, without implementing corrective actions to the validated processes producing defects. CAPA-200736 \u003Cstrong>(b)(4)\u003C\u002Fstrong> to address wrinkles but did not investigate why \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified in initial validations. Wrinkle defects may create channels for microbial contamination.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm characterized the pattern of recurring CAPAs for seal defects as representative of continuous improvement, citing decreases in defect rates, and your firm characterized the sealing processes as “under control”. However, ongoing nonconformances were initiated for wrinkles even after CAPAs were initiated. Your responses do not appear to address why your CAPA process allowed the same problem to require three separate CAPAs over three years without implementing corrections to the validation methodology.\u003C\u002Fp>\u003Cp>d. At the Hachioji facility, your firm failed to identify corrective actions for CAPA 201212, initiated June 20, 2023, in response to an FDA Additional Information request related to a patient death following use of the Evis Exera III Bronchovideoscope. Your CAPA documented that your firm failed to conduct design verification for use conditions and accessory compatibility claims in your IFU; however, no corrective actions were taken to address these design control deficiencies and the suspension of shipping was lifted on July 28, 2023. Your investigation revealed that your firm received 210 similar complaints and your investigation was not completed until November 14, 2025, over two years after CAPA initiation and your decision to continue shipping the devices.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>7. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm implemented actions to address root causes of a Vizishot II component mix-up without classifying them as corrective actions and verifying their effectiveness. CAPA-203041 was opened on June 30, 2025, for the use of the 21G slider components instead of the 22G on the Vizishot II NA-U401SX-4022 line. The Early Closure memo states that “operators were retrained on the line clearance procedure GWI-0705-16 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was modified to restrict access to the sides…”. Neither of these actions were considered a corrective action, nor was a verification of effectiveness conducted to ensure these actions prevented recurrence of the component mix-up.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203041 was prematurely closed because actions taken under the NCR were misclassified as corrections, even though they addressed root-cause-level factors that required corrective actions and verification of effectiveness (VOE). GSOP-00023 Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> did not explicitly distinguish correction from corrective action within the CAPA workflow, which contributed to the omission of VOE. Your firm also indicated an action plan is being developed but has not yet been implemented for CAPA-203705.\u003C\u002Fp>\u003Cp>ii. Your procedures, \u003Cem>Quality Planning\u003C\u002Fem> QSP-5.5 Rev AL and \u003Cem>Quality Plans\u003C\u002Fem> GSOP-5.5-1 Rev AB, have not adequately defined when quality plans contain corrective or preventive actions and should contain a verification that changes are effective and do not adversely affect devices. These procedures do not adequately define the difference between a quality plan and a corrective or preventive action. Additionally, during the inspection your firm had 54 quality plans open, including multiple plans intended to address backlogs in the complaint system and late MDRs. These quality plans directly address deficiencies in your quality system and are also being referenced within and in conjunction with CAPAs addressing the same issues.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203836 determined that the current procedures lack defined criteria for determining when a Quality Plan is not appropriate and a CAPA is required and does not require oversight to ensure appropriate use and completion tracking of Quality Plans. The \u003Cem>Quality Management Review Presentation Template\u003C\u002Fem> GTMP-00077 was revised to require that quality plans be reviewed as part of the Quality Management Review process. The scope of affected quality plans that lacked VOE was not provided. An action plan is being developed but has not yet been implemented for CAPA-203836.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to verify that corrective actions implemented for overpressure events for the UHI-4 Insufflator were effective in preventing recurrence. For example, CAPA-200872 (opened February 2023) relied on prior corrective actions related to pressure sensor failures and concluded that these actions were effective without demonstrating that they prevented recurrence of similar defects or adequately mitigated risk in distributed devices. CAPA-201353 (opened August 2023) was subsequently opened to address overpressure events associated with the UHI-4 insufflation system only after significant adverse events occurred, including cardiac arrest and possible gas embolism, and resulted in a Class I recall (RES 92932). Your CAPA activities did not demonstrate that corrective actions were verified or validated to ensure effectiveness in preventing recurrence of overpressure-related failures.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Several CAPAs remain open, and you have not demonstrated that corrective actions have been verified or validated to ensure effectiveness or to prevent recurrence of similar defects, including overpressure-related failures.\u003C\u002Fp>\u003Cp>8. Failure to analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm is using statistical methods for complaint trending without a documented rationale for the appropriateness of those methods. \u003Cem>Complaint Trending Attributes, Statistical Method, and Trending Rules\u003C\u002Fem> GREF-00157 Rev AA defines your complaint quality data analysis method of using median values and recalculating control limits each month. During the inspection your employees noted the calculations used were originally chosen in 2020, due to COVID-related data irregularities. However, you acknowledged that your firm does not still see these data irregularities and confirmed your firm has not documented a re-assessment or other justification for why this analysis method is still appropriate. The use of median values and monthly recalculation of control limits (that may not be appropriate for post-COVID data) may mask trends or delay detection of increasing complaint rates, potentially allowing serious device problems to persist undetected.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203873 determined that Olympus lacks a global procedure or guidance for statistical techniques, resulting in the absence of defined expectations for the consistent implementation of statistical methods. An action plan is being developed but has not yet been implemented for CAPA-203873.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm did not adequately analyze quality data, including complaints and adverse event information, to identify causes of quality problems. For example, you received a high volume of complaints related to pressure sensor defects and front panel failures associated with the UHI-4 insufflation system (including 325 complaints between November 2020 and October 2022), yet you did not appropriately trend or escalate these data to identify a cause or initiate CAPA in a timely manner. Additionally, you were aware of pressure sensor defects as early as 2018–2021 but did not reassess risk or investigate the increased occurrence of these defects in distributed devices. A CAPA was not initiated until FDA inquiry, indicating that your quality system did not effectively analyze available data sources, including complaints, supplier information, and risk management records.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response states that CAPA deficiencies are being addressed through a combination of local and global CAPAs, including local CAPA-203879, CAPA-203856, CAPA-203850, and global CAPA-203789, CAPA-203525, and CAPA-204150. You indicate that updates to procedures, including GSOP-00023 (CAPA), GSOP-00033 (complaint trending), GSOP-00069 (supplier quality agreement), and GSOP-00079 (supplier corrective action), have been implemented or are in progress. You also state that retrospective reviews of complaint data and supplier corrective action requests have been conducted. Several CAPAs remain open and root cause investigations and corrective actions are ongoing. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific deficiencies have been adequately addressed. Your response further confirms that complaint trend signals were not adequately identified and that supplier-related defects were not appropriately evaluated for field impact at the time they were identified. You have not provided sufficient objective evidence demonstrating implementation or effectiveness of corrective actions, including completion of investigations, verification of corrective actions, or sustained improvements to your CAPA system.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm’s complaint trending failed to include all complaints as required by your procedure. \u003Cem>Trending Attributes, Statistical Method, and Trending Rules\u003C\u002Fem> GREF-00157 Rev AA, section 4.4.2 states “trending will be based on the value of monthly data (i.e. actual number of open complaints per month).” However, trend signal information (TS-1224-WA50042A) for your video telescope (model WA50042A) only includes the trending of MDR reportable complaints and does not include non-reportable complaints.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response did not include an assessment of how the lack of trending of non-reportable complaints may impact already distributed product. For example, if the complaints reveal quality problems that may require correction or removal to address.\u003C\u002Fp>\u003Cp>d. At the Aomori facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to adequately analyze quality data to identify causes of nonconforming product. CAPA-201434, which was initiated to address reports of deformed wires for the Single Use 3-Lumen Sphincterotome, incorrectly identified the root cause as “shortcomings in work procedures” during outsourcing, failing to recognize inadequate design transfer to production specification as the actual cause. Per the CAPA scope, the corrective actions only applied to products distributed to the Japanese market and were not implemented for devices distributed to the U.S. market. It was noted during the inspection that the CAPA task (Task 10012651) assigned to correct the manufacturing process for products destined for the U.S. was cancelled because the products are subject to FDA 510(k) and it would have taken longer to implement the changes which would “prolong the period until the CAPA closes.” Your firm received over 1000 complaints for this device failure, including 24 MDR reportable events.\u003C\u002Fp>\u003Cp>ii. Your firm failed to conduct a timely and adequate analysis of complaint data related to potential causes of nonconforming product for the Thunderbeat 5 mm Front-actuated Grip Type S. Your firm received over 1900 complaints between September 2021 and September 2024, including 1583 that were MDR reportable. CAPA-201438 was initiated on October 18, 2023, but no action was taken as the Health Hazard Evaluation was canceled on January 31, 2024, because it was deemed not necessary based on complaint incident rates and without considering the potential harm to patients. A recall (RES 95950) was initiated on November 25, 2024, over a year later.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response for (i) and (ii) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Acceptance Activities Violations – Brooklyn Park and Shirakawa facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>9. Failure to establish and maintain procedures for acceptance of incoming product, as required by 21 CFR 820.80(b). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm failed to conduct statistical calculations required to demonstrate lot acceptability in accordance with your procedure. \u003Cem>Receiving Acceptance\u003C\u002Fem> GSOP-7.11-1 Rev AT uses a variable sampling plan for receiving inspection of part number 0000315-TAB, according to \u003Cem>Inspection Procedure for 0000315-TAB JAW ASSEMBLY, MACHINED, INNER, POWERSEAL CURVED JAW B\u003C\u002Fem> DN0040655 Rev AE. However, your receiving inspection for each length of this part (PN 0000315-001, 0000315-002 and 0000315-003) does not include calculation of your standard deviation, kLSL, and kUSL as required by GSOP-7.11-1. Additionally, your acceptance procedure for Powerseal Curved Jaw B only includes a specification for sample calculation for dimension 9 but does not document a calculation of the maximum standard deviation (MSD) for any other dimension as required. Finally, your Supplier D also uses the sampling plan, but does not provide you with their standard deviation, kLSL and kUSL calculations. The calculations for standard deviation, lower controls limits and upper control limits are part of the variable sampling plan that demonstrate the acceptability of the lot.\u003C\u002Fp>\u003Cp>Your inspection procedure also allows for CMM measurements to be re-tested by another inspector if they do not pass initially. This was done for 8 of the 10 samples in the \u003Cem>FAI Inspection Request\u003C\u002Fem> for part number 0000315-002, dated March 20, 2025. The only rationale recorded was \"Believed fixture incorrect.\" Our inspection also found that retesting had occurred on all of the most recent receiving records for all sizes of the 000315-TAB. Part Number 0000315-001 was inspected on October 23, 2025, and the record includes failing CMM results for 5 of the 10 parts, as well as the retested data, but the parts were accepted into inventory. When our investigator communicated this to your employee, it was noted that this lot was accepted by mistake and NCR-00048701 was opened to contain the nonconforming material.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203866 was opened to capture corrective actions and noted that GSOP 7.11-1 Rev. AU, \u003Cem>Receiving Acceptance\u003C\u002Fem>, and the inspection procedures did not define the statistical requirements, resulting in incomplete evaluation of incoming product and acceptance of parts without proper statistical justification. Your response noted that you have updated the inspection procedures for all parts subject to ANSI\u002FASQ Z1.9 to require inclusion of sample size rationale for critical dimensions and to ensure that data is provided by their suppliers. Your firm plans to conduct a retrospective review of inspection records from the past 2 years for failed dimensions without a record of appropriate retest or passing results. Based on the results of the review you will take appropriate action; however, it is not clear what those actions would include, nor if the actions will include a risk assessment for product that has been distributed.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to identify defective components used in the UHI-4 insufflation system during acceptance activities. For example, defective pressure sensor components were not identified through incoming inspection or acceptance testing prior to use in manufacturing. As a result, nonconforming components were incorporated into finished devices, contributing to reports of device malfunctions and adverse events received by your firm.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response states that improvements to incoming acceptance activities will be implemented as part of broader corrective actions, including updates to ensure that purchased materials meet specifications. However, you have not provided sufficient detail demonstrating that revised acceptance activities have been implemented or are effective in detecting nonconforming components.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Purchasing Controls Violations – Brooklyn Park, Shirakawa and Hamburg facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>10. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm’s supplier controls procedure (GQS-00013) does not ensure that supplied product that cannot be fully verified by subsequent inspection and test is validated with a high degree of assurance and conforms to specified requirements. On December 4, 2023, your firm issued SCR-0000649 for an increased rate of complaints for broken welds in the ESG PK Cutting Forceps (model PK-CF0533), occurring in the supplied bottom and top jaw assemblies (part numbers P5700259-001 and P5700260-001, respectively). Supplier A determined the cause of the weld breaking was a sub-supplier, Supplier B. In SCR-0000649, Supplier A documented that Supplier B stated the welding process \"could not be controlled or validated.\" Your firm established increased inspection rather than requiring validation or changing suppliers. This complaint trend resulted in a recall (RES 93842) in December 2023. This unvalidated welding process has resulted in weld failures during patient use, creating risk of foreign bodies in patients assessed at Critical (S4) severity and High (S5) probability. Similar welds are also performed by Supplier B for your Halo and Cutting Forceps. Approximately 4,600 units with similar unvalidated welds have been distributed. During the inspection, your firm initiated an NCR and a Global Ship Hold.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened to address the failure to ensure welding performed by the supplier was validated. The CAPA root cause investigation identified that the QAA template used to finalize the Supplier Agreement back in 2014 did not incorporate process validation requirements for suppliers and their Sub-Tier suppliers. Moreover, the Global QAA templates GTMP-00021 Rev AB \u003Cem>QAA Template for Component Suppliers\u003C\u002Fem> and GTMP-00022 Rev AB \u003Cem>QAA\u003C\u002Fem> \u003Cem>Template for Finished Device Suppliers\u003C\u002Fem> lack specificity on sub-tier control for process validation. All impacted product remains on Global Ship Hold (ID 476), and you have halted the manufacture of affected product. The FCA board reviewed and decided to conduct a removal of the impacted products. Your response stated you would submit a Correction and Removal report in compliance with 21 CFR Part 806 requirements. Although an expansion of the recall is being performed, it has been over 2 years between awareness (December 4, 2023) and recall decision (February 3, 2026). Your firm has not explained the delay or assessed patient harm during this period.\u003C\u002Fp>\u003Cp>ii. Your firm accepted failing process capability data after components were remeasured without justification. SCR-0000166 was issued to Supplier C for out of specification components. The investigation led to two design changes to the mating parts used in the Powerseal vessel sealing device: the blue ring (part PN0013810) and the overmolded rotation knob (part PN0013804) and resulted in a class II recall (RES 90788). You accepted first article inspection that included Supplier C “Validation Documents Submission” where parts were remeasured with passing results, “Ppk’s for Cav 2 on PQ1 was right at 1.39 and PQ2 was 1.36 failing the Ppk requirement per protocol of 1.39. 2 parts were remeasured and Ppk came into requirement.” There is no justification for why these remeasurements were considered appropriate.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203872 is ongoing, and the root cause investigation identified that the supplier procedure permitted data remeasurement without documented justification and did not define requirements for documenting the rationale or controls associated with remeasurement activities. In addition, GSOP-00086 Rev AA \u003Cem>Global External Product Qualification\u003C\u002Fem> lacked requirements for justification of remeasurement. Your firm’s response notes that you have planned the process to requalify Supplier C against new global procedure requirements by March 27, 2026, including a new Quality Agreement. The impact on released product has not been evaluated since this will involve the remeasurement at incoming testing after you have updated GSOP-00086 that governs the conditions and permissibility for remeasurement. Your firm has not provided interim results or identified how many additional components may be affected. Your response should also include a retrospective review of similar supplier processes that pose a potential for patient safety risk.\u003C\u002Fp>\u003Cp>iii. Section 3.5 of \u003Cem>First Article Inspection\u003C\u002Fem> GSOP-7.11-2 Rev AG, allows suppliers on risk improvement plans with documented quality concerns to conduct first article inspections without additional verification by your firm. For example, Supplier D has been on a risk improvement plan since January 21, 2025, but a \"Supplier conducted FAI\" for part number 0000315-002, delivered on or before March 5, 2025, and used in the Powerseal vessel sealing device. The process is currently controlled by the two procedures \u003Cem>Global Supplier Risk Improvement \u003C\u002Fem>GSOP-00045 Rev AB and \u003Cem>Global Supplier Risk Improvement with Action Plan\u003C\u002Fem> GWI-00002 Rev AB. Despite the supplier providing out-of-specification components and being on a supplier risk improvement plan, your firm failed to consider the appropriateness of the supplier performing first article inspection measurements following a design change or when implementing a new component.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203866 identified that GSOP-00045 Rev AB \u003Cem>Global Supplier Risk Improvement\u003C\u002Fem> does not require evaluation of internal inspection plans when supplier risk improvement plans are issued or revised in response to changes in part failure rate. Additionally, the procedure lacks defined linkage between supplier risk improvement plans and corresponding receiving inspection requirements. It is not clear from your response whether there is nonconforming product in the field associated with suppliers who are on a heightened inspection status or risk improvement plan and who conducted their own supplier first article inspections.\u003C\u002Fp>\u003Cp>iv. Supplier A has not adequately validated their \u003Cem>Performance Qualification Report\u003C\u002Fem> PQR-10774 Rev A for part number P5700138-001, used to support the weld tensile strength in your legacy Cutting Forceps. According to your firm’s Engineer, the worst-case weld is considered the shortest weld of the group, as the welds all have to meet a minimum weld pull strength of 30 lbs. However, part P5700138-001 has a weld length specification of 0.10 ± 0.02 inches, while parts P5700211-002 and P5700210-002 have a shorter weld length specification of 0.081 ± 0.02 inches.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened and a Health Hazard Assessment (HHA) FY26-062 was conducted to evaluate potential field action. On February 3, 2026, the FCA board reviewed and decided to conduct a removal of the impacted products in the Cutting Forceps product line (RES 98454). Olympus completed the review of validations for Supplier A to determine conformance with Global GSOP-00002 Rev AD \u003Cem>Validation Program\u003C\u002Fem> and GWI-00112 Rev AA \u003Cem>Global Standards for External Product Qualification\u003C\u002Fem> for worst-case trials with documented rationale. The review determined that three (3) components manufactured by Supplier A require additional process validation. The review, however, was limited to products with an active production schedule. Products that have reached end-of-life and are in the process to be discontinued were excluded from the scope (jaw assemblies, ESG Cutting Forceps, Halo, Everest 5mm Cutting Forceps, and PKS Cutting Forceps). It is not clear from your response whether there is product within expiry date that is still in commercial distribution. Your firm will complete a review of applicable supplier-manufactured components documentation, through collaboration with suppliers to identify potential validation gaps.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm did not adequately control suppliers to ensure that components used in the UHI-4 insufflation system met specified requirements. For example, pressure sensor defects associated with supplier-provided components were identified; however, your supplier control processes did not prevent nonconforming components from being incorporated into finished devices. Your CAPA investigations did not adequately evaluate why supplier controls were ineffective or ensure that appropriate corrective actions were implemented to prevent recurrence of similar supplier-related defects. Root cause analysis identified gaps in supplier change control procedures and audit processes, including lack of mechanisms to verify supplier changes against specifications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that supplier control deficiencies are being addressed through local and global CAPAs, including CAPA-203856 and CAPA-203789, and that supplier oversight processes will be enhanced through updated supplier quality agreements and risk-based supplier requalification activities. You also indicate that procedures, including GSOP-00079, have been updated to require assessment of field impact for supplier-related defects. However, investigations into supplier-related root causes remain ongoing, and corrective actions have not been fully implemented. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific supplier control deficiencies have been adequately addressed. You have not provided objective evidence demonstrating that revised supplier controls are effective in preventing recurrence of nonconforming components.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm failed to ensure that purchased services conform to specified requirements. Your firm hired HCL Technologies as part of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to reduce the backlog of complaint investigation and closures; however, your firm did not evaluate HCL Technologies on the basis of their ability to provide contract services to meet specified quality requirements, including their ability to provide qualified staff to perform quality assurance responsibilities. Your firm’s contract services included approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> temporary personnel to investigate and close complaint files. Your firm was unable to demonstrate that the contract personnel received product specific training.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm initiated CAPA-204033 and CAPA-204034. Your firm indicated that your root cause investigation determined that there was no central governance defining shared services requirements within the Quality Management System (QMS) and that as a result, roles and responsibilities between Legal Manufacturers, Global QMS functions, and shared service owners were not consistently defined or understood, leading to fragmented accountability for end-to-end oversight. Your firm is developing a corrective action plan; however, you have not provided corrective actions demonstrating how you will ensure contract personnel are qualified and trained in the services they will perform.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Records Violations – Brooklyn Park and Shirakawa facilities:\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>11. Failure to review, evaluate and investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm's procedure, \u003Cem>Complaint Investigation Tiers and Investigation Activities\u003C\u002Fem> GWI-0809-10 Rev BB, does not require investigations to be completed on complaints in investigation Tier 3. For example, complaints C22097460, C22184070, C22248777, C22249599, C22259835, C22279317, C22332770, and C22387391 all state in the investigation summary that the complaints are “non-PAE, Tier 3 codes. No investigation is required,” in the “Evaluation Result” section (PAE stands for potential adverse event). There is no documentation of a complaint investigation or reference to where an investigation for this failure has previously been investigated or other similar rationale for why this investigation is not required. Lack of investigation only allows trending on this subset of complaints based on date of receipt and device model. After transitioning to your current Trackwise system in November 2024, you indicate you no longer use a tier system; however, your trending is based on 24 months of historical data which is still limited by the lack of investigation results on potential device performance issues.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response does not address the failure to investigate complaints.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to adequately investigate complaints involving serious adverse events to determine whether device malfunction contributed to the reported outcomes. For example, complaints associated with UHI-4 insufflation systems, including reports of overpressure events and serious adverse outcomes such as cardiac arrest and possible gas embolism, were not fully evaluated to determine whether device malfunction contributed to the reported events. Your complaint investigations did not consistently incorporate available device performance data to determine whether the device met specifications during use. For example, complaint CN-249953 reported a death due to gas embolism during use and included the device event log retrieved by the Field Service Engineer; however, this log was not reviewed as part of the investigation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. You state that complaint handling and trending processes have been improved through implementation of GSOP-00033 and that retrospective reviews of complaint data have been conducted to assess whether complaint signals were appropriately escalated. You also indicate that CAPA-203879 was initiated to address missed complaint trend signals. However, CAPA-203879 and related investigations remain ongoing, and you have not provided sufficient objective evidence demonstrating that complaint investigations are comprehensive or that systemic issues are consistently identified and escalated.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection at your Hamburg facility also revealed that your firm’s resection sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>12. Failure to report the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that the firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included in Complaints CN-182867 and CN-184790 reasonably suggests that your firm’s resection set malfunctioned (e.g., broken ceramic insulation) while in use. A serious injury MDR 2951238-2019-00404, submitted by your firm on February 1, 2019, documents a serious injury resulting from the same malfunction involving the same device. That malfunction would be likely to cause or contribute to a death or serious injury if it were to recur, as evidenced by the serious injury MDR 2951238-2019-00404. Accordingly, the referenced adverse events represent MDR-reportable malfunctions as defined under 21 CFR 803.3. Your firm became aware of complaint CN-182867 on February 13, 2025, and submitted the corresponding MDR 9610773-2025-06509 on October 20, 2025; and became aware of CN-184790 on February 12, 2025, and submitted the corresponding MDR 9610773-2025-04016 on June 16, 2025. These two MDRs were submitted beyond the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. The response states that your firm initiated CAPA-204035 to address late reporting, including revising procedures to correctly document event dates and the dates your firm became aware of the events. However, supporting evidence demonstrating completion of these corrective actions was not provided because the corrective actions are still ongoing.\u003C\u002Fp>\u003Cp>Failure to address any violations of the FD&amp;C Act may result in the FDA refusing admission of the devices manufactured by your firm into the United States under section 801(a) of the FD&amp;C Act, 21 U.S.C. § 381(a). Devices under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\u003Cp>Your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facilities to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspections conducted between October 2025 and December 2025 were conducted pursuant to the QS Regulation, which was in effect at the time of the inspections. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>In addition, we also note the following comments:\u003C\u002Fp>\u003Cp>1. In response to three prior warning letters issued to your firm in 2022 and 2023 (including the Hachioji and Hinode facilities), your firm implemented new global procedures, including complaint handling, MDR, and CAPA procedures. Review of these procedures found the roles and responsibilities of manufacturing sites versus your global remote corporate entity have not been clearly defined, including, for example, how your firm will assess that site specific quality issues have been resolved, and how your global CAPA process will provide oversight and ensure correction and prevention of repetitive quality issues within and across your global facilities that follow these procedures.\u003C\u002Fp>\u003Cp>2. Regarding the inspection of Olympus Corporation of the Americas, located at 3500 Corporate Pkwy, Center Valley, PA 18034, FEI 2429304, from November 18, 2025, to December 16, 2025: Multiple complaint files reviewed during the inspection were found to contain insufficient documentation of complaint intake, evaluation, and investigation conclusions. Complete complaint files provide your firm with critical information to detect and trend medical device failures and to make reportability decisions.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to \u003Cstrong>Kristina Donohue\u003C\u002Fstrong> at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS #729208\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: \u003Cstrong>Beckilyn Dorsey\u003C\u002Fstrong> at \u003Cstrong>Rebecca.dorsey@fda.hhs.gov.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Michael J. Hoffmann&nbsp;&nbsp;\u003Cbr>Director&nbsp;&nbsp;\u003Cbr>Office of Health Technologies 3 - Gastrorenal, ObGyn,\u003Cbr>General Hospital, and Urology Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Todd Brill, US Agent, Gyrus ACMI, Inc., \u003Cstrong>(b)(6)\u003C\u002Fstrong>@Olympus.com\u003Cbr>Daniel S. Sampson, Senior Director of Operations, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Richard Reynolds, President, Olympus Corporation of the Americas, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Hiroaki Hosoi, President, Aomori Olympus, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Kota Ishibiki, President, Olympus Medical Systems Corporation \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Shinji Egami, Senior Director, Olympus Medical Systems Corporation, Hinode, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Seiji Morishita, President, Shirakawa Olympus Co., Ltd., \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Carl A. Yallop, Vice President OSTE, SIS Operations &amp; ISC and Managing Director, EMEA, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nOlympus Medical Systems Corporation\n\n2951 Ishikawa-machi\n\nHachioji-shi, Tokyo\n\n192-8507\n\nJapan\n\n(b)(6)@olympus.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS #729208\nOctober 7, 2026\nDear Mr. White:\nThe United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\nOlympus Medical Systems Corporation, located at 2951 Ishikawa-Cho, Hachioji-Shi, Tokyo, JP 192-8507, FEI 3002807795, November 17, 2025, to November 21, 2025 (“Hachioji”)\nAomori Olympus Co., Ltd., located at 2-248-1 Okkonoki, Kuroishi-shi, Aomori, JP, 036-0357, FEI 3003995201, from November 4, 2025, to November 7, 2025 (“Aomori”)\nOlympus Medical Systems Corp. Hinode Plant, located at 34-3 Hirai, Hinode-Machi, Nishitama-Gun, Tokyo, JP, 190-0182, FEI 3003637092, from November 17, 2025, to November 21, 2025 (“Hinode”)\nShirakawa Olympus Co., Ltd., located at 3-1 Okamiyama, Odakura, Nishigo-Mura, Nishishirakawa-Gun, Fukushima, JP 961-8061, FEI 3002808148, November 10, 2025, to November 14, 2025 (“Shirakawa”)\nOlympus Winter & IBE Gmbh, located at Kuehnstrasse 61, Hamburg, DE 22045, FEI 3002807798, from November 10, 2025, to November 21, 2025 (“Hamburg”)\nGyrus ACMI, Inc. [dba Olympus Surgical Technologies (OSTA)], located at 9600 Louisiana Ave North, Brooklyn Park, MN 55445, FEI 3011050570, from October 6, 2025, to November 12, 2025 (“Brooklyn Park”)\nDuring these inspections, our investigators determined that your firm manufactures a variety of surgical and endotherapy devices, including but not limited to, hemostatic metal clips, sphincterotomes, cystoscopes, bronchoscopes, endoscopic distal covers, valves, and insufflators. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThe above-referenced inspections revealed that the devices manufactured at the Hachioji, Aomori, Hinode, Shirakawa, Hamburg, and Brooklyn Park facilities are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. This nonconformity includes issues across the referenced inspected facilities, resulting in the distribution of nonconforming devices and significant risks to patients.\nA Form FDA 483 (FDA 483), List of Inspectional Observations, was issued to the Aomori facility on November 7, 2025, the Brooklyn Park facility on November 12, 2025, the Shirakawa facility on November 14, 2025, the Hachioji facility on November 21, 2025, the Hinode facility on November 21, 2025, and the Hamburg facility on November 21, 2025. We received responses concerning our investigator’s observations noted on these FDA 483s from Robert A. Fryc, Director, Global Quality Compliance, External Regulatory Communications, Olympus Corporation of the Americas, dated December 22, 2025, February 13, 2026, March 30, 2026, May 28, 2026, and July 31, 2026. We address these responses (collectively referred to as “your firm’s response”) below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\nDesign Control Violations – Shirakawa, Aomori, Hamburg, and Hachioji facilities\n1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). For example,\na. At the Shirakawa facility, your firm failed to identify and control known catastrophic hazards in your risk management documentation and failed to validate the device design under actual or simulated use conditions for the UHI-4 insufflator. Catastrophic hazards, including air embolism, arrhythmia, and patient death, were identified through Health Hazard Assessments and complaint investigations associated with CAPA-201353; however, your Risk Management Report (DC00067142, dated November 6, 2025) did not reflect these hazards or ensure implementation of appropriate risk control measures, even after a confirmed patient death and Class I recall of UHI-4 units in 2023. Further, your design validation did not simulate actual or worst-case use conditions related to pressure sensor failure or inaccurate pressure measurements to ensure that the device would operate safely. As a result, devices distributed had design deficiencies that contributed to overpressure events during clinical use.\nThe adequacy of your firm’s response cannot be determined. Your response states that design-related deficiencies are being addressed through global CAPAs, including CAPA-204150 (design control) and CAPA-203525 (risk management), and that a traceability matrix for the UHI-4 will be developed to evaluate design requirements, verification, and validation. You also indicate that additional design verification and\u002For validation testing will be performed as needed and that potential design changes will be assessed by the design owner (Olympus Hachioji). However, these activities remain ongoing, and you have not provided objective evidence demonstrating that design validation deficiencies have been corrected or that revised validation activities adequately address identified risks, including overpressure conditions. Additionally, corrective actions have been deferred to global CAPAs and another facility, and no documentation has been provided demonstrating completion or effectiveness of these actions.\nb. At the Aomori facility, your firm failed to identify and assess known hazards in the risk management documentation and failed to establish risk control measures for manufacturing processes for the Sphincterotome. In your risk management report (E_V-KD_Risk Management Report_Rev.27), the corresponding risk line ID (KD-G158-00) identifies the potential patient harm as “Delay in Treatment” for complaints of deformed wires but fails to include the higher risk identified through analysis of Medical Device Reports of unintended cutting of blood vessels leading to patient bleeding. It also fails to identify any risk control measures for the manufacture of the wire for the Sphincterotome. Additionally, the risk management report (DC00609260_20250910) does not include the known hazard of failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes and does not include risk control measures for this hazard, which can lead to tissue damage and procedural complications.\nThe adequacy of your firm’s response cannot be determined at this time. Your firm has not provided an updated Risk Management Report (DC00609260_20250910) to address the hazard and implement risk control measures for failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes. Additionally, your firm has not provided an updated risk management report (E_V-KD_Risk Management Report) to address the risk of unintended cutting of blood vessels leading to patient bleeding and risk control measures for manufacture of the wire.\nc. At the Hamburg facility, your firm distributed the Continuous Flow Cystoscope (model WA22810A) with instructions for use (IFU) that claimed compatibility with the GreenLight PV ADDstat laser fiber component without conducting design validation testing to ensure compatibility under use conditions. This resulted in two recalls, RES 95584 and RES 98300, due to a risk of damage and\u002For overheating to the tip of the sheath when used together. Unrecognized sheath damage can result in tissue injury or parts of the sheath breaking off into the patient.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response should include a retrospective review of similar devices with IFU compatibility claims to ensure that they are supported by design validation activities to ensure compatibility under use conditions.\nd. At the Hachioji facility:\ni. Your firm distributed the BF-1TH190 bronchoscope with instructions for use (IFU) claiming compatibility with CO2 lasers without conducting design validation testing to ensure compatibility under use conditions. This resulted in a class I recall (RES 93052), due to a risk of endobronchial combustion if high-frequency cauterization is performed while supplying oxygen and\u002For the electrode section of the electrosurgical accessory is too close to the distal end of the endoscope. If endobronchial combustion occurs, the patient may suffer adverse events, including internal burns in their airway or lungs. The related CAPA did not evaluate compatibility claims for all endoscopes and lasers.\nii. Design validation activities were not conducted with an understanding of the actual operating conditions for the Evis Exera Video Imaging System, used with your firm’s endoscopes for processing images. For example, design validation did not consider the conductivity of the electrolyte when it contained dust and moisture, nor did it consider the impact over time of water entering the scope during cleaning. This caused signal transmission problems and resulted in a significant number of complaints and MDRs for image erasure, image transition problems, and poor-quality images.\niii. Your firm failed to complete design verification testing after implementing a change to the 0.2 μm Water Filter (Part MAJ-2318) to demonstrate that the device meets established design requirements and acceptance criteria. This water filter is used in your OER-Elite and OER-Mini Reprocessors for cleaning and high-level disinfection of your flexible endoscopes, their accessories, and endoscope reprocessor accessories. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, requires design verification or validation for all changes. However, ECR ER00006389 (dated December 11, 2024) shows verification testing was incomplete. Document MAJ-318_DC00429244 establishes the requirements and acceptance criteria for the product, including a filter service life of at least one month; however, design verification and validation records did not demonstrate that the filter has a service life of at least one month.\niv. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, and Traceability Activities (OMBS W_7.3.3_03_002) require documentation of design traceability matrices. However, you have not implemented design traceability matrices for the following products: Evis Exera III Bronchovideoscopes, Evis Exera III Video System Center, Evis X1 Video System Center, Single Use Reloadable Clip Applicator, Endoscope Reprocessor, Evis Exera III Duodenovideoscopes. Without design traceability matrices there is no documentation demonstrating that all design requirements, including safety requirements, were properly verified and validated.\nThe adequacy of your firm’s response for (i) through (iv) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nNonconforming Product Violations – Brooklyn Park and Hinode facilities:\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\na. At the Brooklyn Park facility,\ni. Your firm reworked and distributed nonconforming Vizishot 2 FLEX (19G) devices without adequate justification that the rework addressed the cause of the nonconformance. NCR-00038111 was opened on July 30, 2025, to disposition nonconforming material subject to recall (RES 97303) for the detachment of the Vizishot 2 Flex 19G needle [laser cut hypotube (LCH)] after reported complaints and MDRs, including where the device may have contributed to a patient death during explant surgery to recover the detached needle. Your firm reworked product under NCR-00038111 and dispositioned passing products using an automated vision system for release, stating this minimized impact on any product safety, efficacy, or performance of the product\u002Fmaterial. However, the primary CAPA for the LCH ejection issues had not identified a root cause, and there were two additional CAPAs open related to the observed complaints (pebax material degradation and sheath snap lock not engaging), indicating other potential contributing factors to nonconformances. Additionally, your firm circumvented the ship hold in place under the NCR by changing the manufacturing date during rework, which allowed the release of those units.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203864 was opened and determined that the issue was linked to global processes GSOP‑00022 Global NC Management and GSOP‑00023 Global CAPA Management. The process related aspects of this observation are being addressed separately under Global CAPAs, CAPA-203799 and CAPA-204047. Your response acknowledged in CAPA 203864 that the eleven lots of product noted in NCR-00038111 underwent rework outside of your procedures. You reinstated the ship hold and quarantined all Vizishot 2 FLEX product. You executed product removal activities separately for Vizishot 2 FLEX (19G) devices, including a global removal decision made on December 11, 2025, with a corresponding 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203864, CAPA-203799 and CAPA-204047.\nii. Your firm failed to control all nonconforming Shockpulse Lithotripsy generators that were subject to recall due to a miswired component (RES 98360). NCR-00000670 was opened on June 1, 2022, to scope the units affected under recall FY23-OSTA-05, for the miswiring of the Shockpulse generator. This NCR did not include a scope of all affected devices, including 2 lots containing 21 and 25 sub-assemblies, 9 finished units, and 2 service units. NCR-00046008 was opened to address the scoping nonconformance.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203777 was opened and the root cause identified the need to evaluate process gaps in Global Nonconformance Management GSOP-00022, specifically related to scoping methodology, alignment with HHA\u002FFCA teams, and decision-making during NCR and Stop Ship activities. A Global Ship Hold for miswired ShockPulse generator units was initiated on November 12, 2025, and the recall scope was expanded on December 9, 2025, with an 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203777 and CAPA-204047.\nb. At the Hinode facility,\ni. Your firm failed to control nonconforming MAJ 210 single-use biopsy valves when devices failed durability testing during the investigation of CAPA 203270. This CAPA was initiated after receiving multiple complaints reporting fractures of the device, including MDR reportable events. Although devices failed testing during the complaint investigation, your firm did not initiate a nonconformance for these out-of-specification device failures. Your firm eventually initiated NCR-00030581 for the complaint trend, but not for the identified testing failures.\nWe reviewed your firm’s response and determined that it is not adequate. Your firm has initiated actions to address the MAJ-210 failures, including a shipping hold on the device, a plan to modify the device design, and an investigation into the complaint trend. Your response does not address why a nonconformance was not initiated when testing showed the product\u002Ffailed the durability specification per GSOP-00029 Global Complaint Investigation and was only later opened for the complaint trend. It is unclear if you plan to evaluate whether similar issues occurred for other devices and how you will ensure that complaint investigations result in CAPAs when appropriate.\nii. Your firm failed to control nonconforming devices with sterile barrier seal overlap defects that were found to impact seal integrity. A nonconformance (NCR-00025684) was initiated in March 2025 in response to observed defects in sterile seals from September 2024- January 2025. NCR-00025684 identified overlaps as a novel defect that was not included in your visual inspection procedures. CAPA-202690 concluded that because seal overlaps are a large wrinkle, inspectors trained to visually identify wrinkles would identify seal overlap defects. However, wrinkles and seal overlaps represent distinct sterile barrier defects. CAPA-203907 included a retrospective evaluation to demonstrate that existing visual inspection procedures were likely to identify seal overlaps, based on a blind test of engineers. However, this evaluation does not demonstrate that overlaps were identified at the time of the nonconformances.\nWe reviewed your firm’s response and determined that it is not adequate. You state that you are conducting an investigation and root cause analysis as part of your CAPA; however, this is in progress and the details of this investigation and corrective actions are not clear, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nProduction and Process Controls Violations – Brooklyn Park, Hinode, Aomori, and Shirakawa facilities\n3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\na. At the Brooklyn Park facility,\ni. Your firm failed to validate the heat sealing process for the (b)(4) Tray Sealer. The (b)(4) Tray Sealer (P4001467-001 Gyrus ACMI SN:01) Operational Qualification using Universal tray sealing nests, documented in Operational Qualification (OQ) Report D8201348-002 Rev AB, does not contain passing results for the challenge conditions at the high and low setpoints. The validation was intended to cover low setpoints of 200°F, 100 PSI, and 2.0 seconds and high setpoints of 265°F, 125 PSI, and 7.0 seconds. However, visual results showed all failures at the lower setpoints and all failures at the high setpoints for the Universal and PKS Omni products. Only the nominal settings (232°F, 115 PSI, 4.5 seconds) showed passing results, which do not match your current production setpoints (253°F, 118 PSI, 4 seconds).\nDuring the inspection, you re-executed the validation (D8201348-002, Revision AC). While this validation passed seal integrity and seal strength requirements at high and low challenge conditions, the deviation section notes that trays sealed at low settings had spottiness in the seal and trays from high settings had warp that would cause rejection during 100% visual inspection, demonstrating that the process is not capable of consistently producing conforming product throughout the acceptable setpoint ranges.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203841 to address the root cause of inadequate process for assessing procedure revisions that resulted in earlier validations (Operational Qualifications) not being updated to meet regulatory requirements. Specifically, you plan to transition from Process Validation GSOP-7.5-1 to Global Process Validation GSOP-00002. Your response indicates that the retrospective re-validation of the heat sealers is complete except for the (b)(4) sealer for the Universal Tray products and the (b)(4) sealer for the Powerseal vessel sealing product line. You are currently assessing the risks associated with products manufactured and distributed using the (b)(4) Tray Sealer, which failed the retrospective re-validation. Regarding the retrospective revalidation of the (b)(4) heat sealer used for the Powerseal product line you have noted the OQ failed to meet seal width acceptance criteria as detailed in the protocol, however, the OQ\u002FPQ testing will not be repeated at the current process settings (temperature, time, pressure). You have indicated that you will communicate with FDA regarding any actions taken based on the outcome of the completed HHA for distributed product and failed retrospective revalidation.\nii. Your firm failed to validate the heat sealing process for tray material PN0003356 (45cm PETG Tray line) on the (b)(4) sealer SN01. The OQ Report for (b)(4) BM3025-E2W2 for 45cm packaging (DN0010012) and PQ Report for BP (b)(4) BM3025-E2W2 for 45cm packaging (DN0010301) for this material and setpoints is for sealer (b)(4), which was decommissioned and removed from use in 2023. Your firm did not provide documentation showing this material was validated on the (b)(4) sealer or justification for equipment equivalency.\nIn addition, your procedure Process Confirmation for Sterile Barrier Sealing GWI-0704-07 Rev AE dated April 4, 2024, allows for abbreviated validation runs for \"equivalent or duplicate equipment.\" This procedure allows for equipment with the same manufacturer and model number to be considered equivalent, regardless of the year purchased or any other modifications made to the sealers. There is no additional justification or testing required to establish equivalency of the equipment.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203842 to address GWI-0704-07 REV AE, Process Confirmation for Sterile Barrier Sealing, and FM-7.4-3 REV AC, Sterile Barrier Sealing Confirmation, not aligning with GSOP-00002 REV AD, Validation Program, nor GSOP-7.5-1 REV BA, Process Validation. In addition, your response confirmed that the work instructions and form lacked objective evidence to justify equipment equivalency. You are in the process of completing a Health Hazard Assessment (HHA- FY26-071-A) to evaluate any risks associated with sterile barriers for distributed products.\niii. Your firm failed to operate your heat sealers at the validated setpoints used for the Powerseal vessel sealing products. Heat sealer numbers 19-11821 and 23-70915 are only calibrated for time at 5 seconds and 10 seconds, but the nominal setpoint is 3 seconds according to your procedure POWERSEAL MP: Tray Sealer Setup and Peel Test DN0044870 Rev AE. There is no documented justification on why this calibration is acceptable to demonstrate accuracy at the validated setpoint, or potential impact on packaging seal quality and sterile barrier integrity for the Powerseal products.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. For example, GSOP-7.18-1 REV AT, Control of Inspection, Measuring, and Test Equipment, does not ensure consistent implementation of calibration across the intended use range. Additionally, the supporting work instruction, GWI-0718-03 Rev AB Completing a Calibration Request Form, lacked sufficient clarity to implement the requirements of GSOP-7.18-1. Your firm plans to revise GWI-0718-03 to improve clarity, include a requirement to notify external calibration vendors of specification changes, and ensure calibration point selection is documented with clear rationale. The calibration request form (FM 7.18-1) will also be updated to provide traceability, reference the revised work instruction, and ensure alignment with validated set points. GSOP-7.18-1 will be updated to explicitly require calibration points to cover validated set points, document rationale for selected calibration points, and mandate re-evaluation of calibration points when validation parameters or process conditions change.\nb. At the Hinode facility, your firm failed to adequately validate critical process parameters of the (b)(4) to the heat sealing process. An Operational Qualification (OQ) for the heat sealing process for the MAJ-210 Single Use Biopsy valve was conducted in July 2024, after (b)(4) to the heat sealing packaging process to address seal wrinkle defects; however, the process parameters and validation are inadequate. The process parameter range shown in the Operational Qualification lists a lower set value of (b)(4) liters\u002Fminute and a higher set value of (b)(4) liters\u002Fminute, which is flawed because the \"lower\" limit exceeds the \"higher\" limit. The OQ documentation does not detail how the (b)(4).\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm completed an investigation and root cause analysis under CAPA-203908, and as a result, updated GSOP-00002 to provide instruction for how to identify process parameters that require control in a validated process. Your firm is also planning to conduct a review of all validated manufacturing processes in place at the facility to confirm that process parameters are adequately controlled.\nc. At the Aomori facility, your firm failed to validate the cleaning process for metal components used in the production of the HX-610 EZ Clip (hemostasis clip) made according to procedure DC00736661 to remove dirt or other particles. For example, the procedure doesn’t include defining and validating all critical process parameters with acceptable ranges including cleaning solution (type, concentration, temperature), immersion time, drying parameters, and visual inspection criteria.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm initiated a Global Ship Hold (ID.530) and CAPA 203781 as part of your corrective actions.\nd. At the Shirakawa facility, your firm did not adequately validate the testing process used in the production of UHI-4 Insufflation Unit where the results could not be fully verified by subsequent inspection and testing. For example, the software-driven functional testing process used to evaluate device performance was not adequately validated to ensure that it consistently produced devices meeting specifications in that it did not include appropriate test cases to demonstrate user requirements met acceptance criteria.\nThe adequacy of your firm’s response cannot be determined. Your response states that process validation deficiencies are being addressed through ongoing remediation activities and global CAPA efforts, and that validation activities are planned or underway to ensure processes consistently produce conforming devices. You have not provided objective evidence demonstrating that process validation activities have been completed or that affected processes have been validated, including validation protocols, reports, or data demonstrating that processes consistently produce conforming devices.\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). For example,\na. At the Brooklyn Park facility, your firm failed to establish adequate process monitoring to ensure validated sealing processes for the heat sealers used for the Powerseal vessel sealing and Miscellaneous Urology products continue to meet specifications throughout production. Per procedure Peel Strength Test Method for Trays and Pouches D5100327-001 Rev AL, the heat sealer for Powerseal products requires peel strength testing to be completed at the beginning and the end of a lot. The process monitoring does not demonstrate that the heat sealing meets specification throughout the manufacturing operations, nor does the process monitoring demonstrate the machine was fully set up and operational when heat sealing process for a lot occurs over multiple days. The DHR for Lot (b)(4) notes that the sealing took place over two days. However, the process monitoring was conducted according to the procedure and only had a single tray sealing sample for testing at the start of the lot on June 20, 2025, and at shutdown on June 23, 2025. Your firm’s procedure for set-up, “POWERSEAL MP: Tray Sealer Setup and Peel Test” DN0044870 Rev AE states in (b)(4) for the temperature to stabilize prior to use; however, there is no indication that this was done at the start of the second production day. This step is identified as critical, according to your firm’s Symbol Index in DN0044870. Additionally, the sealing procedure, D5100327-001, is also used for the Miscellaneous Urology line and the Cutting Forceps line and requires the pull strength testing be performed at the beginning and end of every day. Your firm has not assessed whether critical parameters remain in control during all production activities, including after equipment set up on subsequent production days and when processing multiple products with different configurations on the same day. Finally, your procedure Process Monitoring - Packaging Data Review D0300188-001 Rev AK states in section 4, step 2 that a process control analysis should include an evaluation of lower and upper control limits. However, these limits are not currently calculated by your firm, and the upper and lower bound specifications are used instead. There is no documented statistical rationale for this decision.\nThe adequacy of your response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203867 to capture corrective actions such as the retraining of employees on process monitoring requirements to include peel testing at the beginning and end of each lot for the affected product lines. You note that you will revise FM-7.5-10, Control Plan requirements with risk assessments to define and align appropriate sample sizes and frequency monitoring. Ongoing actions as part of CAPA-203867 include defining, establishing, and implementing risk-based requirements in Process Controls, GSOP-7.5-4, for ongoing validated process monitoring. You have not performed an assessment of potentially affected units in the field and any ongoing post market monitoring to assess any risks of commercially distributed product. Your firm plans to review all process monitoring plans subject to D0300188-001 Rev AK, to ensure that such plans include justified control limits as well as specification limits. Your firm has not implemented calculated control limits.\n5. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example,\na. At the Hinode facility, your firm failed to revalidate the heat sealing process after implementing process changes in response to seal defects in the MAJ-1555. CAPA-202690 identified the cause of the overlap defects as a misalignment of the bag surfaces when the bag enters the sealing operation to create the sterile barrier. To address this issue, your firm added a sensor to control opening and closing of the extraction arm and receiving arm, which impacts bag surface alignment during sealing. Operational qualification or performance qualification was not performed after these changes to validate that the modified process continued to meet specifications and quality attributes.\nThis is a repeat violation from our 2023 Warning Letter issued to the Hinode facility.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Following an investigation and root cause analysis under CAPA-203919, your firm revised GSOP-00002 to provide additional instruction on how to assess whether a manufacturing change triggers revalidation of the manufacturing process, and your firm established the guidance document GREF-00197 to provide revalidation guidelines. The verification of effectiveness of these actions is not yet complete, and it is unclear whether concerns with process validation have been adequately addressed for other products subject to sealing at your facility. Your response stated that all seals are subject to visual inspection and, therefore, any nonconforming seals would be detected prior to release; however, visual inspection is not a substitute for adequate process validation.\nCorrective and Preventive Action Violations – Brooklyn Park, Shirakawa, Hinode, Hachioji, Hamburg, and Aomori facilities:\n6. Failure to identify the action(s) needed to correct and prevent the recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically,\na. At the Brooklyn Park facility,\ni. Your firm failed to identify corrective actions that address the full scope of multiple Line Clearance Control nonconformances on the Miscellaneous Urology Production Line. CAPA-201354 was opened on August 31, 2023, and included automated verification steps and automated inspections on the lines. However, the CAPA only included implementing the automated verifications for the Soltive laser fibers and did not address corrections for any of the other products made on the Miscellaneous Urology production line, including nonconformances associated with missing syringes in the Irri-Flow line or incorrectly labeled RB Electrodes, as listed in the CAPA Initiation Information.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened and is developing an action plan for CAPA-203705, which revealed that the Miscellaneous Urology product line lacks sufficient process controls and robust automation and further noted that this technical gap creates a potential for the recurrence of nonconformances. While a quality plan was developed per GSOP-5.5-1 Rev AB Quality Plans to address the remaining implementation requirements for this line, the execution of these corrective actions occurred outside of the formal CAPA framework and did not include verification of effectiveness.\nii. Your firm failed to identify corrective actions to address ongoing Supplier Quality Performance rate failures for Vizishot endoscopic aspiration needle slider components. CAPA-202086 was opened on August 15, 2024, to address the Supplier Quality Performance rate (SQ3) not meeting the KPI objective for more than three months in a row. The investigation identified root causes related to supplier capability gaps, including inadequate manufacturing processes, insufficient purchase order review, and delayed drawing revisions. A separate NCR-00028865 due to a SQ2 KPI signal (Part Failure Rate) was escalated to CAPA-202086 on May 20, 2025. CAPA-202086 was closed on October 16, 2025, with no corrective or preventive actions taken, and the SQ3 KPI was eliminated without addressing the underlying quality problems or providing a rationale for no action taken.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203869 confirmed that the early closure of CAPA-202086 occurred because GSOP-00023, Rev AF Global Corrective Action and Preventive Action Management and GWI-00014, Rev AB CAPA Management Work Instruction – Agile did not clearly define requirements for early closure rationale or verification of linked records. An action plan is being developed but has not yet been implemented for CAPA-203869.\niii. Your firm identified a root cause for the blue ring on the Powerseal vessel sealing device detaching from the rotation knob during use (operator error during assembly) but failed to implement corrective actions consistent with that root cause. CAPA-200547 was opened on July 22, 2022, for the detachment, which resulted in a recall (RES 90788). The CAPA found the root cause was an operator error during assembly and not the out of specification supplier component originally documented in the HHA FY23-OSTA-07. However, the scope of corrections for the recall were based on supplier component lots and the scope was not expanded to include all devices assembled during the period when the operator error occurred, allowing potentially defective devices to remain in distribution.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203868 and noted that the Health Hazard Assessment (HHA) and Field Corrective Action (FCA) for CAPA-200547 were not reassessed after the identified root cause changed, as procedure GSOP-00023 Rev AF Global Corrective Action and Preventive Action Management did not define requirements for re-evaluation when new investigation findings modify the identified failure mode. Your firm indicated that since the process is shared among sites, the process related aspects of this observation are being addressed separately under Global CAPA-203799. An action plan is being developed but has not yet been implemented for CAPA-203868.\nb. At the Shirakawa facility, your firm failed to identify corrective actions needed to correct and prevent the recurrence of known quality problems associated with the UHI-4 insufflation system. CAPA-200872 identified pressure sensor failures as the root cause of front panel display issues; however, you relied on prior corrective actions (SCAR-Shirakawa-152-06) and concluded that the risk remained acceptable despite 325 complaints. Your firm failed to implement adequate corrective actions to address supplier control failures, complaint trending deficiencies, and design and risk management process gaps that allowed these repeated failures. As a result, your supplier control processes failed to prevent defective components from entering production and your quality system failed to detect and escalate recurring defects.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response noted planned corrective actions, including reliance on global CAPA procedures (GSOP00023) and proposed improvements to complaint trending, supplier controls, and risk management processes. You indicated that CAPA deficiencies continue to be addressed through ongoing local and global CAPAs and that you have initiated additional CAPAs (e.g., CAPA-203879, CAPA-203856, CAPA-203877).\nc. At the Hinode facility, your firm’s CAPA procedures failed to ensure that corrective actions addressed the root causes and prevented recurrence. Between October 2022 and September 2025, three CAPAs (CAPA-200736, CAPA-201399, CAPA-203398) were opened for wrinkle defects in sterile barrier seals across five products (MAJ-2315, MAJ-1555, MAJ-209, MAJ-210, MAJ-287). Each CAPA identified inadequate process validation as a contributing factor, yet none implemented corrective actions to address the underlying validation methodology deficiency that allowed critical process parameters to be missed. For example, CAPA-203398 identified the root cause as \"Method Inadequate validation\" but did not implement corrective actions to address the validation failure. CAPA-201399 identified wrinkles across multiple products but concluded that inspection would remove nonconforming product, without implementing corrective actions to the validated processes producing defects. CAPA-200736 (b)(4) to address wrinkles but did not investigate why (b)(4) identified in initial validations. Wrinkle defects may create channels for microbial contamination.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm characterized the pattern of recurring CAPAs for seal defects as representative of continuous improvement, citing decreases in defect rates, and your firm characterized the sealing processes as “under control”. However, ongoing nonconformances were initiated for wrinkles even after CAPAs were initiated. Your responses do not appear to address why your CAPA process allowed the same problem to require three separate CAPAs over three years without implementing corrections to the validation methodology.\nd. At the Hachioji facility, your firm failed to identify corrective actions for CAPA 201212, initiated June 20, 2023, in response to an FDA Additional Information request related to a patient death following use of the Evis Exera III Bronchovideoscope. Your CAPA documented that your firm failed to conduct design verification for use conditions and accessory compatibility claims in your IFU; however, no corrective actions were taken to address these design control deficiencies and the suspension of shipping was lifted on July 28, 2023. Your investigation revealed that your firm received 210 similar complaints and your investigation was not completed until November 14, 2025, over two years after CAPA initiation and your decision to continue shipping the devices.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\n7. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example,\na. At the Brooklyn Park facility,\ni. Your firm implemented actions to address root causes of a Vizishot II component mix-up without classifying them as corrective actions and verifying their effectiveness. CAPA-203041 was opened on June 30, 2025, for the use of the 21G slider components instead of the 22G on the Vizishot II NA-U401SX-4022 line. The Early Closure memo states that “operators were retrained on the line clearance procedure GWI-0705-16 and (b)(4)” and “the (b)(4) was modified to restrict access to the sides…”. Neither of these actions were considered a corrective action, nor was a verification of effectiveness conducted to ensure these actions prevented recurrence of the component mix-up.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203041 was prematurely closed because actions taken under the NCR were misclassified as corrections, even though they addressed root-cause-level factors that required corrective actions and verification of effectiveness (VOE). GSOP-00023 Rev AF Global Corrective Action and Preventive Action Management did not explicitly distinguish correction from corrective action within the CAPA workflow, which contributed to the omission of VOE. Your firm also indicated an action plan is being developed but has not yet been implemented for CAPA-203705.\nii. Your procedures, Quality Planning QSP-5.5 Rev AL and Quality Plans GSOP-5.5-1 Rev AB, have not adequately defined when quality plans contain corrective or preventive actions and should contain a verification that changes are effective and do not adversely affect devices. These procedures do not adequately define the difference between a quality plan and a corrective or preventive action. Additionally, during the inspection your firm had 54 quality plans open, including multiple plans intended to address backlogs in the complaint system and late MDRs. These quality plans directly address deficiencies in your quality system and are also being referenced within and in conjunction with CAPAs addressing the same issues.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203836 determined that the current procedures lack defined criteria for determining when a Quality Plan is not appropriate and a CAPA is required and does not require oversight to ensure appropriate use and completion tracking of Quality Plans. The Quality Management Review Presentation Template GTMP-00077 was revised to require that quality plans be reviewed as part of the Quality Management Review process. The scope of affected quality plans that lacked VOE was not provided. An action plan is being developed but has not yet been implemented for CAPA-203836.\nb. At the Shirakawa facility, your firm failed to verify that corrective actions implemented for overpressure events for the UHI-4 Insufflator were effective in preventing recurrence. For example, CAPA-200872 (opened February 2023) relied on prior corrective actions related to pressure sensor failures and concluded that these actions were effective without demonstrating that they prevented recurrence of similar defects or adequately mitigated risk in distributed devices. CAPA-201353 (opened August 2023) was subsequently opened to address overpressure events associated with the UHI-4 insufflation system only after significant adverse events occurred, including cardiac arrest and possible gas embolism, and resulted in a Class I recall (RES 92932). Your CAPA activities did not demonstrate that corrective actions were verified or validated to ensure effectiveness in preventing recurrence of overpressure-related failures.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Several CAPAs remain open, and you have not demonstrated that corrective actions have been verified or validated to ensure effectiveness or to prevent recurrence of similar defects, including overpressure-related failures.\n8. Failure to analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example,\na. At the Brooklyn Park facility, your firm is using statistical methods for complaint trending without a documented rationale for the appropriateness of those methods. Complaint Trending Attributes, Statistical Method, and Trending Rules GREF-00157 Rev AA defines your complaint quality data analysis method of using median values and recalculating control limits each month. During the inspection your employees noted the calculations used were originally chosen in 2020, due to COVID-related data irregularities. However, you acknowledged that your firm does not still see these data irregularities and confirmed your firm has not documented a re-assessment or other justification for why this analysis method is still appropriate. The use of median values and monthly recalculation of control limits (that may not be appropriate for post-COVID data) may mask trends or delay detection of increasing complaint rates, potentially allowing serious device problems to persist undetected.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203873 determined that Olympus lacks a global procedure or guidance for statistical techniques, resulting in the absence of defined expectations for the consistent implementation of statistical methods. An action plan is being developed but has not yet been implemented for CAPA-203873.\nb. At the Shirakawa facility, your firm did not adequately analyze quality data, including complaints and adverse event information, to identify causes of quality problems. For example, you received a high volume of complaints related to pressure sensor defects and front panel failures associated with the UHI-4 insufflation system (including 325 complaints between November 2020 and October 2022), yet you did not appropriately trend or escalate these data to identify a cause or initiate CAPA in a timely manner. Additionally, you were aware of pressure sensor defects as early as 2018–2021 but did not reassess risk or investigate the increased occurrence of these defects in distributed devices. A CAPA was not initiated until FDA inquiry, indicating that your quality system did not effectively analyze available data sources, including complaints, supplier information, and risk management records.\nWe reviewed your firm’s response and determined that it is not adequate. Your response states that CAPA deficiencies are being addressed through a combination of local and global CAPAs, including local CAPA-203879, CAPA-203856, CAPA-203850, and global CAPA-203789, CAPA-203525, and CAPA-204150. You indicate that updates to procedures, including GSOP-00023 (CAPA), GSOP-00033 (complaint trending), GSOP-00069 (supplier quality agreement), and GSOP-00079 (supplier corrective action), have been implemented or are in progress. You also state that retrospective reviews of complaint data and supplier corrective action requests have been conducted. Several CAPAs remain open and root cause investigations and corrective actions are ongoing. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific deficiencies have been adequately addressed. Your response further confirms that complaint trend signals were not adequately identified and that supplier-related defects were not appropriately evaluated for field impact at the time they were identified. You have not provided sufficient objective evidence demonstrating implementation or effectiveness of corrective actions, including completion of investigations, verification of corrective actions, or sustained improvements to your CAPA system.\nc. At the Hamburg facility, your firm’s complaint trending failed to include all complaints as required by your procedure. Trending Attributes, Statistical Method, and Trending Rules GREF-00157 Rev AA, section 4.4.2 states “trending will be based on the value of monthly data (i.e. actual number of open complaints per month).” However, trend signal information (TS-1224-WA50042A) for your video telescope (model WA50042A) only includes the trending of MDR reportable complaints and does not include non-reportable complaints.\nWe reviewed your firm’s response and determined that it is not adequate. Your response did not include an assessment of how the lack of trending of non-reportable complaints may impact already distributed product. For example, if the complaints reveal quality problems that may require correction or removal to address.\nd. At the Aomori facility,\ni. Your firm failed to adequately analyze quality data to identify causes of nonconforming product. CAPA-201434, which was initiated to address reports of deformed wires for the Single Use 3-Lumen Sphincterotome, incorrectly identified the root cause as “shortcomings in work procedures” during outsourcing, failing to recognize inadequate design transfer to production specification as the actual cause. Per the CAPA scope, the corrective actions only applied to products distributed to the Japanese market and were not implemented for devices distributed to the U.S. market. It was noted during the inspection that the CAPA task (Task 10012651) assigned to correct the manufacturing process for products destined for the U.S. was cancelled because the products are subject to FDA 510(k) and it would have taken longer to implement the changes which would “prolong the period until the CAPA closes.” Your firm received over 1000 complaints for this device failure, including 24 MDR reportable events.\nii. Your firm failed to conduct a timely and adequate analysis of complaint data related to potential causes of nonconforming product for the Thunderbeat 5 mm Front-actuated Grip Type S. Your firm received over 1900 complaints between September 2021 and September 2024, including 1583 that were MDR reportable. CAPA-201438 was initiated on October 18, 2023, but no action was taken as the Health Hazard Evaluation was canceled on January 31, 2024, because it was deemed not necessary based on complaint incident rates and without considering the potential harm to patients. A recall (RES 95950) was initiated on November 25, 2024, over a year later.\nThe adequacy of your firm’s response for (i) and (ii) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nAcceptance Activities Violations – Brooklyn Park and Shirakawa facilities:\n9. Failure to establish and maintain procedures for acceptance of incoming product, as required by 21 CFR 820.80(b). For example,\na. At the Brooklyn Park facility, your firm failed to conduct statistical calculations required to demonstrate lot acceptability in accordance with your procedure. Receiving Acceptance GSOP-7.11-1 Rev AT uses a variable sampling plan for receiving inspection of part number 0000315-TAB, according to Inspection Procedure for 0000315-TAB JAW ASSEMBLY, MACHINED, INNER, POWERSEAL CURVED JAW B DN0040655 Rev AE. However, your receiving inspection for each length of this part (PN 0000315-001, 0000315-002 and 0000315-003) does not include calculation of your standard deviation, kLSL, and kUSL as required by GSOP-7.11-1. Additionally, your acceptance procedure for Powerseal Curved Jaw B only includes a specification for sample calculation for dimension 9 but does not document a calculation of the maximum standard deviation (MSD) for any other dimension as required. Finally, your Supplier D also uses the sampling plan, but does not provide you with their standard deviation, kLSL and kUSL calculations. The calculations for standard deviation, lower controls limits and upper control limits are part of the variable sampling plan that demonstrate the acceptability of the lot.\nYour inspection procedure also allows for CMM measurements to be re-tested by another inspector if they do not pass initially. This was done for 8 of the 10 samples in the FAI Inspection Request for part number 0000315-002, dated March 20, 2025. The only rationale recorded was \"Believed fixture incorrect.\" Our inspection also found that retesting had occurred on all of the most recent receiving records for all sizes of the 000315-TAB. Part Number 0000315-001 was inspected on October 23, 2025, and the record includes failing CMM results for 5 of the 10 parts, as well as the retested data, but the parts were accepted into inventory. When our investigator communicated this to your employee, it was noted that this lot was accepted by mistake and NCR-00048701 was opened to contain the nonconforming material.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203866 was opened to capture corrective actions and noted that GSOP 7.11-1 Rev. AU, Receiving Acceptance, and the inspection procedures did not define the statistical requirements, resulting in incomplete evaluation of incoming product and acceptance of parts without proper statistical justification. Your response noted that you have updated the inspection procedures for all parts subject to ANSI\u002FASQ Z1.9 to require inclusion of sample size rationale for critical dimensions and to ensure that data is provided by their suppliers. Your firm plans to conduct a retrospective review of inspection records from the past 2 years for failed dimensions without a record of appropriate retest or passing results. Based on the results of the review you will take appropriate action; however, it is not clear what those actions would include, nor if the actions will include a risk assessment for product that has been distributed.\nb. At the Shirakawa facility, your firm failed to identify defective components used in the UHI-4 insufflation system during acceptance activities. For example, defective pressure sensor components were not identified through incoming inspection or acceptance testing prior to use in manufacturing. As a result, nonconforming components were incorporated into finished devices, contributing to reports of device malfunctions and adverse events received by your firm.\nThe adequacy of your firm’s response cannot be determined. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response states that improvements to incoming acceptance activities will be implemented as part of broader corrective actions, including updates to ensure that purchased materials meet specifications. However, you have not provided sufficient detail demonstrating that revised acceptance activities have been implemented or are effective in detecting nonconforming components.\nPurchasing Controls Violations – Brooklyn Park, Shirakawa and Hamburg facilities:\n10. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example,\na. At the Brooklyn Park facility,\ni. Your firm’s supplier controls procedure (GQS-00013) does not ensure that supplied product that cannot be fully verified by subsequent inspection and test is validated with a high degree of assurance and conforms to specified requirements. On December 4, 2023, your firm issued SCR-0000649 for an increased rate of complaints for broken welds in the ESG PK Cutting Forceps (model PK-CF0533), occurring in the supplied bottom and top jaw assemblies (part numbers P5700259-001 and P5700260-001, respectively). Supplier A determined the cause of the weld breaking was a sub-supplier, Supplier B. In SCR-0000649, Supplier A documented that Supplier B stated the welding process \"could not be controlled or validated.\" Your firm established increased inspection rather than requiring validation or changing suppliers. This complaint trend resulted in a recall (RES 93842) in December 2023. This unvalidated welding process has resulted in weld failures during patient use, creating risk of foreign bodies in patients assessed at Critical (S4) severity and High (S5) probability. Similar welds are also performed by Supplier B for your Halo and Cutting Forceps. Approximately 4,600 units with similar unvalidated welds have been distributed. During the inspection, your firm initiated an NCR and a Global Ship Hold.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened to address the failure to ensure welding performed by the supplier was validated. The CAPA root cause investigation identified that the QAA template used to finalize the Supplier Agreement back in 2014 did not incorporate process validation requirements for suppliers and their Sub-Tier suppliers. Moreover, the Global QAA templates GTMP-00021 Rev AB QAA Template for Component Suppliers and GTMP-00022 Rev AB QAA Template for Finished Device Suppliers lack specificity on sub-tier control for process validation. All impacted product remains on Global Ship Hold (ID 476), and you have halted the manufacture of affected product. The FCA board reviewed and decided to conduct a removal of the impacted products. Your response stated you would submit a Correction and Removal report in compliance with 21 CFR Part 806 requirements. Although an expansion of the recall is being performed, it has been over 2 years between awareness (December 4, 2023) and recall decision (February 3, 2026). Your firm has not explained the delay or assessed patient harm during this period.\nii. Your firm accepted failing process capability data after components were remeasured without justification. SCR-0000166 was issued to Supplier C for out of specification components. The investigation led to two design changes to the mating parts used in the Powerseal vessel sealing device: the blue ring (part PN0013810) and the overmolded rotation knob (part PN0013804) and resulted in a class II recall (RES 90788). You accepted first article inspection that included Supplier C “Validation Documents Submission” where parts were remeasured with passing results, “Ppk’s for Cav 2 on PQ1 was right at 1.39 and PQ2 was 1.36 failing the Ppk requirement per protocol of 1.39. 2 parts were remeasured and Ppk came into requirement.” There is no justification for why these remeasurements were considered appropriate.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203872 is ongoing, and the root cause investigation identified that the supplier procedure permitted data remeasurement without documented justification and did not define requirements for documenting the rationale or controls associated with remeasurement activities. In addition, GSOP-00086 Rev AA Global External Product Qualification lacked requirements for justification of remeasurement. Your firm’s response notes that you have planned the process to requalify Supplier C against new global procedure requirements by March 27, 2026, including a new Quality Agreement. The impact on released product has not been evaluated since this will involve the remeasurement at incoming testing after you have updated GSOP-00086 that governs the conditions and permissibility for remeasurement. Your firm has not provided interim results or identified how many additional components may be affected. Your response should also include a retrospective review of similar supplier processes that pose a potential for patient safety risk.\niii. Section 3.5 of First Article Inspection GSOP-7.11-2 Rev AG, allows suppliers on risk improvement plans with documented quality concerns to conduct first article inspections without additional verification by your firm. For example, Supplier D has been on a risk improvement plan since January 21, 2025, but a \"Supplier conducted FAI\" for part number 0000315-002, delivered on or before March 5, 2025, and used in the Powerseal vessel sealing device. The process is currently controlled by the two procedures Global Supplier Risk Improvement GSOP-00045 Rev AB and Global Supplier Risk Improvement with Action Plan GWI-00002 Rev AB. Despite the supplier providing out-of-specification components and being on a supplier risk improvement plan, your firm failed to consider the appropriateness of the supplier performing first article inspection measurements following a design change or when implementing a new component.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203866 identified that GSOP-00045 Rev AB Global Supplier Risk Improvement does not require evaluation of internal inspection plans when supplier risk improvement plans are issued or revised in response to changes in part failure rate. Additionally, the procedure lacks defined linkage between supplier risk improvement plans and corresponding receiving inspection requirements. It is not clear from your response whether there is nonconforming product in the field associated with suppliers who are on a heightened inspection status or risk improvement plan and who conducted their own supplier first article inspections.\niv. Supplier A has not adequately validated their Performance Qualification Report PQR-10774 Rev A for part number P5700138-001, used to support the weld tensile strength in your legacy Cutting Forceps. According to your firm’s Engineer, the worst-case weld is considered the shortest weld of the group, as the welds all have to meet a minimum weld pull strength of 30 lbs. However, part P5700138-001 has a weld length specification of 0.10 ± 0.02 inches, while parts P5700211-002 and P5700210-002 have a shorter weld length specification of 0.081 ± 0.02 inches.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened and a Health Hazard Assessment (HHA) FY26-062 was conducted to evaluate potential field action. On February 3, 2026, the FCA board reviewed and decided to conduct a removal of the impacted products in the Cutting Forceps product line (RES 98454). Olympus completed the review of validations for Supplier A to determine conformance with Global GSOP-00002 Rev AD Validation Program and GWI-00112 Rev AA Global Standards for External Product Qualification for worst-case trials with documented rationale. The review determined that three (3) components manufactured by Supplier A require additional process validation. The review, however, was limited to products with an active production schedule. Products that have reached end-of-life and are in the process to be discontinued were excluded from the scope (jaw assemblies, ESG Cutting Forceps, Halo, Everest 5mm Cutting Forceps, and PKS Cutting Forceps). It is not clear from your response whether there is product within expiry date that is still in commercial distribution. Your firm will complete a review of applicable supplier-manufactured components documentation, through collaboration with suppliers to identify potential validation gaps.\nb. At the Shirakawa facility, your firm did not adequately control suppliers to ensure that components used in the UHI-4 insufflation system met specified requirements. For example, pressure sensor defects associated with supplier-provided components were identified; however, your supplier control processes did not prevent nonconforming components from being incorporated into finished devices. Your CAPA investigations did not adequately evaluate why supplier controls were ineffective or ensure that appropriate corrective actions were implemented to prevent recurrence of similar supplier-related defects. Root cause analysis identified gaps in supplier change control procedures and audit processes, including lack of mechanisms to verify supplier changes against specifications.\nThe adequacy of your firm’s response cannot be determined. Your response states that supplier control deficiencies are being addressed through local and global CAPAs, including CAPA-203856 and CAPA-203789, and that supplier oversight processes will be enhanced through updated supplier quality agreements and risk-based supplier requalification activities. You also indicate that procedures, including GSOP-00079, have been updated to require assessment of field impact for supplier-related defects. However, investigations into supplier-related root causes remain ongoing, and corrective actions have not been fully implemented. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific supplier control deficiencies have been adequately addressed. You have not provided objective evidence demonstrating that revised supplier controls are effective in preventing recurrence of nonconforming components.\nc. At the Hamburg facility, your firm failed to ensure that purchased services conform to specified requirements. Your firm hired HCL Technologies as part of “(b)(4)” to reduce the backlog of complaint investigation and closures; however, your firm did not evaluate HCL Technologies on the basis of their ability to provide contract services to meet specified quality requirements, including their ability to provide qualified staff to perform quality assurance responsibilities. Your firm’s contract services included approximately (b)(4) temporary personnel to investigate and close complaint files. Your firm was unable to demonstrate that the contract personnel received product specific training.\nWe reviewed your firm’s response and determined that it is not adequate. Your firm initiated CAPA-204033 and CAPA-204034. Your firm indicated that your root cause investigation determined that there was no central governance defining shared services requirements within the Quality Management System (QMS) and that as a result, roles and responsibilities between Legal Manufacturers, Global QMS functions, and shared service owners were not consistently defined or understood, leading to fragmented accountability for end-to-end oversight. Your firm is developing a corrective action plan; however, you have not provided corrective actions demonstrating how you will ensure contract personnel are qualified and trained in the services they will perform.\nRecords Violations – Brooklyn Park and Shirakawa facilities:\n11. Failure to review, evaluate and investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example,\na. At the Brooklyn Park facility, your firm's procedure, Complaint Investigation Tiers and Investigation Activities GWI-0809-10 Rev BB, does not require investigations to be completed on complaints in investigation Tier 3. For example, complaints C22097460, C22184070, C22248777, C22249599, C22259835, C22279317, C22332770, and C22387391 all state in the investigation summary that the complaints are “non-PAE, Tier 3 codes. No investigation is required,” in the “Evaluation Result” section (PAE stands for potential adverse event). There is no documentation of a complaint investigation or reference to where an investigation for this failure has previously been investigated or other similar rationale for why this investigation is not required. Lack of investigation only allows trending on this subset of complaints based on date of receipt and device model. After transitioning to your current Trackwise system in November 2024, you indicate you no longer use a tier system; however, your trending is based on 24 months of historical data which is still limited by the lack of investigation results on potential device performance issues.\nWe reviewed your firm’s response and determined that it is not adequate. Your response does not address the failure to investigate complaints.\nb. At the Shirakawa facility, your firm failed to adequately investigate complaints involving serious adverse events to determine whether device malfunction contributed to the reported outcomes. For example, complaints associated with UHI-4 insufflation systems, including reports of overpressure events and serious adverse outcomes such as cardiac arrest and possible gas embolism, were not fully evaluated to determine whether device malfunction contributed to the reported events. Your complaint investigations did not consistently incorporate available device performance data to determine whether the device met specifications during use. For example, complaint CN-249953 reported a death due to gas embolism during use and included the device event log retrieved by the Field Service Engineer; however, this log was not reviewed as part of the investigation.\nWe reviewed your firm’s response and determined that it is not adequate. You state that complaint handling and trending processes have been improved through implementation of GSOP-00033 and that retrospective reviews of complaint data have been conducted to assess whether complaint signals were appropriately escalated. You also indicate that CAPA-203879 was initiated to address missed complaint trend signals. However, CAPA-203879 and related investigations remain ongoing, and you have not provided sufficient objective evidence demonstrating that complaint investigations are comprehensive or that systemic issues are consistently identified and escalated.\nMedical Device Reporting (MDR) Violations\nOur inspection at your Hamburg facility also revealed that your firm’s resection sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n12. Failure to report the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that the firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included in Complaints CN-182867 and CN-184790 reasonably suggests that your firm’s resection set malfunctioned (e.g., broken ceramic insulation) while in use. A serious injury MDR 2951238-2019-00404, submitted by your firm on February 1, 2019, documents a serious injury resulting from the same malfunction involving the same device. That malfunction would be likely to cause or contribute to a death or serious injury if it were to recur, as evidenced by the serious injury MDR 2951238-2019-00404. Accordingly, the referenced adverse events represent MDR-reportable malfunctions as defined under 21 CFR 803.3. Your firm became aware of complaint CN-182867 on February 13, 2025, and submitted the corresponding MDR 9610773-2025-06509 on October 20, 2025; and became aware of CN-184790 on February 12, 2025, and submitted the corresponding MDR 9610773-2025-04016 on June 16, 2025. These two MDRs were submitted beyond the required 30-calendar-day reporting timeframe.\nThe adequacy of your firm’s response cannot be determined at this time. The response states that your firm initiated CAPA-204035 to address late reporting, including revising procedures to correctly document event dates and the dates your firm became aware of the events. However, supporting evidence demonstrating completion of these corrective actions was not provided because the corrective actions are still ongoing.\nFailure to address any violations of the FD&C Act may result in the FDA refusing admission of the devices manufactured by your firm into the United States under section 801(a) of the FD&C Act, 21 U.S.C. § 381(a). Devices under this authority that appear to be adulterated may be detained or refused admission.\nYour firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facilities to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspections conducted between October 2025 and December 2025 were conducted pursuant to the QS Regulation, which was in effect at the time of the inspections. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nIn addition, we also note the following comments:\n1. In response to three prior warning letters issued to your firm in 2022 and 2023 (including the Hachioji and Hinode facilities), your firm implemented new global procedures, including complaint handling, MDR, and CAPA procedures. Review of these procedures found the roles and responsibilities of manufacturing sites versus your global remote corporate entity have not been clearly defined, including, for example, how your firm will assess that site specific quality issues have been resolved, and how your global CAPA process will provide oversight and ensure correction and prevention of repetitive quality issues within and across your global facilities that follow these procedures.\n2. Regarding the inspection of Olympus Corporation of the Americas, located at 3500 Corporate Pkwy, Center Valley, PA 18034, FEI 2429304, from November 18, 2025, to December 16, 2025: Multiple complaint files reviewed during the inspection were found to contain insufficient documentation of complaint intake, evaluation, and investigation conclusions. Complete complaint files provide your firm with critical information to detect and trend medical device failures and to make reportability decisions.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Kristina Donohue at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS #729208” when replying. If you have any questions about the contents of this letter, please contact: Beckilyn Dorsey at Rebecca.dorsey@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMichael J. Hoffmann\nDirector\nOffice of Health Technologies 3 - Gastrorenal, ObGyn,\nGeneral Hospital, and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nTodd Brill, US Agent, Gyrus ACMI, Inc., (b)(6)@Olympus.com\nDaniel S. Sampson, Senior Director of Operations, (b)(6)@olympus.com\nRichard Reynolds, President, Olympus Corporation of the Americas, (b)(6)@olympus.com\nHiroaki Hosoi, President, Aomori Olympus, (b)(6)@olympus.com\nKota Ishibiki, President, Olympus Medical Systems Corporation (b)(6)@olympus.com\nShinji Egami, Senior Director, Olympus Medical Systems Corporation, Hinode, (b)(6)@olympus.com\nSeiji Morishita, President, Shirakawa Olympus Co., Ltd., (b)(6)@olympus.com\nCarl A. Yallop, Vice President OSTE, SIS Operations & ISC and Managing Director, EMEA, (b)(6)@olympus.com","Olympus Medical Systems Corporation","olympus-medical-systems-corporation-729208-10072026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-729208-10072026","2026-11-17T01:02:03.701861+00:00","2026-10-20","729208","2026-10-27T01:19:05.406+00:00","2026-10-07",{"id":49,"raw":50,"subject":12,"body_html":55,"body_text":56,"firm_name":57,"letter_id":58,"created_at":59,"fei_number":19,"letter_url":60,"updated_at":61,"action_type":22,"case_status":23,"posted_date":62,"marcs_cms_no":63,"product_type":26,"closeout_date":19,"issuing_office":64,"recipient_name":65,"body_fetched_at":66,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":67,"medical_device_id":19,"response_letter_date":19},2105,[51,52,53,54,12,13,13,13],"\u003Ctime datetime=\"2023-05-16T13:20:00Z\">05\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-04T04:00:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsea-long-medical-systems-llc-647320-04042023\">Sea-Long Medical Systems, LLC\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations West ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mrs. Valarie A. Austin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO) and Co-owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sea-Long Medical Systems, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2498 FM 66, Building 1021\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waxahachie\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75167\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vaustin@sea-long.com\"> vaustin@sea-long.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations West \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 647320\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 4, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mrs. &amp; Mr. Austin,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 2498 FM 66, Building 1021, Waxahachie, TX 75167 on 08\u002F22\u002F2022 through 09\u002F08\u002F2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of a latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5012, 5015, 5002 and 5005), a non-latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5035, 5025, 5022 and 5000), a non-latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5335, 5325, 5322, and 5300) and a latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5312, 5315, 5302 and 5305), hereafter referred to as Sea-Long Medical Treatment Hoods. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Quality System Regulation Provisions and Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received a response from your firm on 09\u002F21\u002F2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your complaint handling procedures, “Customer Complaint - (MDR) Medical Device Reporting and Recall” (OP-85-01, dated 09\u002F08\u002F2017) and “How to process a Customer Complaint Procedure” do not adequately include requirements to document the nature and details of the complaint and the dates and results for any investigation. Your firm is missing this information in the five (5) complaint records listed below:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Customer complaint record dated 12\u002F07\u002F2020 related to “hood with a hole”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 03\u002F04\u002F2021 related to “damage hoods”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 12\u002F07\u002F2021 related to “hood defect”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 07\u002F13\u002F2022 related to “bad weld on hoods and small hole in neck seals”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 02\u002F08\u002F2022 related to “neck seals ripped”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm also determined that the devices involved in the complaint records above failed to meet specification and are manufacturing defects, and at least three (3) complaint events involved a device that was used during treatment or analysis. However, all five (5) complaint\u003Cbr>\nrecords did not contain a “Corrective Action\u002FPreventive Action form” and “Root Cause Analysis form” as required by your complaint handling procedure. Also, there was no rationale why no investigation was necessary and the name of the person(s) responsible for the decision not to investigate in any of the records.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your firm is missing a complaint log as acknowledged by your management and product IDs for all 5 complaint records above as required by your complaint handling procedures. Your firm is missing device serial numbers (complaint record dated 12\u002F07\u002F2021, 07\u002F13\u002F2022, and 02\u002F28\u002F2022) as required by your complaint handling procedures.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures for process validation where the results of a process cannot be fully verified by subsequent inspection and test; failure to validate the process with a high degree of assurance; and failure to approve the process according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not conduct process validation per your established procedure, “Verification and Validation” (SP-000004, dated 08\u002F22\u002F2022), for the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> welding process used to manufacture the Treatment Hoods (hyperbaric chambers). Your firm utilizes \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;welding machines (serial numbers: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for manufacturing of your Treatment Hoods. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> welding machines utilize various welding parameters such as seal time, cooling time, and power.\u003C\u002Fli>\n\t\u003Cli>The cleaning process used in cleaning of your Treatment Hoods (specifically the hood component) that are reusable on multiple patients. Your firm’s “Sea-Long Product Cleaning Guideline” (with no document number, dated 2020) for your Treatment Hoods (consisting of the hood and neck seal) provides information on the use of EPA registered hospital disinfectants (Sanizide Pro or Plus). The cleaning guidelines provide a contact time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for most EPA-registered hospital disinfectants as well as at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> based on multiple scientific studies on hospital disinfectants against pathogens.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and maintain procedures for design change to ensure the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, as acknowledged by your management, your firm has not established design change procedures for your Treatment Hoods (hyperbaric chambers).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to establish a procedure for implementing corrective and preventive actions. During the inspection, your management stated that your firm has not established any quality system procedures including CAPA procedures. Also, the “Masterlist of Operating Procedures” (print dated 08\u002F21\u002F2022) directs firm personnel to use the old CAPA procedure (SP-000022, dated 09\u002F02\u002F2005) from the firm’s previous quality management system. Review of the old procedure directs the person to an electronic file; however, the file path was corrupt, and the file was unable to open or unretrievable.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not adequately establish your nonconforming procedure, “Non-Conforming Material” (OP-83-00, dated 03\u002F14\u002F2021). For example, your management stated that your firm is utilizing the “Inspection Specification Sheet” (created on 04\u002F08\u002F2004) to document leaks, scratches, and dents during the hood quality checks. The “Inspection Specification Sheet” is not referenced or captured in your nonconforming material procedure. Also, your firm does not store or maintain records of completed Inspection Specification Sheets and was unable to provide the investigator with records from 2021.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for finished device acceptance, to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not have written procedures for finished Treatment Hood device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria. During the inspection, your management stated that you had not established any procedure addressing finished device acceptance. Also, during the inspection, your firm created and provided the “Treatment Hood Inspection Process” procedure (OP-85- 02 version 1.0, effective 08\u002F26\u002F2022). This new procedure did not address requirements for completing and retaining your “Inspection Specification Sheet” (no form number and created on 04\u002F08\u002F2004) and “Quality Control \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tracking Report” (no form number or date). The “Inspection Specification Sheet” requires recording pass\u002Ffail results during hood inspections for criteria such as:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Assurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\u003C\u002Fli>\n\t\u003Cli>Assurance that the weld of the ring is secure and completely sealed\u003C\u002Fli>\n\t\u003Cli>Assurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\u003C\u002Fli>\n\t\u003Cli>Assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is completely sealed around the ports to prevent leaks\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and maintain procedures for acceptance of incoming product to ensure acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not establish your Inspection and Testing procedure (SP-000028, dated 09\u002F19\u002F2017) and “Warehouse Receiving Inspection” (OP-74-03, no date). For example, your firm did not document incoming inspections for at least 12 out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> product shipments from supplier of latex neck seals and \u003Cstrong>(b)(4)\u003C\u002Fstrong> neck seals that you received between July 2020 to August 2022.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to maintain device master records (DMRs), as required by 21 CFR 820.181.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not maintain device master records (DMRs) for the Treatment Hood (hyperbaric chamber), to include or refer to the location of current device specifications (e.g., drawings and component specifications), production and process specifications, quality assurance procedures, and packaging and labeling specifications to ensure that each DMR is prepared and approved in accordance with document controls.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and maintain procedures for device history records (DHRs) to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR part 820, as required by 21 CFR 820.184.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not establish a procedure for creating and adequately documenting device history records (DHR) for the Treatment Hoods (hyperbaric chambers). For example, your firm's last documented DHR for the Treatment Hoods using manufacturing procedure router was in 2018 and your Office Manager indicated that your firm has been manufacturing Treatment Hoods (including hood and neck seals) after 2018.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for quality audits and to conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to establish your Internal Audits Procedure (OP-82-02, dated 08\u002F22\u002F2022). According to your procedure, “Quality Manager will plan and determine the audit schedule on an ongoing basis.” Your procedure failed to define and document what “ongoing basis” means in the procedure. Also, your firm did not have any documented evidence of audits being conducted or documentation of review of any audit reports since 2018, and your management stated that the firm had not conducted any quality audit since 2016.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>11. Failure to establish procedures for management review to ensure that management with executive responsibility shall review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency, as required by 21 CFR 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to establish your “Management Review” procedure (OP-56-01, version 1.2). Your procedure requires management reviews to be conducted at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, your firm did not have any documented evidence of any annual management review meetings since 2018.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Other Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm currently holds a 510(k) clearance (K010659) for the “Sea-Long Medical Treatment Hood,” which was issued on May 16, 2001. The device was classified under regulation number 21 CFR 868.5470, \u003Cem>Hyperbaric chamber\u003C\u002Fem>, with the following Indications for Use statement: “The Treatment Hood is intended to: provide the use any place that a clinician would normally use a mask for medical purposes of supplying gas\u002Foxygen\u002Fair. There is a connector attachment on the hood to allow the Treatment Hood to be connected to a standard gas\u002Foxygen\u002Fair supply source.”\u003C\u002Fp>\n\n\u003Cp>However, statements on your firm’s website\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and in materials collected during the inspection indicate that the device is also intended for noninvasive ventilation (NIV), respiratory distress\u002Fillness, acute respiratory distress syndrome (ARDS), pressure support ventilation (PSV)\u002Fpositive end-expiratory pressure (PEEP), COVID-19 treatment, and other additional uses, which constitute major changes or modifications to its intended use for which your firm lacks clearance or approval. Examples include the following:\u003C\u002Fp>\n\n\u003Cp>Your website (https:\u002F\u002Fwww.sea-long.com) promotes the following new intended uses:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your “About” page states, “Second Study by pulmonologist John P. Kress, MD showing the helmet ‘confers several advantages over the face mask’. Check out the study here” and includes a link that takes the viewer to an article on The University of Chicago Medicine’s website dated March 25, 2020, and titled, “Helmet-based ventilation is superior to face mask for patients with respiratory distress.” The article indicates that “In a second study published in 2018, the researchers followed up with the same patients after one year. The patients who received helmet ventilation were more likely to be functionally independent than those given a face mask and spent more days living at home. The initial study, published in JAMA, followed 83 patients with ARDS, a severe and often lethal injury to the lungs. ARDS causes fluid to accumulate in the lungs' microscopic air sacs. It can lead to partial collapse of the lungs, dangerously low blood-oxygen levels and death.” [ARDS]\u003C\u002Fli>\n\t\u003Cli>Your “Media” page includes excerpts from and links to various media articles and videos, including:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o An NBC news article and video titled, “Texas ‘mom and pop’ business flooded with orders for helmet-style ventilation device,” dated March 31, 2020. The description under the title states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating patients suffering with respiratory illness amid a ventilator shortage during the pandemic.” The link takes you to the NBC news article with video. The description under the title of the NBC news article states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating COVID-19 patients amid a ventilator shortage.” The article states that the “helmet was originally designed to supply oxygen to patients receiving treatment in hyperbaric chambers. But doctors in Italy, where a version of the helmet has long been used to treat people experiencing breathing problems, found it to be effective in helping some COVID-19 patients […] Dr. Bhakti Patel, who has been studying the devices for six years, said they hold promise as an early intervention that could spare respiratory patients the need to be put on the more traditional — and costly and invasive — ventilators. […] The original devices were made to run through ventilators. But working with Patel and her mentor, Dr. John Kress, Sea-Long has modified the helmets so they can be hooked up to a hospital’s regular oxygen supply, keeping the ventilators free for those who need them most. They have also made another significant modification, adding a viral filter to prevent possible COVID-19 exposure to others. […] Other companies make similar ventilator helmets, but Sea-Long’s is the only helmet available in the U.S. that meets requirements of the Food and Drug Administration and has been validated in a clinical study for acute respiratory syndrome. No studies have yet been done, however, examining the effectiveness of the devices in treating COVID-19 patients.” [COVID-19 and ARDS]\u003C\u002Fp>\n\n\u003Cp>&nbsp; o A Fox News article with the description, “Company flooded with orders for helmet ventilators calls for government assistance to ‘scale up’ production,” published April 2, 2020. The article states that “[t]he owner of Sea Long Medical Systems said on Thursday that the flood of ventilator mask orders at his company requires a ‘scaling up’ of production to meet the demand from hospitals fighting the coronavirus outbreak. ‘We’re just completely inundated with phone calls from all over the world from India to anywhere you can think of plus the majority of the hospitals in the United States,’ Chris Austin told ‘America’s Newsroom’. […] Austin said that the masks are used in hospitals at the University of Chicago, University of Pennsylvania, a ‘few’ veterans' hospitals and others.” [COVID-19]\u003C\u002Fp>\n\n\u003Cp>&nbsp; o A Fox News video titled, “Company demonstrates how helmet ventilation device works amid pandemic,” and a video with a chyron at the bottom of the screen that states, “CHRIS AUSTIN | SEA-LONG MEDICAL SYSTEMS OWNER” and “HELMET VENTILATORS COULD HELP EASE SHORTAGE OF TRADITIONAL VENTILATORS AMID PANDEMIC.” The video shows a snapshot of Sea-Long Medical System’s website stating “COVID - 19 Update: Please contact us for updated information and break thru uses for our products with CPAP, BIPAP and NON-INVASIVE VENTILATION. Check out the information from the Helmet Based Ventilation website-based ventilation is a solution for COVID-19 treatment.” [Ventilator, CPAP, and BIPAP]\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your “Media” page has an embedded link to a video from the CBS DFW YouTube channel uploaded March 27, 2020 with the description, “Family-Owned Business Making Medical Devices that Can Ease the Ventilator Shortage: A small family-owned business is making medical devices to help fight the shortage of ventilators during the pandemic.” The video narration introduces a small family own business in Waxahachie and states that “Christopher Austin is the owner of Sea-Long Medical Systems.” The narration states that “once used to supply oxygen to patients receiving treatment in hyperbaric chambers. The device now called the COVID-19 helmet.” [Ventilator and COVID-19]\u003C\u002Fp>\n\n\u003Cp>Your YouTube Channel (https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCQ2YgVWpxMr8gYyMlaWhBA\u002Ffeatured) promotes the following intended uses:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Watch this video to learn how to install a Sea-Long Covid 19 kit. www.sea-long.com.” Also, the YouTube channel directly links (1-click away) to the Sea-Long Medical Systems, LLC’s website. [COVID-19]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The Directions for Use (DFU) promotes the following intended uses:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“One-Piece Neck Seal &amp; Heat Tent […] Non-Invasive Ventilation (NIV)” [NIV]\u003C\u002Fli>\n\t\u003Cli>“Start the ventilator in Pressure Support Ventilation with a PEEP of 5-7 cmH20 at least switching off the alarms for 2 minutes. [PSV]\u003C\u002Fli>\n\t\u003Cli>“Use the device only with devices and appliances suitable to the Non-Invasive Ventilation (NIV) and Pressure Support Ventilation (PSV).” [PSV]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You have not submitted any new 510(k) in association with the statements made in the labeling of the Treatment Hood describing these new intended uses. The Treatment Hood as currently labeled is therefore misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified MCH Devices, as required by section 510(k) of the Act. Our inspection, including our review of your website, revealed that the Treatment Hood (hyperbaric chamber) is also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>The inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Sea-Long Medical Treatment Hood devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\n\n\u003Cp>In addition, your Sea-Long Medical Treatment Hood devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, Subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\n\n\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 647320 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh N. Adams, Compliance Officer, at (916) 930-3674 ext. 1111 or lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Regards,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nShari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Malvina Eydelman\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\u003Cbr>\nENT &amp; Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc: Mr. Christopher L. Austin, President and Co-owner (via UPS)\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Website content last verified on March 30, 2023.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMrs. Valarie A. Austin\n\nRecipient Title\n\nChief Executive Officer (CEO) and Co-owner\n\nSea-Long Medical Systems, LLC\n\n2498 FM 66, Building 1021\n\nWaxahachie, TX 75167\n\nUnited States\n\nvaustin@sea-long.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS 647320\n\nApril 4, 2023\n\nDear Mrs. & Mr. Austin,\n\nDuring an inspection of your firm located at 2498 FM 66, Building 1021, Waxahachie, TX 75167 on 08\u002F22\u002F2022 through 09\u002F08\u002F2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of a latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5012, 5015, 5002 and 5005), a non-latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5035, 5025, 5022 and 5000), a non-latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5335, 5325, 5322, and 5300) and a latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5312, 5315, 5302 and 5305), hereafter referred to as Sea-Long Medical Treatment Hoods. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nObservations Pertaining to Quality System Regulation Provisions and Regulations\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from your firm on 09\u002F21\u002F2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nSpecifically, your complaint handling procedures, “Customer Complaint - (MDR) Medical Device Reporting and Recall” (OP-85-01, dated 09\u002F08\u002F2017) and “How to process a Customer Complaint Procedure” do not adequately include requirements to document the nature and details of the complaint and the dates and results for any investigation. Your firm is missing this information in the five (5) complaint records listed below:\n\nCustomer complaint record dated 12\u002F07\u002F2020 related to “hood with a hole”\n\nCustomer complaint record dated 03\u002F04\u002F2021 related to “damage hoods”\n\nCustomer complaint record dated 12\u002F07\u002F2021 related to “hood defect”\n\nCustomer complaint record dated 07\u002F13\u002F2022 related to “bad weld on hoods and small hole in neck seals”\n\nCustomer complaint record dated 02\u002F08\u002F2022 related to “neck seals ripped”\n\nYour firm also determined that the devices involved in the complaint records above failed to meet specification and are manufacturing defects, and at least three (3) complaint events involved a device that was used during treatment or analysis. However, all five (5) complaint\n\nrecords did not contain a “Corrective Action\u002FPreventive Action form” and “Root Cause Analysis form” as required by your complaint handling procedure. Also, there was no rationale why no investigation was necessary and the name of the person(s) responsible for the decision not to investigate in any of the records.\n\nFurthermore, your firm is missing a complaint log as acknowledged by your management and product IDs for all 5 complaint records above as required by your complaint handling procedures. Your firm is missing device serial numbers (complaint record dated 12\u002F07\u002F2021, 07\u002F13\u002F2022, and 02\u002F28\u002F2022) as required by your complaint handling procedures.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\n\n2. Failure to establish procedures for process validation where the results of a process cannot be fully verified by subsequent inspection and test; failure to validate the process with a high degree of assurance; and failure to approve the process according to established procedures, as required by 21 CFR 820.75(a).\n\nSpecifically, your firm did not conduct process validation per your established procedure, “Verification and Validation” (SP-000004, dated 08\u002F22\u002F2022), for the following:\n\nThe (b)(4) welding process used to manufacture the Treatment Hoods (hyperbaric chambers). Your firm utilizes (b)(4) welding machines (serial numbers: (b)(4), and (b)(4)) for manufacturing of your Treatment Hoods. The (b)(4) welding machines utilize various welding parameters such as seal time, cooling time, and power.\n\nThe cleaning process used in cleaning of your Treatment Hoods (specifically the hood component) that are reusable on multiple patients. Your firm’s “Sea-Long Product Cleaning Guideline” (with no document number, dated 2020) for your Treatment Hoods (consisting of the hood and neck seal) provides information on the use of EPA registered hospital disinfectants (Sanizide Pro or Plus). The cleaning guidelines provide a contact time of (b)(4) for most EPA-registered hospital disinfectants as well as at least (b)(4) based on multiple scientific studies on hospital disinfectants against pathogens.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\n\n3. Failure to establish and maintain procedures for design change to ensure the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i).\n\nSpecifically, as acknowledged by your management, your firm has not established design change procedures for your Treatment Hoods (hyperbaric chambers).\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\n\nSpecifically, your firm failed to establish a procedure for implementing corrective and preventive actions. During the inspection, your management stated that your firm has not established any quality system procedures including CAPA procedures. Also, the “Masterlist of Operating Procedures” (print dated 08\u002F21\u002F2022) directs firm personnel to use the old CAPA procedure (SP-000022, dated 09\u002F02\u002F2005) from the firm’s previous quality management system. Review of the old procedure directs the person to an electronic file; however, the file path was corrupt, and the file was unable to open or unretrievable.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n5. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\n\nSpecifically, your firm did not adequately establish your nonconforming procedure, “Non-Conforming Material” (OP-83-00, dated 03\u002F14\u002F2021). For example, your management stated that your firm is utilizing the “Inspection Specification Sheet” (created on 04\u002F08\u002F2004) to document leaks, scratches, and dents during the hood quality checks. The “Inspection Specification Sheet” is not referenced or captured in your nonconforming material procedure. Also, your firm does not store or maintain records of completed Inspection Specification Sheets and was unable to provide the investigator with records from 2021.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n6. Failure to establish and maintain procedures for finished device acceptance, to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\n\nSpecifically, your firm did not have written procedures for finished Treatment Hood device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria. During the inspection, your management stated that you had not established any procedure addressing finished device acceptance. Also, during the inspection, your firm created and provided the “Treatment Hood Inspection Process” procedure (OP-85- 02 version 1.0, effective 08\u002F26\u002F2022). This new procedure did not address requirements for completing and retaining your “Inspection Specification Sheet” (no form number and created on 04\u002F08\u002F2004) and “Quality Control (b)(4) Tracking Report” (no form number or date). The “Inspection Specification Sheet” requires recording pass\u002Ffail results during hood inspections for criteria such as:\n\nAssurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\n\nAssurance that the weld of the ring is secure and completely sealed\n\nAssurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\n\nAssurance that the (b)(4) is completely sealed around the ports to prevent leaks\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n7. Failure to establish and maintain procedures for acceptance of incoming product to ensure acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\n\nSpecifically, your firm did not establish your Inspection and Testing procedure (SP-000028, dated 09\u002F19\u002F2017) and “Warehouse Receiving Inspection” (OP-74-03, no date). For example, your firm did not document incoming inspections for at least 12 out of (b)(4) product shipments from supplier of latex neck seals and (b)(4) neck seals that you received between July 2020 to August 2022.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n8. Failure to maintain device master records (DMRs), as required by 21 CFR 820.181.\n\nSpecifically, your firm did not maintain device master records (DMRs) for the Treatment Hood (hyperbaric chamber), to include or refer to the location of current device specifications (e.g., drawings and component specifications), production and process specifications, quality assurance procedures, and packaging and labeling specifications to ensure that each DMR is prepared and approved in accordance with document controls.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n9. Failure to establish and maintain procedures for device history records (DHRs) to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR part 820, as required by 21 CFR 820.184.\n\nSpecifically, your firm did not establish a procedure for creating and adequately documenting device history records (DHR) for the Treatment Hoods (hyperbaric chambers). For example, your firm's last documented DHR for the Treatment Hoods using manufacturing procedure router was in 2018 and your Office Manager indicated that your firm has been manufacturing Treatment Hoods (including hood and neck seals) after 2018.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n10. Failure to establish procedures for quality audits and to conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\n\nSpecifically, your firm failed to establish your Internal Audits Procedure (OP-82-02, dated 08\u002F22\u002F2022). According to your procedure, “Quality Manager will plan and determine the audit schedule on an ongoing basis.” Your procedure failed to define and document what “ongoing basis” means in the procedure. Also, your firm did not have any documented evidence of audits being conducted or documentation of review of any audit reports since 2018, and your management stated that the firm had not conducted any quality audit since 2016.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n11. Failure to establish procedures for management review to ensure that management with executive responsibility shall review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency, as required by 21 CFR 820.20(c).\n\nSpecifically, your firm failed to establish your “Management Review” procedure (OP-56-01, version 1.2). Your procedure requires management reviews to be conducted at least (b)(4); however, your firm did not have any documented evidence of any annual management review meetings since 2018.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\nObservations Pertaining to Other Regulations\n\nYour firm currently holds a 510(k) clearance (K010659) for the “Sea-Long Medical Treatment Hood,” which was issued on May 16, 2001. The device was classified under regulation number 21 CFR 868.5470, Hyperbaric chamber, with the following Indications for Use statement: “The Treatment Hood is intended to: provide the use any place that a clinician would normally use a mask for medical purposes of supplying gas\u002Foxygen\u002Fair. There is a connector attachment on the hood to allow the Treatment Hood to be connected to a standard gas\u002Foxygen\u002Fair supply source.”\n\nHowever, statements on your firm’s website1 and in materials collected during the inspection indicate that the device is also intended for noninvasive ventilation (NIV), respiratory distress\u002Fillness, acute respiratory distress syndrome (ARDS), pressure support ventilation (PSV)\u002Fpositive end-expiratory pressure (PEEP), COVID-19 treatment, and other additional uses, which constitute major changes or modifications to its intended use for which your firm lacks clearance or approval. Examples include the following:\n\nYour website (https:\u002F\u002Fwww.sea-long.com) promotes the following new intended uses:\n\nYour “About” page states, “Second Study by pulmonologist John P. Kress, MD showing the helmet ‘confers several advantages over the face mask’. Check out the study here” and includes a link that takes the viewer to an article on The University of Chicago Medicine’s website dated March 25, 2020, and titled, “Helmet-based ventilation is superior to face mask for patients with respiratory distress.” The article indicates that “In a second study published in 2018, the researchers followed up with the same patients after one year. The patients who received helmet ventilation were more likely to be functionally independent than those given a face mask and spent more days living at home. The initial study, published in JAMA, followed 83 patients with ARDS, a severe and often lethal injury to the lungs. ARDS causes fluid to accumulate in the lungs' microscopic air sacs. It can lead to partial collapse of the lungs, dangerously low blood-oxygen levels and death.” [ARDS]\n\nYour “Media” page includes excerpts from and links to various media articles and videos, including:\n\no An NBC news article and video titled, “Texas ‘mom and pop’ business flooded with orders for helmet-style ventilation device,” dated March 31, 2020. The description under the title states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating patients suffering with respiratory illness amid a ventilator shortage during the pandemic.” The link takes you to the NBC news article with video. The description under the title of the NBC news article states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating COVID-19 patients amid a ventilator shortage.” The article states that the “helmet was originally designed to supply oxygen to patients receiving treatment in hyperbaric chambers. But doctors in Italy, where a version of the helmet has long been used to treat people experiencing breathing problems, found it to be effective in helping some COVID-19 patients […] Dr. Bhakti Patel, who has been studying the devices for six years, said they hold promise as an early intervention that could spare respiratory patients the need to be put on the more traditional — and costly and invasive — ventilators. […] The original devices were made to run through ventilators. But working with Patel and her mentor, Dr. John Kress, Sea-Long has modified the helmets so they can be hooked up to a hospital’s regular oxygen supply, keeping the ventilators free for those who need them most. They have also made another significant modification, adding a viral filter to prevent possible COVID-19 exposure to others. […] Other companies make similar ventilator helmets, but Sea-Long’s is the only helmet available in the U.S. that meets requirements of the Food and Drug Administration and has been validated in a clinical study for acute respiratory syndrome. No studies have yet been done, however, examining the effectiveness of the devices in treating COVID-19 patients.” [COVID-19 and ARDS]\n\no A Fox News article with the description, “Company flooded with orders for helmet ventilators calls for government assistance to ‘scale up’ production,” published April 2, 2020. The article states that “[t]he owner of Sea Long Medical Systems said on Thursday that the flood of ventilator mask orders at his company requires a ‘scaling up’ of production to meet the demand from hospitals fighting the coronavirus outbreak. ‘We’re just completely inundated with phone calls from all over the world from India to anywhere you can think of plus the majority of the hospitals in the United States,’ Chris Austin told ‘America’s Newsroom’. […] Austin said that the masks are used in hospitals at the University of Chicago, University of Pennsylvania, a ‘few’ veterans' hospitals and others.” [COVID-19]\n\no A Fox News video titled, “Company demonstrates how helmet ventilation device works amid pandemic,” and a video with a chyron at the bottom of the screen that states, “CHRIS AUSTIN | SEA-LONG MEDICAL SYSTEMS OWNER” and “HELMET VENTILATORS COULD HELP EASE SHORTAGE OF TRADITIONAL VENTILATORS AMID PANDEMIC.” The video shows a snapshot of Sea-Long Medical System’s website stating “COVID - 19 Update: Please contact us for updated information and break thru uses for our products with CPAP, BIPAP and NON-INVASIVE VENTILATION. Check out the information from the Helmet Based Ventilation website-based ventilation is a solution for COVID-19 treatment.” [Ventilator, CPAP, and BIPAP]\n\no Your “Media” page has an embedded link to a video from the CBS DFW YouTube channel uploaded March 27, 2020 with the description, “Family-Owned Business Making Medical Devices that Can Ease the Ventilator Shortage: A small family-owned business is making medical devices to help fight the shortage of ventilators during the pandemic.” The video narration introduces a small family own business in Waxahachie and states that “Christopher Austin is the owner of Sea-Long Medical Systems.” The narration states that “once used to supply oxygen to patients receiving treatment in hyperbaric chambers. The device now called the COVID-19 helmet.” [Ventilator and COVID-19]\n\nYour YouTube Channel (https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCQ2YgVWpxMr8gYyMlaWhBA\u002Ffeatured) promotes the following intended uses:\n\n“Watch this video to learn how to install a Sea-Long Covid 19 kit. www.sea-long.com.” Also, the YouTube channel directly links (1-click away) to the Sea-Long Medical Systems, LLC’s website. [COVID-19]\n\nThe Directions for Use (DFU) promotes the following intended uses:\n\n“One-Piece Neck Seal & Heat Tent […] Non-Invasive Ventilation (NIV)” [NIV]\n\n“Start the ventilator in Pressure Support Ventilation with a PEEP of 5-7 cmH20 at least switching off the alarms for 2 minutes. [PSV]\n\n“Use the device only with devices and appliances suitable to the Non-Invasive Ventilation (NIV) and Pressure Support Ventilation (PSV).” [PSV]\n\nYou have not submitted any new 510(k) in association with the statements made in the labeling of the Treatment Hood describing these new intended uses. The Treatment Hood as currently labeled is therefore misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified MCH Devices, as required by section 510(k) of the Act. Our inspection, including our review of your website, revealed that the Treatment Hood (hyperbaric chamber) is also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThe inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Sea-Long Medical Treatment Hood devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\n\nIn addition, your Sea-Long Medical Treatment Hood devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, Subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\n\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 647320 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh N. Adams, Compliance Officer, at (916) 930-3674 ext. 1111 or lindalinh.adams@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nRegards,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest\n\n\u002FS\u002F\n\nDr. Malvina Eydelman\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\n\nENT & Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc: Mr. Christopher L. Austin, President and Co-owner (via UPS)\n\n_____________________\n\n1 Website content last verified on March 30, 2023.","Sea-Long Medical Systems, LLC","sea-long-medical-systems-llc-647320-04042023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsea-long-medical-systems-llc-647320-04042023","2026-10-26T08:09:54.778439+00:00","2023-05-16","647320","Division of Medical Device and Radiological Health Operations West","Mrs. Valarie A. Austin","2026-08-20T01:07:14.815+00:00","2023-04-04",{"id":69,"raw":70,"subject":74,"body_html":75,"body_text":76,"firm_name":77,"letter_id":78,"created_at":59,"fei_number":19,"letter_url":79,"updated_at":80,"action_type":22,"case_status":23,"posted_date":81,"marcs_cms_no":82,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":83,"body_fetched_at":84,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":85,"medical_device_id":19,"response_letter_date":19},2160,[71,72,73,11,74,13,13,13],"\u003Ctime datetime=\"2023-03-17T15:00:00Z\">03\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-15T04:00:00Z\">03\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corp-654013-03152023\">Olympus Medical Systems Corp.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Seiji Morishita\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Olympus Medical Systems Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-3 Hirai Hinode-machi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nishitama-gun\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>190-0182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 15, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Morishita:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tokyo, Japan on November 7, 2022, through November 10, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures endoscopes and endoscope accessories including, Single-Use Distal Covers for Duodenoscopes and Single-Use Suction Valve Accessories for Bronchoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are accessories intended to be used with endoscopes for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Mr. Seiji Morishita, Director of Olympus Medical Systems Corp, Hinode dated December 5, 2022, January 10, 2023, and February 13, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>A. Since November 2020, Olympus Medical has received approximately 160 complaints describing the “distal end cover” model number MAJ-2315 has “dropped out.” Your firm performed trending and identified that number of complaints was above the expected numbers for that type of complaint. However, your firm did not consider this increasing trend of complaints to be a quality data input to initiate a corrective and preventive action.\u003C\u002Fp>\n\n\u003Cp>B. The process flow diagram of Procedure for Complaint Handling\u002FOMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong> describes that complaint investigations that would require evaluation for reportability would not be considered for Corrective and Preventive Action. Complaints are specifically required to be analyzed for inclusion into the CAPA subsystem and complaints that are deemed reportable are of the highest risk complaints and therefore especially important to be considered for corrective and preventive action implementation.\u003C\u002Fp>\n\n\u003Cp>C. Non-Conformances \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were opened for observed wrinkles in the package seal of Distal End Cap\u002FMAJ-2315 between October 13 to October 23, 2022. Your firm stated that yield control may be appropriate for some low risk nonconformances instead of using its Nonconforming Product procedure. Yield control allows for an acceptable level of package seal defects, even though there is no assurance that visually observed seal defects would not compromise the sterile barrier. Package sealing is a validated process, which results cannot be verified when the validated requirements of the seal are not met. A potential breach of sterility in the packaging seal would not be considered a low risk nonconformance. Because yield control was inappropriately applied to the package seal defect, the nonconformances were not considered as nonconforming product and not included as quality data for the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200735 to investigate complaints of MAJ-2315 “dropped out” and after conducting a Health Hazard Analysis (HHA), concluded that no additional action is required and they will continue to monitor complaints for the distal cap falling off in the patient. However, FDA does not agree that the risk to the patient is of a low enough risk to not warrant further action at this time. The HHA conducted does not discuss how\u002Fwhy the risk to the patient is not increased by exposure to the uncovered endoscope during the procedure as it is removed. The HHA does not consider the risk of tissue injury from navigating the gastrointestinal tract with an uncovered scope tip. Further, your firm’s documentation concludes that the distal cap is unlikely to fall off if the user has applied it correctly. CAPA-200735 does not consider whether the device actually meets user needs as required by 21 CFR 820.30(g), including the ability to recognize imperfections in the cap and attach it to the scope correctly without damaging it. While your firm did initiate a systemic corrective and preventive action to determine why this complaint trend was not escalated to a CAPA, the investigation into the issue itself, the cap falling off the scope in the patient, appears to be inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example, Nonconformance \u003Cstrong>(b)(4)\u003C\u002Fstrong> was opened due to wrinkles and air bubbles in the package seal of MAJ-210\u002FLot H2410 a sterile product. Your firm made a modification to the manufacturing equipment to increase the cooling rate of the package after sealing. While some testing was performed to demonstrate seal integrity, no re-validation of the process was made. Because sterility of the product is a critical requirement and the process cannot be fully verified by subsequent inspection and test, the process must be validated and re-validated when a modification such as this is made.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm identified its plan to perform revalidation for MAJ-201 sealing operation by January 31, 2023. Also, your firm stated that it will revise \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Process Validation and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Conduct of Process Validation by February 23, 2023, to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made; and revise \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assembly\u002FProcessing Equipment Control by February 28, 2023, to ensure that the change control process is followed when process or equipment changes are made.\u003C\u002Fp>\n\n\u003Cp>Your firm reviewed complaints and MDRs from the last two years associated with all products distributed to the US to determine if any signals exist to suggest sterility was compromised as a result of the modification made to the sealing process. It is not clear whether your firm evaluated devices shipped to other markets as well that would have the same concern or could possibly be imported into the US by a third party. Your firm should clarify this. Your firm performed a retrospective review of all changes for all products marketed in the US since each product’s last full validation to determine if any other changes have been made to any products marketed in the US that should have prompted a full or partial revalidation and opened several nonconformances for changes without adequate documentation of necessity for revalidation to investigate impact to product and revalidation requirements. Your firm completed its revalidation of MAJ-210 sealing process on January 31, 2023. Your firm has additional corrective actions planned, including revising its Process Validation procedures to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made. Your firm also plans to implement a change to its Assembly\u002FProcessing Equipment Control procedure to ensure that the change control process is followed when process or equipment changes are made. However, your firm did not mention a plan to train its personnel on these new procedures, nor did it clarify that the retrospective reviews that were done were in line with the new requirements of its procedures. Your firm should provide clarification to these two points and provide documentation of implementation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>For example, Complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> was received by Olympus Medical on November 21, 2020. The complaint described that \"a patient sustained esophageal trauma\" and \"tissue from the esophagus was caught up in the distal tip of the device.\" The complaint also stated that the \"customer attributes these events to cracked caps\" and that they noticed a \"few already cracked when coming out of the packaging.\" Your firm’s complaint handling procedure, OMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires investigations of complaints to be made within 30 days. The investigation of the complaint was not made until 2022.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200739 to determine the root cause of Observation 4a of the FDA-483. It appears your firm identified the root cause to be related to be a lack of linkage between the scopes and the caps within their system. Your firm completed a retrospective review of all complaints associated with MAJ-2315, expanding the search to other scopes that use the distal cap in addition to TJF-Q190V. Your firm found that there were 98 complaints not initiated according to their procedure during this retrospective review. Your firm stated that it will conduct the necessary investigation and submit MDRs as needed by February 28, 2023.\u003C\u002Fp>\n\n\u003Cp>Your firm revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaint Handling, which included instructions for ensuring individual complaints are opened for all related\u002Fconcomitant devices. Your firm revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaint Investigation Work Instruction, which included detailed instruction for ensuring individual complaints are opened for all related\u002Fconcomitant devices while performing complaint investigation. Your firm confirmed in its plan that personnel have been trained on the new procedures.\u003C\u002Fp>\n\n\u003Cp>Your firm plans to do a retrospective review of complaint records in the past two years related to the issue of cracked caps coming out of the packaging by February 28, 2023.\u003C\u002Fp>\n\n\u003Cp>However, it is not clear based on your firm’s CAPA and documentation whether they have investigated why the investigation into the complaint did not occur for two years, while your firm’s procedure requires it to be made within 30 days.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Single-Use Distal Cover (MAJ-2315) devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a).\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified the document titled “Medical Device Reporting Work Instruction”, OMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 10\u002F26\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>A. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure includes definitions from 21 CFR 803.3 for the terms “become aware”, “malfunction”, “MDR reportable event”, and the definition of the term “reasonably suggest” found in 803.20(c)(1). However, the procedure omits definitions of the terms “caused or contributed” and “serious injury” from the 21 CFR Part 803.3. The exclusion of the definitions for those terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>B. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\u003C\u002Fp>\n\n\u003Cp>a. For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The MDR Decision Tree in your firm’s MDR procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\u003C\u002Fp>\n\n\u003Cp>C. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a).\u003Cbr>\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response did not address the procedural deficiencies noted above, as they were not identified in the FDA-483.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong> reasonably suggests your firm’s duodenovideoscope with a distal cover MAJ-2315 malfunctioned (e.g., cracked cap) while in use, leading to potential mucosal tissue damage. Your firm initiated recall Z-1292-2021 for the referenced malfunction. Per the Preamble, in Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced device malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Although your firm submitted the MDRs (MDR# 8010047-2021-03794, 8010047-2022-02861, 8010047-2021-03786, 8010047-2022-02867, 8010047-2021-03796, 8010047-2022-02865) corresponding to each of the referenced events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm initiated a series of CAPAs to investigate the root cause of the cracked cap problem and have plans to address it accordingly. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm is in the process of completing CAPAs to address the referenced malfunction and updating the complaint handling process. Additionally, your firm conducted a retrospective review of all complaints associated with MAJ-2315 and complaints for the endoscopes (TJF-Q190V, TJF-Q290V, TJF-Q170V), which are used in conjunction with MAJ-2315. As a result, 98 complaints were identified for further investigation and your firm is evaluating them for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm completed the update of its complaint handling procedures and is evaluating newly identified events related to cracked caps for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including the submission of newly identified reportable events, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #654013 when replying. If you have any questions about the contents of this letter, please contact: Shanil Haugen, Ph.D., at Shanil.Haugen@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nTodd Brill\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 508 8042600 Ext\u003Cbr>\nEmail: Todd.Brill@Olympus.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Seiji Morishita\n\nRecipient Title\n\nDirector\n\nOlympus Medical Systems Corp.\n\n34-3 Hirai Hinode-machi\n\nNishitama-gun, Tokyo\n\n190-0182\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nMarch 15, 2023\n\nWARNING LETTER\n\nDear Mr. Morishita:\n\nDuring an inspection of your firm located in Tokyo, Japan on November 7, 2022, through November 10, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures endoscopes and endoscope accessories including, Single-Use Distal Covers for Duodenoscopes and Single-Use Suction Valve Accessories for Bronchoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are accessories intended to be used with endoscopes for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Mr. Seiji Morishita, Director of Olympus Medical Systems Corp, Hinode dated December 5, 2022, January 10, 2023, and February 13, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\n\nA. Since November 2020, Olympus Medical has received approximately 160 complaints describing the “distal end cover” model number MAJ-2315 has “dropped out.” Your firm performed trending and identified that number of complaints was above the expected numbers for that type of complaint. However, your firm did not consider this increasing trend of complaints to be a quality data input to initiate a corrective and preventive action.\n\nB. The process flow diagram of Procedure for Complaint Handling\u002FOMBS (b)(4) describes that complaint investigations that would require evaluation for reportability would not be considered for Corrective and Preventive Action. Complaints are specifically required to be analyzed for inclusion into the CAPA subsystem and complaints that are deemed reportable are of the highest risk complaints and therefore especially important to be considered for corrective and preventive action implementation.\n\nC. Non-Conformances (b)(4) and (b)(4) were opened for observed wrinkles in the package seal of Distal End Cap\u002FMAJ-2315 between October 13 to October 23, 2022. Your firm stated that yield control may be appropriate for some low risk nonconformances instead of using its Nonconforming Product procedure. Yield control allows for an acceptable level of package seal defects, even though there is no assurance that visually observed seal defects would not compromise the sterile barrier. Package sealing is a validated process, which results cannot be verified when the validated requirements of the seal are not met. A potential breach of sterility in the packaging seal would not be considered a low risk nonconformance. Because yield control was inappropriately applied to the package seal defect, the nonconformances were not considered as nonconforming product and not included as quality data for the corrective and preventive actions.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200735 to investigate complaints of MAJ-2315 “dropped out” and after conducting a Health Hazard Analysis (HHA), concluded that no additional action is required and they will continue to monitor complaints for the distal cap falling off in the patient. However, FDA does not agree that the risk to the patient is of a low enough risk to not warrant further action at this time. The HHA conducted does not discuss how\u002Fwhy the risk to the patient is not increased by exposure to the uncovered endoscope during the procedure as it is removed. The HHA does not consider the risk of tissue injury from navigating the gastrointestinal tract with an uncovered scope tip. Further, your firm’s documentation concludes that the distal cap is unlikely to fall off if the user has applied it correctly. CAPA-200735 does not consider whether the device actually meets user needs as required by 21 CFR 820.30(g), including the ability to recognize imperfections in the cap and attach it to the scope correctly without damaging it. While your firm did initiate a systemic corrective and preventive action to determine why this complaint trend was not escalated to a CAPA, the investigation into the issue itself, the cap falling off the scope in the patient, appears to be inadequate.\n\n2. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example, Nonconformance (b)(4) was opened due to wrinkles and air bubbles in the package seal of MAJ-210\u002FLot H2410 a sterile product. Your firm made a modification to the manufacturing equipment to increase the cooling rate of the package after sealing. While some testing was performed to demonstrate seal integrity, no re-validation of the process was made. Because sterility of the product is a critical requirement and the process cannot be fully verified by subsequent inspection and test, the process must be validated and re-validated when a modification such as this is made.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm identified its plan to perform revalidation for MAJ-201 sealing operation by January 31, 2023. Also, your firm stated that it will revise (b)(4), Process Validation and (b)(4), Conduct of Process Validation by February 23, 2023, to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made; and revise (b)(4) Assembly\u002FProcessing Equipment Control by February 28, 2023, to ensure that the change control process is followed when process or equipment changes are made.\n\nYour firm reviewed complaints and MDRs from the last two years associated with all products distributed to the US to determine if any signals exist to suggest sterility was compromised as a result of the modification made to the sealing process. It is not clear whether your firm evaluated devices shipped to other markets as well that would have the same concern or could possibly be imported into the US by a third party. Your firm should clarify this. Your firm performed a retrospective review of all changes for all products marketed in the US since each product’s last full validation to determine if any other changes have been made to any products marketed in the US that should have prompted a full or partial revalidation and opened several nonconformances for changes without adequate documentation of necessity for revalidation to investigate impact to product and revalidation requirements. Your firm completed its revalidation of MAJ-210 sealing process on January 31, 2023. Your firm has additional corrective actions planned, including revising its Process Validation procedures to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made. Your firm also plans to implement a change to its Assembly\u002FProcessing Equipment Control procedure to ensure that the change control process is followed when process or equipment changes are made. However, your firm did not mention a plan to train its personnel on these new procedures, nor did it clarify that the retrospective reviews that were done were in line with the new requirements of its procedures. Your firm should provide clarification to these two points and provide documentation of implementation.\n\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198.\n\nFor example, Complaint (b)(4) was received by Olympus Medical on November 21, 2020. The complaint described that \"a patient sustained esophageal trauma\" and \"tissue from the esophagus was caught up in the distal tip of the device.\" The complaint also stated that the \"customer attributes these events to cracked caps\" and that they noticed a \"few already cracked when coming out of the packaging.\" Your firm’s complaint handling procedure, OMBS (b)(4) requires investigations of complaints to be made within 30 days. The investigation of the complaint was not made until 2022.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200739 to determine the root cause of Observation 4a of the FDA-483. It appears your firm identified the root cause to be related to be a lack of linkage between the scopes and the caps within their system. Your firm completed a retrospective review of all complaints associated with MAJ-2315, expanding the search to other scopes that use the distal cap in addition to TJF-Q190V. Your firm found that there were 98 complaints not initiated according to their procedure during this retrospective review. Your firm stated that it will conduct the necessary investigation and submit MDRs as needed by February 28, 2023.\n\nYour firm revised (b)(4) Complaint Handling, which included instructions for ensuring individual complaints are opened for all related\u002Fconcomitant devices. Your firm revised (b)(4) Complaint Investigation Work Instruction, which included detailed instruction for ensuring individual complaints are opened for all related\u002Fconcomitant devices while performing complaint investigation. Your firm confirmed in its plan that personnel have been trained on the new procedures.\n\nYour firm plans to do a retrospective review of complaint records in the past two years related to the issue of cracked caps coming out of the packaging by February 28, 2023.\n\nHowever, it is not clear based on your firm’s CAPA and documentation whether they have investigated why the investigation into the complaint did not occur for two years, while your firm’s procedure requires it to be made within 30 days.\n\nOur inspection also revealed that your firm’s Single-Use Distal Cover (MAJ-2315) devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a).\n\nFor example, during the inspection, your firm identified the document titled “Medical Device Reporting Work Instruction”, OMBS (b)(4), dated 10\u002F26\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n\nA. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure includes definitions from 21 CFR 803.3 for the terms “become aware”, “malfunction”, “MDR reportable event”, and the definition of the term “reasonably suggest” found in 803.20(c)(1). However, the procedure omits definitions of the terms “caused or contributed” and “serious injury” from the 21 CFR Part 803.3. The exclusion of the definitions for those terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nB. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\n\na. For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The MDR Decision Tree in your firm’s MDR procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\n\nC. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a).\n\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\n\nYour firm’s response did not address the procedural deficiencies noted above, as they were not identified in the FDA-483.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included for Complaints (b)(4) and (b)(4) reasonably suggests your firm’s duodenovideoscope with a distal cover MAJ-2315 malfunctioned (e.g., cracked cap) while in use, leading to potential mucosal tissue damage. Your firm initiated recall Z-1292-2021 for the referenced malfunction. Per the Preamble, in Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced device malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Although your firm submitted the MDRs (MDR# 8010047-2021-03794, 8010047-2022-02861, 8010047-2021-03786, 8010047-2022-02867, 8010047-2021-03796, 8010047-2022-02865) corresponding to each of the referenced events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm initiated a series of CAPAs to investigate the root cause of the cracked cap problem and have plans to address it accordingly. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\n\nYour firm is in the process of completing CAPAs to address the referenced malfunction and updating the complaint handling process. Additionally, your firm conducted a retrospective review of all complaints associated with MAJ-2315 and complaints for the endoscopes (TJF-Q190V, TJF-Q290V, TJF-Q170V), which are used in conjunction with MAJ-2315. As a result, 98 complaints were identified for further investigation and your firm is evaluating them for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\n\nYour firm completed the update of its complaint handling procedures and is evaluating newly identified events related to cracked caps for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including the submission of newly identified reportable events, as these actions are still ongoing.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\n\nWe will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #654013 when replying. If you have any questions about the contents of this letter, please contact: Shanil Haugen, Ph.D., at Shanil.Haugen@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\ncc:\n\nTodd Brill\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 508 8042600 Ext\n\nEmail: Todd.Brill@Olympus.com","Olympus Medical Systems Corp.","olympus-medical-systems-corp-654013-03152023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corp-654013-03152023","2026-10-26T08:09:37.557484+00:00","2023-03-17","654013","Mr. Seiji Morishita","2026-08-20T01:11:43.772+00:00","2023-03-15",{"id":87,"raw":88,"subject":92,"body_html":93,"body_text":94,"firm_name":39,"letter_id":95,"created_at":59,"fei_number":19,"letter_url":96,"updated_at":97,"action_type":22,"case_status":23,"posted_date":98,"marcs_cms_no":99,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":100,"body_fetched_at":101,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":102,"medical_device_id":19,"response_letter_date":19},2263,[89,90,91,11,92,13,13,13],"\u003Ctime datetime=\"2023-01-10T14:20:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-12T05:00:00Z\">12\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-649726-12122022\">Olympus Medical Systems Corporation\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tomohisa Sakurai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Olympus Medical Systems Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2951, Ishikawa-cho\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hachioji-shi\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>192-8507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Tomohisa Sakurai:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Hachioji-shi, Tokyo, Japan, on September 6, 2022, through September 9, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures gastrointestinal and surgical endoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm's gastrointestinal and surgical endoscopes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. We received a response from your firm, dated September 30, 2022, to the Form FDA 483 (FDA 483). We address this response below, in relation to each of the noted violation(s). These violation(s) include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information in complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-02641), complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-07387), complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-11050), and complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-09059), reasonably suggests that your firm’s Uretero-Reno Fiberscope and Uretero-Reno Videoscope malfunctioned (e.g., device breakage or rupture) while in use. Your firm failed to submit an MDR for each of the referenced complaints within the required 30-calendar day timeframe. As a result of these complaints, your firm conducted recall Z-2518-2018, for the Uretero-reno fiberscope URF-P6, where it was established that such events could result in potential perforation of a patient’s organs. Per 21 CFR 803.3, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. As such, each of the referenced complaints represents an MDR-reportable malfunction, as defined in 21 CFR 803.3.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated September 30, 2022, cannot be determined at this time as the response notes that your firm is continuing to implement its systemic corrective actions, including optimizing the MDR reporting process and staff training. However, the adequacy of your firm’s response cannot be determined because your firm’s actions are presently ongoing. When your firm’s corrective actions are completed, please provide documentation or evidence of the systemic corrective actions, including a copy of your revised MDR procedure and a retrospective review of complaints for reportability.\u003C\u002Fp>\n\n\u003Cp>U.S. federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violation, as well as an explanation of how your firm plans to prevent the violation, or similar violation, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violation included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case # 478315\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violation at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nTodd Brill\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 508 8042600 Ext\u003Cbr>\nEmail: Todd.Brill@Olympus.Com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTomohisa Sakurai\n\nRecipient Title\n\nPresident\n\nOlympus Medical Systems Corporation\n\n2951, Ishikawa-cho\n\nHachioji-shi, Tokyo\n\n192-8507\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDecember 12, 2022\n\nDear Tomohisa Sakurai:\n\nDuring an inspection of your firm located in Hachioji-shi, Tokyo, Japan, on September 6, 2022, through September 9, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures gastrointestinal and surgical endoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nOur inspection revealed that your firm's gastrointestinal and surgical endoscopes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. We received a response from your firm, dated September 30, 2022, to the Form FDA 483 (FDA 483). We address this response below, in relation to each of the noted violation(s). These violation(s) include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information in complaint (b)(4) (MDR# 8010047-2021-02641), complaint (b)(4) (MDR# 8010047-2021-07387), complaint (b)(4) (MDR# 8010047-2021-11050), and complaint (b)(4) (MDR# 8010047-2021-09059), reasonably suggests that your firm’s Uretero-Reno Fiberscope and Uretero-Reno Videoscope malfunctioned (e.g., device breakage or rupture) while in use. Your firm failed to submit an MDR for each of the referenced complaints within the required 30-calendar day timeframe. As a result of these complaints, your firm conducted recall Z-2518-2018, for the Uretero-reno fiberscope URF-P6, where it was established that such events could result in potential perforation of a patient’s organs. Per 21 CFR 803.3, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. As such, each of the referenced complaints represents an MDR-reportable malfunction, as defined in 21 CFR 803.3.\n\nThe adequacy of your firm’s response dated September 30, 2022, cannot be determined at this time as the response notes that your firm is continuing to implement its systemic corrective actions, including optimizing the MDR reporting process and staff training. However, the adequacy of your firm’s response cannot be determined because your firm’s actions are presently ongoing. When your firm’s corrective actions are completed, please provide documentation or evidence of the systemic corrective actions, including a copy of your revised MDR procedure and a retrospective review of complaints for reportability.\n\nU.S. federal agencies may take your compliance history into account when considering the award of contracts.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violation, as well as an explanation of how your firm plans to prevent the violation, or similar violation, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violation included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case # 478315\n\nIf you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violation at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nTodd Brill\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 508 8042600 Ext\n\nEmail: Todd.Brill@Olympus.Com","olympus-medical-systems-corporation-649726-12122022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-649726-12122022","2026-10-26T08:09:37.595173+00:00","2023-01-10","649726","Tomohisa Sakurai","2026-08-20T01:19:56.315+00:00","2022-12-12",{"id":104,"raw":105,"subject":12,"body_html":110,"body_text":111,"firm_name":112,"letter_id":113,"created_at":114,"fei_number":19,"letter_url":115,"updated_at":116,"action_type":22,"case_status":117,"posted_date":118,"marcs_cms_no":119,"product_type":26,"closeout_date":120,"issuing_office":11,"recipient_name":121,"body_fetched_at":122,"delivery_method":123,"recipient_title":19,"reference_number":19,"action_taken_date":124,"medical_device_id":19,"response_letter_date":19},2802,[106,107,108,11,12,13,109,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-06T05:00:00Z\">01\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-01062022\">Unimicro Medical Systems-Shenzhen Co., Ltd.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-05182023\">\u003Ctime datetime=\"2023-05-31T04:00:00Z\">05\u002F31\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roly Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unimicro Medical Systems-Shenzhen Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>201, Bldg 38 101 Heshui Kou\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gongmingzhen Longgang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>518106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Roly Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Shenzhen, China, on September 15, 2021, through September 26, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not established a disposition process for product that does not conform to specified requirements. Your firm was not able to provide the disposition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> package heat sealed nonconforming products. In Nonconforming Product Handling Sheet (No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your firm noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> package heat sealing nonconformances. For these \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconforming products, the final determination was stated as “return to warehouse” and no final disposition was provided or conducted, per Nonconforming Product Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Therefore, it is unknown where these products are or how they were handled. Additionally, your firm’s staff was unaware of the nonconforming product procedure or handling and disposition of nonconforming products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to stop any products exporting to the United States of America until corrective actions are completed and deactivate all products from your Device Listings until the corrective actions are completed. You also plan to modify the Nonconforming Product Control Procedure, train relevant personnel of the design, purchasing, quality, production, warehouse, logistics, and sales department according to the revised procedure. You state you will also perform retrospective review for all products which have been sold for the US market, to analyze if there is any quality issue or adverse events that have occurred. However, to ensure a sufficient evaluation of the risk posed by the situation, you should also actively evaluate the risks associated with the device presently and take any needed actions to mitigate those risks. This should not rely only on adverse event reporting or other outside reporting. Additionally, your Corrective Action Plan does not include ensuring the disposition of nonconforming products are documented. As part of your corrective actions, you should document the disposition of the identified nonconforming products.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities as described in the Design and Development Control Procedures (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), related to the veress pneumoperitoneum needles. In this document, the procedures for design control are described in detail. The procedures include steps to review the design input, output, verification and validation, design changes, design transfer, and design history. However, your firm was unable to provide documentation and data demonstrating design requirements for the veress pneumoperitoneum needles wet met, as required by the Design and Development Control Procedures.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the Design and Development Control Procedure based on the requirements of 21 CFR 820.30 Design Control, train all design personnel according to the revised procedure, and to retrospectively review all products which have been sold for the U.S market, to analyze if there is any quality issue or adverse events occurred. However, you have no plan to evaluate the retrospectively conduct design control activities for affected products. You should conduct a review of your products to determine which products did not have design control activities conducted and retrospectively conduct those activities to ensure products meet design requirements. In addition, you should actively assess if lack of design control activities could have led to the distribution of nonconforming products (aside from review of adverse event or malfunction reports). If any risks are identified, you should take appropriate action to mitigate those risks.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was unable to provide validation documentation with objective evidence and data for activities related to the manufacturing of medical devices, specifically EtO Sterilization, Heat Sealing Packaging, and UV Glue Curing documented in the Validation Management Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Sealing Machine Sealing Effect Re-Verification Program (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Sealing Machine Sealing Effect Re-Verification Report (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), UV Curing Re-Verification Program (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Your firm also did not have personnel familiar with process validation.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the validation management control procedure based on the requirement of 21 CFR 820.75 Process validation, train all validation personnel according to the revised procedure, re-validate all other special processes identified for U.S products such as the ultrasonic cleaning process and ultrasonic welding process, and re-validate the EtO sterilization process, heat sealing packaging process, and UV glue curing process. However, these activities have not been completed. In addition, you have not indicated if or how you plan to assess any potential impacts of the lack of process validation on previously distributed product and how you plan to mitigate any associated risks. To ensure safety and conformity of product, it is important that you assess the potential impact the lack of process validation as described above, may have had on previously distributed products as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm did not provide a severity determination, or a root cause analysis conducted for CAPA events deemed “necessary”. The CAPA states a root cause analysis is required to be conducted only if necessary. However, your firm has not defined what CAPA events are necessary in the Corrective and Preventive Actions Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). In the document, your firm utilizes an in-process CAPA, which requires a severity determination, which is not defined in the procedure. There is no documented definition, requirement, or guidance in the procedure for the severity determination. Also, no root cause analysis was performed in your firm’s two most recent CAPAs, (Abnormal Manufacturing Process Feedback Memo \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Model MND11500 and Model MND11200).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the Corrective and Preventive Action Control Procedure to define severity (Major, Moderate, or Minor), and define what is “necessary” when requiring a root cause analysis. You intend to train relevant personnel of all departments according to the revised procedure. You also state you will investigate the past CAPAs and customer complaints, to confirm whether there is any improper handling of CAPAs or customer complaints, and to evaluate the risks to the products that have been sold in the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was not able to provide calibration documentation and data related to equipment and instruments including leakage tester and push &amp; pull tester, used in the manufacturing of medical devices intended for the US market. Your firm was able to provide the calibration procedure, Production Equipment Management Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, when calibration documentation for equipment and instruments used during the manufacturing of the Class II Veress Needles, such as their Leakage Tester and Push &amp; Pull Tester, your firm was unable to provide calibration documentation and data.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the production equipment management control procedure based on the requirements of 21 CFR 820.72(a) and train relevant personnel of quality, production, and warehouse departments according to the revised procedure. You also plan to send Leakage Tester and Push&amp;Pull Tester to the Calibration institute for calibration. Additionally, you state that you will review the impact of their Leakage Tester and Push&amp;Pull Tester on the product test results during the failure period based on the calibration results. Lastly, you plan to review the measuring and test equipment for any of the same issues for other inspection, measuring, and test equipment. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed, and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>6. Failure to adequately establish and maintain acceptance procedures, where appropriate, to ensure that specified requirements for in-process product are met as required by 21 CFR 820.80(c).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s Veress Needle Quality Inspection Standard (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not adequately established, as the quality control personnel were conducting in-process acceptance activities that did not include connection bond testing, and puncture testing of the subject device. Your firm has not established and maintained in-process acceptance activity procedures to ensure specified requirements for in-process products are met. The quality personnel were conducting acceptance activities based on the Inspection Standard used to conduct in-process acceptance activities for the Veress Needles. However, according to the investigator, your firm’s quality staff conducting the in-process acceptance activities were not familiar with the testing process and stated there were no established in-process acceptance procedures for the connection bond and puncture testing. However, in the Semi-Finished Inspection Record (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), there is a requirement included to conduct a connection bond test and puncture test, that the quality staff conducting the in-process acceptance activities were not familiar with. The requirement listed in the semi-finished inspection record was not included in the final Veress Needle Quality Inspection Standard.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress Needle Quality Inspection Standard and all other quality inspection standards, train relevant personnel of the quality and production department according to the revised Quality Inspection Standards, and perform retrospective review for all products which had been sold for the U.S market, to analyze if there is any quality issue or adverse event occurred. These actions have not been completed. In addition, your firm has not identified plans to evaluate their document control system, to make changes to ensure the requirements are consistent across documents. To ensure conformance to the standard across all relevant in-process acceptance activities, you should evaluate your document control system as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>7. Failure to adequately establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR, and the requirements of this part as required by 21 CFR 820.184\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was not able to provide Device History Records for their manufactured medical devices intended and exported to the US market. Your firm was unfamiliar with FDA regulations and requirements for manufactures to include the DHR requirements and their Device History Record Control Procedures (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You state you intend to modify their DHR control procedures based on the requirements of 21 CFR 820.184 and perform sample inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of the subject device based on the revised procedure, to confirm the integrity and correctness of the DHRs. You also plan to train relevant personnel on design, purchasing, quality, production, warehouse, logistics, PMC, and sales department according to the revised procedures and your firm plans to perform a retrospective review for all products which had been sold for the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>8. Failure to maintain device master records (DMRs) as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not maintained their Device Master Records related to the subject device, and the personnel was unfamiliar with documents, processes, and medical devices related to the U.S market. Additionally, the manager of the site was not familiar with the FDA regulatory requirements to include DMRs for medical device manufacturers.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to output DMRs according to the reorganized Device History File for all products exported and intended for the U.S market, and to retrospectively review for all products which have been sold for the US market, to analyze if there are any quality issues or adverse events that have occurred. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as 'detention without physical examination,' until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case #424228 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: OHT Assistant Director, Jason Roberts at jason.roberts@fda.hhs.gov or (240)402-6400\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nZeyu Chen\u003Cbr>\n238 Fernwood Ave, Edison, NEW JERSEY 08837\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoly Lee\n\nRecipient Title\n\nGeneral Manager\n\nUnimicro Medical Systems-Shenzhen Co., Ltd.\n\n201, Bldg 38 101 Heshui Kou\n\nGongmingzhen Longgang\n\nShenzhen\n\n518106\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nJanuary 6, 2022\n\nDear Roly Lee:\n\nDuring an inspection of your firm located in Shenzhen, China, on September 15, 2021, through September 26, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\n\nFor example: Your firm has not established a disposition process for product that does not conform to specified requirements. Your firm was not able to provide the disposition of (b)(4) package heat sealed nonconforming products. In Nonconforming Product Handling Sheet (No. (b)(4), dated (b)(4)), your firm noted (b)(4) package heat sealing nonconformances. For these (b)(4) nonconforming products, the final determination was stated as “return to warehouse” and no final disposition was provided or conducted, per Nonconforming Product Control Procedure (Doc No. (b)(4), Ver. (b)(4), and dated (b)(4)). Therefore, it is unknown where these products are or how they were handled. Additionally, your firm’s staff was unaware of the nonconforming product procedure or handling and disposition of nonconforming products.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to stop any products exporting to the United States of America until corrective actions are completed and deactivate all products from your Device Listings until the corrective actions are completed. You also plan to modify the Nonconforming Product Control Procedure, train relevant personnel of the design, purchasing, quality, production, warehouse, logistics, and sales department according to the revised procedure. You state you will also perform retrospective review for all products which have been sold for the US market, to analyze if there is any quality issue or adverse events that have occurred. However, to ensure a sufficient evaluation of the risk posed by the situation, you should also actively evaluate the risks associated with the device presently and take any needed actions to mitigate those risks. This should not rely only on adverse event reporting or other outside reporting. Additionally, your Corrective Action Plan does not include ensuring the disposition of nonconforming products are documented. As part of your corrective actions, you should document the disposition of the identified nonconforming products.\n\n2. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met as required by 21 CFR 820.30(a).\n\nFor example: Your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities as described in the Design and Development Control Procedures (Doc No. (b)(4), Ver. (b)(4), dated (b)(4)), related to the veress pneumoperitoneum needles. In this document, the procedures for design control are described in detail. The procedures include steps to review the design input, output, verification and validation, design changes, design transfer, and design history. However, your firm was unable to provide documentation and data demonstrating design requirements for the veress pneumoperitoneum needles wet met, as required by the Design and Development Control Procedures.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the Design and Development Control Procedure based on the requirements of 21 CFR 820.30 Design Control, train all design personnel according to the revised procedure, and to retrospectively review all products which have been sold for the U.S market, to analyze if there is any quality issue or adverse events occurred. However, you have no plan to evaluate the retrospectively conduct design control activities for affected products. You should conduct a review of your products to determine which products did not have design control activities conducted and retrospectively conduct those activities to ensure products meet design requirements. In addition, you should actively assess if lack of design control activities could have led to the distribution of nonconforming products (aside from review of adverse event or malfunction reports). If any risks are identified, you should take appropriate action to mitigate those risks.\n\n3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\n\nFor example: Your firm was unable to provide validation documentation with objective evidence and data for activities related to the manufacturing of medical devices, specifically EtO Sterilization, Heat Sealing Packaging, and UV Glue Curing documented in the Validation Management Control Procedure (Doc No. (b)(4), Ver. No. (b)(4) and dated (b)(4)), Sealing Machine Sealing Effect Re-Verification Program (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)), Sealing Machine Sealing Effect Re-Verification Report (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)), UV Curing Re-Verification Program (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)). Your firm also did not have personnel familiar with process validation.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the validation management control procedure based on the requirement of 21 CFR 820.75 Process validation, train all validation personnel according to the revised procedure, re-validate all other special processes identified for U.S products such as the ultrasonic cleaning process and ultrasonic welding process, and re-validate the EtO sterilization process, heat sealing packaging process, and UV glue curing process. However, these activities have not been completed. In addition, you have not indicated if or how you plan to assess any potential impacts of the lack of process validation on previously distributed product and how you plan to mitigate any associated risks. To ensure safety and conformity of product, it is important that you assess the potential impact the lack of process validation as described above, may have had on previously distributed products as part of your corrective action plan.\n\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a).\n\nFor example: Your firm did not provide a severity determination, or a root cause analysis conducted for CAPA events deemed “necessary”. The CAPA states a root cause analysis is required to be conducted only if necessary. However, your firm has not defined what CAPA events are necessary in the Corrective and Preventive Actions Control Procedure (Doc No. (b)(4) Ver. (b)(4) dated (b)(4)). In the document, your firm utilizes an in-process CAPA, which requires a severity determination, which is not defined in the procedure. There is no documented definition, requirement, or guidance in the procedure for the severity determination. Also, no root cause analysis was performed in your firm’s two most recent CAPAs, (Abnormal Manufacturing Process Feedback Memo (b)(4) for Model MND11500 and Model MND11200).\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the Corrective and Preventive Action Control Procedure to define severity (Major, Moderate, or Minor), and define what is “necessary” when requiring a root cause analysis. You intend to train relevant personnel of all departments according to the revised procedure. You also state you will investigate the past CAPAs and customer complaints, to confirm whether there is any improper handling of CAPAs or customer complaints, and to evaluate the risks to the products that have been sold in the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\n5. Failure to adequately establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nFor example: Your firm was not able to provide calibration documentation and data related to equipment and instruments including leakage tester and push & pull tester, used in the manufacturing of medical devices intended for the US market. Your firm was able to provide the calibration procedure, Production Equipment Management Control Procedure (Doc No. (b)(4), Ver. (b)(4), and dated (b)(4)). However, when calibration documentation for equipment and instruments used during the manufacturing of the Class II Veress Needles, such as their Leakage Tester and Push & Pull Tester, your firm was unable to provide calibration documentation and data.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the production equipment management control procedure based on the requirements of 21 CFR 820.72(a) and train relevant personnel of quality, production, and warehouse departments according to the revised procedure. You also plan to send Leakage Tester and Push&Pull Tester to the Calibration institute for calibration. Additionally, you state that you will review the impact of their Leakage Tester and Push&Pull Tester on the product test results during the failure period based on the calibration results. Lastly, you plan to review the measuring and test equipment for any of the same issues for other inspection, measuring, and test equipment. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed, and documentation verifying the successful completion of these actions are provided.\n\n6. Failure to adequately establish and maintain acceptance procedures, where appropriate, to ensure that specified requirements for in-process product are met as required by 21 CFR 820.80(c).\n\nFor example: Your firm’s Veress Needle Quality Inspection Standard (Doc No. (b)(4), Ver. (b)(4), dated (b)(4)) is not adequately established, as the quality control personnel were conducting in-process acceptance activities that did not include connection bond testing, and puncture testing of the subject device. Your firm has not established and maintained in-process acceptance activity procedures to ensure specified requirements for in-process products are met. The quality personnel were conducting acceptance activities based on the Inspection Standard used to conduct in-process acceptance activities for the Veress Needles. However, according to the investigator, your firm’s quality staff conducting the in-process acceptance activities were not familiar with the testing process and stated there were no established in-process acceptance procedures for the connection bond and puncture testing. However, in the Semi-Finished Inspection Record ((b)(4)), there is a requirement included to conduct a connection bond test and puncture test, that the quality staff conducting the in-process acceptance activities were not familiar with. The requirement listed in the semi-finished inspection record was not included in the final Veress Needle Quality Inspection Standard.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress Needle Quality Inspection Standard and all other quality inspection standards, train relevant personnel of the quality and production department according to the revised Quality Inspection Standards, and perform retrospective review for all products which had been sold for the U.S market, to analyze if there is any quality issue or adverse event occurred. These actions have not been completed. In addition, your firm has not identified plans to evaluate their document control system, to make changes to ensure the requirements are consistent across documents. To ensure conformance to the standard across all relevant in-process acceptance activities, you should evaluate your document control system as part of your corrective action plan.\n\n7. Failure to adequately establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR, and the requirements of this part as required by 21 CFR 820.184\n\nFor example: Your firm was not able to provide Device History Records for their manufactured medical devices intended and exported to the US market. Your firm was unfamiliar with FDA regulations and requirements for manufactures to include the DHR requirements and their Device History Record Control Procedures (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)).\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You state you intend to modify their DHR control procedures based on the requirements of 21 CFR 820.184 and perform sample inspection of (b)(4) batches of the subject device based on the revised procedure, to confirm the integrity and correctness of the DHRs. You also plan to train relevant personnel on design, purchasing, quality, production, warehouse, logistics, PMC, and sales department according to the revised procedures and your firm plans to perform a retrospective review for all products which had been sold for the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\n8. Failure to maintain device master records (DMRs) as required by 21 CFR 820.181.\n\nFor example: Your firm has not maintained their Device Master Records related to the subject device, and the personnel was unfamiliar with documents, processes, and medical devices related to the U.S market. Additionally, the manager of the site was not familiar with the FDA regulatory requirements to include DMRs for medical device manufacturers.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to output DMRs according to the reorganized Device History File for all products exported and intended for the U.S market, and to retrospectively review for all products which have been sold for the US market, to analyze if there are any quality issues or adverse events that have occurred. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\nGiven the serious nature of the violations of the Act, Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as 'detention without physical examination,' until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case #424228 when replying. If you have any questions about the contents of this letter, please contact: OHT Assistant Director, Jason Roberts at jason.roberts@fda.hhs.gov or (240)402-6400\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nZeyu Chen\n\n238 Fernwood Ave, Edison, NEW JERSEY 08837","Unimicro Medical Systems-Shenzhen Co., Ltd.","unimicro-medical-systems-shenzhen-co-ltd-624560-01062022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-01062022","2026-10-26T08:10:17.543342+00:00","Closed Out","2022-03-22","624560","2023-05-31","Roly Lee","2026-08-20T02:05:33.087+00:00","VIA UNITED PARCEL SERVICE","2022-01-06",{"id":126,"raw":127,"subject":132,"body_html":133,"body_text":134,"firm_name":135,"letter_id":136,"created_at":137,"fei_number":19,"letter_url":138,"updated_at":139,"action_type":22,"case_status":23,"posted_date":140,"marcs_cms_no":141,"product_type":142,"closeout_date":19,"issuing_office":131,"recipient_name":143,"body_fetched_at":144,"delivery_method":29,"recipient_title":19,"reference_number":145,"action_taken_date":146,"medical_device_id":19,"response_letter_date":19},42,[128,129,130,131,132,13,13,13],"\u003Ctime datetime=\"2026-07-14T04:00:00Z\">07\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-02T04:00:00Z\">07\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-medication-systems-limited-727560-07022026\">International Medication Systems Limited\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-99\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Jack Y. Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>International Medication Systems Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1886 Santa Anita Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South El Monte\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91733\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-99\u003C\u002Fp>\u003Cp>July 2, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Zhang:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Medication System Limited, FEI 2016148, at 1886 Santa Anita Avenue, South El Monte, from December 9 to 19, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your January 15, 2026, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures active pharmaceutical ingredients and sterile injectable drug products. The sterile injectable products include aseptically filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm failed to conduct adequate investigations. For example, you inadequately investigated multiple too-numerous-to-count (TNTC) microbial findings during the manufacture of epinephrine injection, lot EA038A5. Specifically, a viable air environmental monitoring plate, located next to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your ISO 5 aseptic filling area, yielded a too-numerous-to-count result with confluent bacterial growth and numerous insect larvae. On the same day, personnel monitoring plates for an individual in the adjacent ISO 7 \u003Cstrong>(b)(4)\u003C\u002Fstrong> also yielded TNTC results and contained insect larvae.\u003C\u002Fp>\u003Cp>Your investigation failed to identify a scientifically-supported root cause, instead attributing these exceedingly high environmental monitoring findings to an unsubstantiated hypothesis involving insect infiltration of sealed monitoring plates. Notably, written procedures require inspection of plates before use to ensure they are not contaminated or defective, and also require very strict handling measures following sampling (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags, sterile tape). The microbiological growth media batch also passed negative control testing. Although your deviation report lacked evidence of defects or sampling error, you assessed the contamination risk as “low” based on overreliance on passing sterility test results, and the quality unit approved the release of epinephrine injection, lot EA038A5.\u003C\u002Fp>\u003Cp>The presence of insect larvae and gross microbial contamination in your aseptic processing area demonstrates a critical failure of your contamination control program. The decision to release a lot manufactured under these conditions also demonstrates that your quality unit failed to exercise its responsibility to ensure drug products are manufactured under appropriate conditions and to reject any lot produced under conditions that compromise its quality.\u003C\u002Fp>\u003Cp>In your response, you reiterate that your investigation concluded the contamination was “post-exposure adventitious contamination external to the filling suite,” based on mostly acceptable environmental monitoring data in other locations that day. Using this rationale, you determined the two environmental contamination events were isolated incidents and the risk to the product was low. You also determined that no corrective actions were needed.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your investigation outcome based on a “post-exposure” hypothesis remains poorly supported by data. The occurrence of two severe contamination events on the same day in adjacent rooms indicates a significant breakdown in contamination control. Additionally, your failure to implement corrective actions reflects a critical deficiency in your investigation and indicates inadequate oversight of the state of control of the aseptic processing operation.\u003C\u002Fp>\u003Cp>We also note that, between March 2021 and March 2026, your firm filed three field alert reports for contamination issues with sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Since December 2023, you received over 90 customer complaints, many related to container-closure deficiencies such as glass breakage\u002Fvial cracking, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Many of your investigations were closed without identifying a root cause.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, third-party assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A comprehensive, independent review and update of all field alert reports and customer complaints for drug products within expiry, including scientifically sound root cause analyses, corrective actions implemented, and timelines for completion of the investigations. This review should include, where applicable, re-investigation of all complaints involving potential contamination and container-closure deficiencies. Include documentation of all investigative steps taken, potential root causes considered and those systematically ruled out, and any interim controls or preventive measures implemented. Include your corrective action plan based on this in-depth review and trend analysis.\u003C\u002Fli>\u003Cli>A comprehensive, third-party assessment and remediation plan for your pest control program. The assessment should include, but not be limited to, a review of facility design and maintenance, effectiveness of monitoring program, investigation procedures, historical findings, and personnel training.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.42(c)(10) and 21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s aseptic processing lines and operations were inadequately designed, controlled, and monitored to prevent microbiological contamination.\u003C\u002Fp>\u003Cp>Your firm refers to your aseptic processing lines as restricted access barrier systems (RABS). However, your equipment lacks fundamental design elements of a RABS, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Without this basic feature, as well as other design provisions, your processing lines cannot be categorized as RABS.\u003C\u002Fp>\u003Cp>In addition to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, RABS include various design elements that are essential for minimizing or eliminating direct gowned personnel interventions (\u003Cstrong>(b)(4)\u003C\u002Fstrong> interactions) into the critical (ISO 5) area during batch manufacturing.\u003C\u002Fp>\u003Cp>Your current process requires an operator to stand within a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ISO 5 area. The operator manually cuts open numerous (e.g., approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>) stopper bags per batch and transfers stoppers using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> scoop. These manually-intensive interventions pose a significant and repeated risk of microbial contamination. Despite the critical nature of this activity, your firm failed to conduct environmental monitoring in this area to evaluate its impact on the aseptic environment. This represents a serious gap in environmental control oversight.\u003C\u002Fp>\u003Cp>Your firm also failed to adequately evaluate unidirectional airflow in the critical area, as the smoke studies conducted were fundamentally flawed. The placement and movement of the wand as well as other factors precluded meaningful assessment of airflow directionality.\u003C\u002Fp>\u003Cp>The design of your aseptic filling line presents inherent contamination risks that are exacerbated by inadequate controls. These conditions are insufficient to ensure robust aseptic production of sterile drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you added a new environmental monitoring location in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and conducted airflow studies in the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> area. You claim that operator movement has “no impact to 1st air, maintaining unidirectional airflow and minimal turbulence.” You also propose a long-term plan to upgrade the facility within two years, including upgrading the adjacent \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ISO 5.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your proposal does not address the fundamental design flaws of your aseptic processing lines, as the primary contamination risks stem from extensive manual interventions within the ISO 5 processing area itself. Additionally, a long-term plan to upgrade the facility in two years is inadequate because it does not address how you will mitigate the immediate and ongoing risk to product quality posed by your current operations.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fsterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow – movement throughout all rooms used to conduct and support sterile operations, and all material transfers\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\u003Cli>A retrospective review and risk assessment for drug product batches within expiry that were manufactured in the affected aseptic processing area. Provide a formal risk assessment evaluating the potential for non-sterility hazards for each batch, along with a report detailing your subsequent actions, such as customer notifications or product recalls.\u003C\u002Fli>\u003Cli>Perform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system was inadequately designed, monitored, and maintained.\u003C\u002Fp>\u003Cp>You use \u003Cstrong>(b)(4)\u003C\u002Fstrong> for cleaning drug manufacturing equipment, and the same system feeds your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. During the inspection, we observed gross contamination in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> storage tank feeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system with interior surfaces coated in dark-colored plaques. Further compounding these concerns, investigators observed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been repaired with \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealant material, and that threaded connections with seal tape were used in place of sanitary fittings. These systems failed to adhere to appropriate \u003Cstrong>(b)(4) \u003C\u002Fstrong>system design and maintenance standards.\u003C\u002Fp>\u003Cp>In your response, you identify the observed dark-colored plaques in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, non-sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank as \u003Cstrong>(b)(4)\u003C\u002Fstrong> biofilm, characterizing the contamination as “predictable and environmentally normal.” You add that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank was \u003Cstrong>(b)(4)\u003C\u002Fstrong> allowed transmission of ambient light, which enabled photosynthesis and extensive \u003Cstrong>(b)(4)\u003C\u002Fstrong> growth on the tank walls. You assert that there was no impact on the quality of the downstream \u003Cstrong>(b)(4)\u003C\u002Fstrong>, relying on passing test results to support this claim. The primary corrective action you reported was cleaning the affected tank.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your proposed corrective action of simply cleaning the storage tank is insufficient because it fails to address the fundamental design and maintenance flaws that allowed unchecked \u003Cstrong>(b)(4)\u003C\u002Fstrong> growth and gross contamination. A source \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank should be designed and maintained to prevent it from becoming a reservoir for biological contamination as the resulting bioburden can potentially overwhelm downstream \u003Cstrong>(b)(4)\u003C\u002Fstrong> steps. Furthermore, your rationale of using passing downstream test results to justify the use of a grossly contaminated source tank is not in accord with basic system design and control standards. It is your responsibility to ensure that all equipment used in the manufacture of your drug products is appropriately designed, maintained, and controlled.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive third-party assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design, control, and maintenance.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, including:\u003Cbr>o A comprehensive evaluation of vulnerabilities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design and control and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system \u003Cstrong>(b)(4)\u003C\u002Fstrong>, materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\u003Cbr>o Your interim plans for assuring the quality of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> during your remediation.\u003Cbr>o A validation report for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system obtained after an appropriately designed system has been installed. Include the system validation protocol (installation qualification, operational qualification, and performance qualification), complete test results, and the final validation report.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On March 26, 2026, FDA held a teleconference with you recommending you recall epinephrine injection USP 0.1 mg\u002FmL lot EA038A5 from the U.S. market. On April 1, 2026, you initiated a voluntary recall of epinephrine injection USP 0.1 mg\u002FmL, lot EA038A5, due to lack of sterility assurance. The recall was posted to the FDA’s Enforcement Report website at:\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219475\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Assurance of Sterility – Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>It should be noted that a sterility test, while a critical final quality control for all aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release each drug product batch. The sterility test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Finished product testing alone does not establish sterility of all units because contamination is typically episodic and not uniformly distributed. Product contamination may go undetected for substantial periods if your firm is placing too much reliance on the final quality control test for sterility to become aware of a problem in aseptic manufacturing. It should also be noted that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem and a prompt review of the qualification status of your aseptic process.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2016148 and ATTN: Emily Wu.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003Cbr>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-99\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Jack Y. Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nInternational Medication Systems Limited\n\n1886 Santa Anita Avenue\n\nSouth El Monte, CA 91733\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-99\nJuly 2, 2026\nDear Dr. Zhang:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Medication System Limited, FEI 2016148, at 1886 Santa Anita Avenue, South El Monte, from December 9 to 19, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your January 15, 2026, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures active pharmaceutical ingredients and sterile injectable drug products. The sterile injectable products include aseptically filled (b)(4).\nYour firm failed to conduct adequate investigations. For example, you inadequately investigated multiple too-numerous-to-count (TNTC) microbial findings during the manufacture of epinephrine injection, lot EA038A5. Specifically, a viable air environmental monitoring plate, located next to the (b)(4) in your ISO 5 aseptic filling area, yielded a too-numerous-to-count result with confluent bacterial growth and numerous insect larvae. On the same day, personnel monitoring plates for an individual in the adjacent ISO 7 (b)(4) also yielded TNTC results and contained insect larvae.\nYour investigation failed to identify a scientifically-supported root cause, instead attributing these exceedingly high environmental monitoring findings to an unsubstantiated hypothesis involving insect infiltration of sealed monitoring plates. Notably, written procedures require inspection of plates before use to ensure they are not contaminated or defective, and also require very strict handling measures following sampling (e.g., (b)(4) bags, sterile tape). The microbiological growth media batch also passed negative control testing. Although your deviation report lacked evidence of defects or sampling error, you assessed the contamination risk as “low” based on overreliance on passing sterility test results, and the quality unit approved the release of epinephrine injection, lot EA038A5.\nThe presence of insect larvae and gross microbial contamination in your aseptic processing area demonstrates a critical failure of your contamination control program. The decision to release a lot manufactured under these conditions also demonstrates that your quality unit failed to exercise its responsibility to ensure drug products are manufactured under appropriate conditions and to reject any lot produced under conditions that compromise its quality.\nIn your response, you reiterate that your investigation concluded the contamination was “post-exposure adventitious contamination external to the filling suite,” based on mostly acceptable environmental monitoring data in other locations that day. Using this rationale, you determined the two environmental contamination events were isolated incidents and the risk to the product was low. You also determined that no corrective actions were needed.\nYour response is inadequate. Your investigation outcome based on a “post-exposure” hypothesis remains poorly supported by data. The occurrence of two severe contamination events on the same day in adjacent rooms indicates a significant breakdown in contamination control. Additionally, your failure to implement corrective actions reflects a critical deficiency in your investigation and indicates inadequate oversight of the state of control of the aseptic processing operation.\nWe also note that, between March 2021 and March 2026, your firm filed three field alert reports for contamination issues with sterile (b)(4) drug products. Since December 2023, you received over 90 customer complaints, many related to container-closure deficiencies such as glass breakage\u002Fvial cracking, (b)(4). Many of your investigations were closed without identifying a root cause.\nIn response to this letter, provide:\nA comprehensive, third-party assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\nA comprehensive, independent review and update of all field alert reports and customer complaints for drug products within expiry, including scientifically sound root cause analyses, corrective actions implemented, and timelines for completion of the investigations. This review should include, where applicable, re-investigation of all complaints involving potential contamination and container-closure deficiencies. Include documentation of all investigative steps taken, potential root causes considered and those systematically ruled out, and any interim controls or preventive measures implemented. Include your corrective action plan based on this in-depth review and trend analysis.\nA comprehensive, third-party assessment and remediation plan for your pest control program. The assessment should include, but not be limited to, a review of facility design and maintenance, effectiveness of monitoring program, investigation procedures, historical findings, and personnel training.\n2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.42(c)(10) and 21 CFR 211.113(b)).\nYour firm’s aseptic processing lines and operations were inadequately designed, controlled, and monitored to prevent microbiological contamination.\nYour firm refers to your aseptic processing lines as restricted access barrier systems (RABS). However, your equipment lacks fundamental design elements of a RABS, including (b)(4). Without this basic feature, as well as other design provisions, your processing lines cannot be categorized as RABS.\nIn addition to (b)(4), RABS include various design elements that are essential for minimizing or eliminating direct gowned personnel interventions ((b)(4) interactions) into the critical (ISO 5) area during batch manufacturing.\nYour current process requires an operator to stand within a (b)(4) ISO 5 area. The operator manually cuts open numerous (e.g., approximately (b)(4)) stopper bags per batch and transfers stoppers using a (b)(4) scoop. These manually-intensive interventions pose a significant and repeated risk of microbial contamination. Despite the critical nature of this activity, your firm failed to conduct environmental monitoring in this area to evaluate its impact on the aseptic environment. This represents a serious gap in environmental control oversight.\nYour firm also failed to adequately evaluate unidirectional airflow in the critical area, as the smoke studies conducted were fundamentally flawed. The placement and movement of the wand as well as other factors precluded meaningful assessment of airflow directionality.\nThe design of your aseptic filling line presents inherent contamination risks that are exacerbated by inadequate controls. These conditions are insufficient to ensure robust aseptic production of sterile drug products.\nIn your response, you state that you added a new environmental monitoring location in the (b)(4) area and conducted airflow studies in the ISO 5 (b)(4) area. You claim that operator movement has “no impact to 1st air, maintaining unidirectional airflow and minimal turbulence.” You also propose a long-term plan to upgrade the facility within two years, including upgrading the adjacent (b)(4) to ISO 5.\nYour response is inadequate. Your proposal does not address the fundamental design flaws of your aseptic processing lines, as the primary contamination risks stem from extensive manual interventions within the ISO 5 processing area itself. Additionally, a long-term plan to upgrade the facility in two years is inadequate because it does not address how you will mitigate the immediate and ongoing risk to product quality posed by your current operations.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fsterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel flow and material flow – movement throughout all rooms used to conduct and support sterile operations, and all material transfers\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\nA retrospective review and risk assessment for drug product batches within expiry that were manufactured in the affected aseptic processing area. Provide a formal risk assessment evaluating the potential for non-sterility hazards for each batch, along with a report detailing your subsequent actions, such as customer notifications or product recalls.\nPerform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\n3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYour (b)(4) system was inadequately designed, monitored, and maintained.\nYou use (b)(4) for cleaning drug manufacturing equipment, and the same system feeds your (b)(4) system. During the inspection, we observed gross contamination in the (b)(4) storage tank feeding the (b)(4) system with interior surfaces coated in dark-colored plaques. Further compounding these concerns, investigators observed that (b)(4) had been repaired with (b)(4) sealant material, and that threaded connections with seal tape were used in place of sanitary fittings. These systems failed to adhere to appropriate (b)(4) system design and maintenance standards.\nIn your response, you identify the observed dark-colored plaques in your (b)(4), non-sterile (b)(4) tank as (b)(4) biofilm, characterizing the contamination as “predictable and environmentally normal.” You add that the (b)(4) tank was (b)(4) allowed transmission of ambient light, which enabled photosynthesis and extensive (b)(4) growth on the tank walls. You assert that there was no impact on the quality of the downstream (b)(4), relying on passing test results to support this claim. The primary corrective action you reported was cleaning the affected tank.\nYour response is inadequate. Your proposed corrective action of simply cleaning the storage tank is insufficient because it fails to address the fundamental design and maintenance flaws that allowed unchecked (b)(4) growth and gross contamination. A source (b)(4) tank should be designed and maintained to prevent it from becoming a reservoir for biological contamination as the resulting bioburden can potentially overwhelm downstream (b)(4) steps. Furthermore, your rationale of using passing downstream test results to justify the use of a grossly contaminated source tank is not in accord with basic system design and control standards. It is your responsibility to ensure that all equipment used in the manufacture of your drug products is appropriately designed, maintained, and controlled.\nIn response to this letter, provide:\nA comprehensive third-party assessment of your (b)(4) system design, control, and maintenance.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system, including:\no A comprehensive evaluation of vulnerabilities of (b)(4) system design and control and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system (b)(4), materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\no Your interim plans for assuring the quality of your (b)(4) during your remediation.\no A validation report for the (b)(4) system obtained after an appropriately designed system has been installed. Include the system validation protocol (installation qualification, operational qualification, and performance qualification), complete test results, and the final validation report.\nDrug Recall\nOn March 26, 2026, FDA held a teleconference with you recommending you recall epinephrine injection USP 0.1 mg\u002FmL lot EA038A5 from the U.S. market. On April 1, 2026, you initiated a voluntary recall of epinephrine injection USP 0.1 mg\u002FmL, lot EA038A5, due to lack of sterility assurance. The recall was posted to the FDA’s Enforcement Report website at:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219475\nQuality Unit Authority\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nAssurance of Sterility – Aseptic Processing\nIt should be noted that a sterility test, while a critical final quality control for all aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release each drug product batch. The sterility test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Finished product testing alone does not establish sterility of all units because contamination is typically episodic and not uniformly distributed. Product contamination may go undetected for substantial periods if your firm is placing too much reliance on the final quality control test for sterility to become aware of a problem in aseptic manufacturing. It should also be noted that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem and a prompt review of the qualification status of your aseptic process.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.2 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2016148 and ATTN: Emily Wu.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","International Medication Systems Limited","international-medication-systems-limited-727560-07022026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-medication-systems-limited-727560-07022026","2026-10-26T08:09:00.176574+00:00","2026-07-14","727560","Drugs","Dr. Jack Y. Zhang","2026-08-19T04:29:55.749+00:00","320-26-99","2026-07-02",{"id":148,"raw":149,"subject":12,"body_html":153,"body_text":154,"firm_name":155,"letter_id":156,"created_at":157,"fei_number":19,"letter_url":158,"updated_at":159,"action_type":22,"case_status":23,"posted_date":160,"marcs_cms_no":161,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":162,"body_fetched_at":163,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":164,"medical_device_id":19,"response_letter_date":19},1879,[150,151,152,11,12,13,13,13],"\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-31T04:00:00Z\">08\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaltag-medsystems-ltd-662115-08312023\">Caltag Medsystems Ltd\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tim Almond, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Caltag Medsystems Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Whiteleaf Business Centre, 11 Little Balmer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Buckingham\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Buckingshire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>MK18 1TF\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@caltagmedsystems.co.uk\"> (b)(6)@caltagmedsystems.co.uk\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 31, 2023\u003Cbr>\n\u003Cbr>\nDear Dr. Tim Almond:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Buckingham, United Kingdom on May 2 through May 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the TransFix\u002FEDTA Vacuum Blood Collection Tubes (TVTs). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Nicki Kaenzig, Chief Scientific Officer, and Quality Manager\u002FManagement Representative, dated May 26, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspection Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, including verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100. For example, SOP10-001, Version 6 (v6), titled “Corrective and Preventive Action (CAPA)” dated, February 2, 2023, describes the procedures and documentation for implementing preventive actions. In the “CAPA Effectiveness” section of the SOP10-001 v6, it states “The CAPA is approved and closed by a member of the Management Team.” However, CP2019\u002F017 lacked documentation of verification or validation of effectiveness. Specifically, CP2019\u002F017 was not reviewed and signed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm states that the CAP SOP (SOP10-001 v7) has been updated and a new investigation report template has been created (10-008.01 v1) and a new Quality Review Form (01-011.02v1) has been created for review of non-conformances, complaints &amp; CAPA which is signed by the CAPA Leader\u002FNon- Conformance Lead and the Reviewer which is attached to all the documents. However, no documents were provided as evidence that the three CAPAs noted during the inspection were corrected nor were evidence or training provided to ensure that the procedures for implementing corrective and preventive actions are adequate or have been implemented. Also, your firm did not indicate whether there are plans to perform a retrospective review. Your firm should provide evidence that CAPA record CP2019\u002F017 was corrected and that the corrective actions were verified or validated. Your firm should also provide a copy of their revised and new documents and evidence of training. Further, your firm should perform a retrospective review to ensure that other CAPAs were appropriately handled.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures to ensure that formal documented reviews of the design results are planned and conducted at appropriate stages of the device's design development, as required by 21 CFR 820.30(e). For example:\u003C\u002Fp>\n\n\u003Cp>a. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design review. However, the procedure does not define how your firm will ensure that the results of a design review, including identification of the design, the date, and the individual(s) performing the review, will be documented in the design history file (DHF). Nor does this procedure ensure that all of the functions and people involved with the stage under design review are included in the design review.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection records of design reviews for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that the results of the design review have not been maintained.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, including how they plan to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF or perform a systemic review of other DHFs to ensure they are complete. Your firm also states that they plan to revise SOP12-002 to ensure that design review is adequately covered. However, no documents were provided. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF and their plan to ensure other DHFs are complete.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain adequate procedures to ensure that the device design is correctly translated into production specification, as required by 21 CFR 820.30(h). For example:\u003C\u002Fp>\n\n\u003Cp>a. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design transfer. However, this procedure does not explain how your firm will conduct the final review and approval of design and development activities in order to transfer the design to manufacturing. Nor does it describe what design documents comprise the device master record.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection, design transfer records for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that no design transfer records were created as part of the Design History File.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm states that they plan to revise SOP12-002 with design transfer procedures and ensure that the design transfer procedure is followed by the contract manufacturer. However, no documents were provided as evidence. Also, your firm’s proposal to revise their SOP did not address how they plan to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly transferred into production nor did your firm indicate whether there are plans to perform a systemic review of other products. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly translated into production and their plan to ensure other devices were correctly translated in addition to evidence of implementation.\u003C\u002Fp>\n\n\u003Cp>4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, that the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). Specifically, your firm uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong> process for packing and labeling of TransFix Vacuum Blood Collection Tubes. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a process for which the results cannot be fully verified and your firm failed to validate this packing and labeling process, as there were no process validation record and no record of the parameter settings. During the inspection, the process validation records were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that you have chosen to verify the process via a visual check.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. This is a repeat violation from the 2019 inspection which has not been adequately corrected. Your firm stated “that they performed validation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, no documentation of the validation procedure(s) or individual validation plan(s) for each process that will be validated for the device under review or the results were provided. Your firm did not address the corrective action to ensure future processes which cannot be verified are validated nor did the firm conduct a systemic review of other processes. Your firm should include the validation protocols and final reports for the heat sealing process. The protocols should contain or refer to objective and measurable acceptance criteria and describe how appropriate statistical method for data collection and analysis are used. Your firm should provide documentation and evidence of their corrective action as well as perform a systemic review to ensure all process which cannot be fully verified are appropriately validated.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained. These activities shall be documented, as required by 21 CFR 820.72(a). For example:\u003C\u002Fp>\n\n\u003Cp>a. PLAN-VAL-005v3, titled “Validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Flow Cytometer for use in the QC of CE\u002FIVD TVTs and FDA cleared TVTs for the US Market”, dated Feb 2020, describes procedures to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Flow Cytometer for use the Quality Control testing of CE\u002FIVD TVTs and FDA-cleared TVTs. However, your firm has not adequately documented, reviewed and approved the procedures. Specifically, your firm’s Installation Qualification (IQ) phase of Flow Cytometer was not adequately reviewed and approved. During the inspection, validation records were requested, and the records showed that the “Reviewer\u002FApprover” signatures had not been signed. Further, on May 8, 2014 \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed onsite maintenance of instrument and reported to your firm that the instrument is run in a room with “no or little air conditioning” which may affect the instrument.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection the procedures were requested and reviewed; however, there was not record of performance qualification (PQ) phase. Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative had agreed to correct the deficiency.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that we could not determine the adequacy at this time. Your firm plans to perform IQ\u002FPQ validation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> flow cytometer. However no documentation was provided nor did your firm include a corrective action or systemic corrective action. Your firm should provide a copy of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Flow Cytometer qualification protocol and report. Your firm should also provide their corrective action to ensure that all equipment will be suitable for its intended purpose and capable of producing valid results. Your firm should also conduct a systemic review to determine if other equipment has been appropriately qualified.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain adequate procedures to control labeling activities, including ensuring that labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, among other things, the correct unique device identifier (UDI) or universal product code (UPC), as required by 21 CFR 820.120(b). For example, SOP07-009 Version 12 (v12), titled “Dispensing and Packaging Cytomark Products Containing TransFix” dated January 15, 2021, describes your firm’s process for labeling and packaging the product. SOP07-009 v12 includes steps to verify and check for accuracy and completion before use of labeling. However, your procedures do not describe the process of examining the labeling for accuracy. Specifically, Manufacturing Batch Record of Transfix for lots 29985.33, 29985.34, 29990 and 29943 show no record of UDI compliant labels.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, in that they did not indicate whether there are plans to perform a systemic review of other device labeling. Your firm states that they plan to perform the following corrective actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Prevent any more TVT 3ml IVD products entering the USA. Email all staff with immediate message to this effect.\u003C\u002Fli>\n\t\u003Cli>Ensure UDI information on EUDAMED and GUDID is the same to enable a single harmonised label for TVT-03-50 and TVT-03-2 pouch label.\u003C\u002Fli>\n\t\u003Cli>Master new labels with barcode to replace existing stock immediately.\u003C\u002Fli>\n\t\u003Cli>Review Form 01-013.03 Label CE Marking Checklist to ensure FDA requirements are fully included.\u003C\u002Fli>\n\t\u003Cli>Prepare new Technical Sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and ensure transfer conducted properly.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, no documents were provided for review. Your firm should provide copies of their revised procedures and evidence of training and their plans to review all device labeling practices to ensure that all devices conform to the UDI requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov.&nbsp;\u003Cstrong>Refer to CMS case #662115 when replying.\u003C\u002Fstrong> If you have any questions about the contents of this letter, please contact: Christopher Blackwood, Ph.D. at +1 (240)-402-1665 or Christopher.blackwood@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, MD, PhD\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nNadine Shabat\u003Cbr>\nBion Enterprises, Ltd.\u003Cbr>\nUS Agent\u003Cbr>\nNadine.Shabat@Aesku-Bion.Com\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTim Almond, PhD\n\nRecipient Title\n\nCEO\u002FFounder\n\nCaltag Medsystems Ltd\n\nWhiteleaf Business Centre, 11 Little Balmer\n\nBuckingham\n\nBuckingshire\n\nMK18 1TF\n\nUnited Kingdom\n\n(b)(6)@caltagmedsystems.co.uk\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nAugust 31, 2023\n\nDear Dr. Tim Almond:\n\nDuring an inspection of your firm located in Buckingham, United Kingdom on May 2 through May 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the TransFix\u002FEDTA Vacuum Blood Collection Tubes (TVTs). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Nicki Kaenzig, Chief Scientific Officer, and Quality Manager\u002FManagement Representative, dated May 26, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspection Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, including verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100. For example, SOP10-001, Version 6 (v6), titled “Corrective and Preventive Action (CAPA)” dated, February 2, 2023, describes the procedures and documentation for implementing preventive actions. In the “CAPA Effectiveness” section of the SOP10-001 v6, it states “The CAPA is approved and closed by a member of the Management Team.” However, CP2019\u002F017 lacked documentation of verification or validation of effectiveness. Specifically, CP2019\u002F017 was not reviewed and signed.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm states that the CAP SOP (SOP10-001 v7) has been updated and a new investigation report template has been created (10-008.01 v1) and a new Quality Review Form (01-011.02v1) has been created for review of non-conformances, complaints & CAPA which is signed by the CAPA Leader\u002FNon- Conformance Lead and the Reviewer which is attached to all the documents. However, no documents were provided as evidence that the three CAPAs noted during the inspection were corrected nor were evidence or training provided to ensure that the procedures for implementing corrective and preventive actions are adequate or have been implemented. Also, your firm did not indicate whether there are plans to perform a retrospective review. Your firm should provide evidence that CAPA record CP2019\u002F017 was corrected and that the corrective actions were verified or validated. Your firm should also provide a copy of their revised and new documents and evidence of training. Further, your firm should perform a retrospective review to ensure that other CAPAs were appropriately handled.\n\n2. Failure to establish and maintain adequate procedures to ensure that formal documented reviews of the design results are planned and conducted at appropriate stages of the device's design development, as required by 21 CFR 820.30(e). For example:\n\na. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design review. However, the procedure does not define how your firm will ensure that the results of a design review, including identification of the design, the date, and the individual(s) performing the review, will be documented in the design history file (DHF). Nor does this procedure ensure that all of the functions and people involved with the stage under design review are included in the design review.\n\nb. During the inspection records of design reviews for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that the results of the design review have not been maintained.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, including how they plan to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF or perform a systemic review of other DHFs to ensure they are complete. Your firm also states that they plan to revise SOP12-002 to ensure that design review is adequately covered. However, no documents were provided. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF and their plan to ensure other DHFs are complete.\n\n3. Failure to establish and maintain adequate procedures to ensure that the device design is correctly translated into production specification, as required by 21 CFR 820.30(h). For example:\n\na. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design transfer. However, this procedure does not explain how your firm will conduct the final review and approval of design and development activities in order to transfer the design to manufacturing. Nor does it describe what design documents comprise the device master record.\n\nb. During the inspection, design transfer records for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that no design transfer records were created as part of the Design History File.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm states that they plan to revise SOP12-002 with design transfer procedures and ensure that the design transfer procedure is followed by the contract manufacturer. However, no documents were provided as evidence. Also, your firm’s proposal to revise their SOP did not address how they plan to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly transferred into production nor did your firm indicate whether there are plans to perform a systemic review of other products. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly translated into production and their plan to ensure other devices were correctly translated in addition to evidence of implementation.\n\n4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, that the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). Specifically, your firm uses a (b)(4) process for packing and labeling of TransFix Vacuum Blood Collection Tubes. (b)(4) is a process for which the results cannot be fully verified and your firm failed to validate this packing and labeling process, as there were no process validation record and no record of the parameter settings. During the inspection, the process validation records were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that you have chosen to verify the process via a visual check.\n\nWe reviewed your firm’s response and concluded that it is not adequate. This is a repeat violation from the 2019 inspection which has not been adequately corrected. Your firm stated “that they performed validation of (b)(4)”. However, no documentation of the validation procedure(s) or individual validation plan(s) for each process that will be validated for the device under review or the results were provided. Your firm did not address the corrective action to ensure future processes which cannot be verified are validated nor did the firm conduct a systemic review of other processes. Your firm should include the validation protocols and final reports for the heat sealing process. The protocols should contain or refer to objective and measurable acceptance criteria and describe how appropriate statistical method for data collection and analysis are used. Your firm should provide documentation and evidence of their corrective action as well as perform a systemic review to ensure all process which cannot be fully verified are appropriately validated.\n\n5. Failure to establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained. These activities shall be documented, as required by 21 CFR 820.72(a). For example:\n\na. PLAN-VAL-005v3, titled “Validation of the (b)(4) Flow Cytometer for use in the QC of CE\u002FIVD TVTs and FDA cleared TVTs for the US Market”, dated Feb 2020, describes procedures to validate the (b)(4) Flow Cytometer for use the Quality Control testing of CE\u002FIVD TVTs and FDA-cleared TVTs. However, your firm has not adequately documented, reviewed and approved the procedures. Specifically, your firm’s Installation Qualification (IQ) phase of Flow Cytometer was not adequately reviewed and approved. During the inspection, validation records were requested, and the records showed that the “Reviewer\u002FApprover” signatures had not been signed. Further, on May 8, 2014 (b)(4) performed onsite maintenance of instrument and reported to your firm that the instrument is run in a room with “no or little air conditioning” which may affect the instrument.\n\nb. During the inspection the procedures were requested and reviewed; however, there was not record of performance qualification (PQ) phase. Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative had agreed to correct the deficiency.\n\nWe reviewed your firm’s response and concluded that we could not determine the adequacy at this time. Your firm plans to perform IQ\u002FPQ validation of (b)(4) flow cytometer. However no documentation was provided nor did your firm include a corrective action or systemic corrective action. Your firm should provide a copy of the (b)(4) Flow Cytometer qualification protocol and report. Your firm should also provide their corrective action to ensure that all equipment will be suitable for its intended purpose and capable of producing valid results. Your firm should also conduct a systemic review to determine if other equipment has been appropriately qualified.\n\n6. Failure to establish and maintain adequate procedures to control labeling activities, including ensuring that labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, among other things, the correct unique device identifier (UDI) or universal product code (UPC), as required by 21 CFR 820.120(b). For example, SOP07-009 Version 12 (v12), titled “Dispensing and Packaging Cytomark Products Containing TransFix” dated January 15, 2021, describes your firm’s process for labeling and packaging the product. SOP07-009 v12 includes steps to verify and check for accuracy and completion before use of labeling. However, your procedures do not describe the process of examining the labeling for accuracy. Specifically, Manufacturing Batch Record of Transfix for lots 29985.33, 29985.34, 29990 and 29943 show no record of UDI compliant labels.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, in that they did not indicate whether there are plans to perform a systemic review of other device labeling. Your firm states that they plan to perform the following corrective actions:\n\n“Prevent any more TVT 3ml IVD products entering the USA. Email all staff with immediate message to this effect.\n\nEnsure UDI information on EUDAMED and GUDID is the same to enable a single harmonised label for TVT-03-50 and TVT-03-2 pouch label.\n\nMaster new labels with barcode to replace existing stock immediately.\n\nReview Form 01-013.03 Label CE Marking Checklist to ensure FDA requirements are fully included.\n\nPrepare new Technical Sheet for (b)(4) and ensure transfer conducted properly.”\n\nHowever, no documents were provided for review. Your firm should provide copies of their revised procedures and evidence of training and their plans to review all device labeling practices to ensure that all devices conform to the UDI requirements.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #662115 when replying. If you have any questions about the contents of this letter, please contact: Christopher Blackwood, Ph.D. at +1 (240)-402-1665 or Christopher.blackwood@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, MD, PhD\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nNadine Shabat\n\nBion Enterprises, Ltd.\n\nUS Agent\n\nNadine.Shabat@Aesku-Bion.Com","Caltag Medsystems Ltd","caltag-medsystems-ltd-662115-08312023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaltag-medsystems-ltd-662115-08312023","2026-10-26T08:08:10.563662+00:00","2023-09-05","662115","Tim Almond, PhD","2026-08-20T00:42:49.102+00:00","2023-08-31",{"id":166,"raw":167,"subject":172,"body_html":173,"body_text":174,"firm_name":175,"letter_id":176,"created_at":177,"fei_number":19,"letter_url":178,"updated_at":179,"action_type":22,"case_status":23,"posted_date":180,"marcs_cms_no":181,"product_type":26,"closeout_date":19,"issuing_office":171,"recipient_name":182,"body_fetched_at":183,"delivery_method":184,"recipient_title":19,"reference_number":19,"action_taken_date":185,"medical_device_id":19,"response_letter_date":19},1322,[168,169,170,171,172,13,13,13],"\u003Ctime datetime=\"2024-08-13T13:20:00Z\">08\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-15T04:00:00Z\">07\u002F15\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobus-medical-inc-685606-07152024\">Globus Medical, Inc.\u003C\u002Fa>","Office of Medical Device and Radiological Health Division I","CGMP\u002FQSR\u002FDrug\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel T. Scavilla\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Globus Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Valley Forge Business Center\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>2560 General Armistead Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Audubon\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19403\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS# 685606\u003C\u002Fp>\n\n\u003Cp>July 15, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Scavilla:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 2560 General Armistead Avenue, Audubon, Pennsylvania 19403 on February 15, 2024, through March 7, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the Class II Excelsius GPS (EGPS) surgical robot and associated interbody spine and cranial modules intended for use as an aid for precisely locating anatomical structures and for the spatial positioning and orientation of an instrument holder or guide tube to be used by surgeons for navigating and\u002For guiding compatible surgical instruments in open or percutaneous procedures provided that the required fiducial markers and rigid patient anatomy can be identified on CT scans or fluoroscopy. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quality System Regulation\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Daniel S. Paul, Senior Vice President of Quality Assurance, and Information Technology, dated March 28, 2024, and May 31, 2024, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology, as required by 21 CFR 820.100(a)(1).\u003C\u002Fstrong> The specifically section of Observation 5 states that you did not follow your Corrective and Preventative Action Procedure (SOP 8.5.2; Rev.K: Eff: 10\u002F18\u002F19) to conduct a CAPA investigation upon receipt of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Two examples were provided to highlight that you did not initiate CAPAs despite documentation in complaints COM-20-2011 (10\u002F6\u002F20) and COM-22-0414 (2\u002F1\u002F22) that there were 55 and 76, previous complaints of misplaced screws, respectively. You explained that the subsequent revision of SOP 8.5.2 was changed to require a trend analysis and risk reconciliation before determination of whether a CAPA is warranted.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated March 28, 2024 and May 31, 2024 and concluded that they are not adequate. In your responses, you provided data showing counts of misplaced screws per 10,000 screws implanted from 2017 to 2024. However, there was no additional level of data analyses, using appropriate statistical methodology, to determine whether there are any trends associated with part numbers, including the spine and cranial modules; lot numbers; patient symptoms; confirmed and alleged defects; causes determined by complaint investigations (e.g., software, components, user error); etc. for complaints specifically related to misplaced screws navigated by the EGPS surgical robot. Therefore, the overarching concern is that the trend analysis you rely on to determine whether CAPAs should be initiated does not employ appropriate statistical methodology to detect recurring quality problems. Furthermore, there was no information provided on how your firm evaluated risk as a factor in determining whether to initiate a CAPA for this issue.\u003C\u002Fp>\n\n\u003Cp>You also provided a revised complaint procedure which includes more details on how to conduct investigations, perform risk reconciliation, and determine when CAPAs should be initiated. Additional corrective actions included restructuring the complaint database to add additional fields for complaint investigations and risk reconciliation and developing a trend analysis procedure. No timelines were provided for corrective actions except to state that the next update will be provided by July 31, 2024. Overall, it is not clear if the identified corrective actions will follow all the requirements of 21 CFR 820.100(a)(2) to (a)(4), including verification that corrective actions are effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to review, evaluate, and investigate complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR 820.198(c).\u003C\u002Fstrong> Specifically, you did not follow your Product Complaint Procedure (SOP 8.3.1; Rev.T, U; Eff: 4\u002F22\u002F20, 1\u002F19\u002F22), which requires comprehensive complaint investigations. Moreover, this procedure did not include details on what constitutes a “comprehensive” investigation. For example, your complaint record lacked details on how you concluded that there was no device malfunction or user error for complaint COM-21-3115 (10\u002F5\u002F21) where the EGPS surgical robot was in use when a patient experienced adverse health effects and passed away. In addition, the complaint record for COM-22-0414 (2\u002F10\u002F22), received for “screw missed pedicle which then went superior into the disc space and the screw was removed,” lacked evidence that you made multiple attempts to verify whether a malfunction occurred.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated March 28, 2024 and May 31, 2024 and concluded that they are not adequate. In your responses, you acknowledge that autopsy results or a physician statement would have been beneficial in supporting the conclusion that the cause of death was not device-related. You further stated that COM-21-3115 was submitted as an MDR out of abundance of caution after discussion with investigators. You also provided a revised complaint procedure which includes more details on how to conduct investigations, perform risk reconciliation, and determine when CAPAs should be initiated. Additional corrective actions included restructuring the complaint database to add additional fields for complaint investigations and risk reconciliation and developing a trend analysis procedure. No timelines were provided for corrective actions except to state that the next update will be provided by July 31, 2024.\u003C\u002Fp>\n\n\u003Cp>Overall, it is not clear if identified corrective actions will follow the requirements of 21 CFR 820.100(a)(2) to (a)(4), including verification that corrective actions are effective. Also, there was no action identified to retrospectively review complaints for all of your products, for a reasonable period of time, to determine whether there are other examples of inadequate complaint investigations, which require corrections. Lastly, there was no correction identified to obtain information and update COM-21-3115 and COM-22-0414 with additional investigation details.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Medical Device Reporting (MDR)\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nOur inspection (also) revealed that your firm’s EGPS devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fstrong> For example, the information included for Complaint COM-19-2014 (Exhibit 15) describes an event where a patient’s dural lining of the spinal cord was damaged during a procedure with your firm’s EGPS spinal robotic system, necessitating surgical intervention and repair. There is no information reasonably suggesting that the device might not be a contributing factor to the patient’s serious injury. As such, the referenced event meets the criteria for an MDR reportable serious injury, as defined in 21 CFR 803.3. Your firm became aware of this event on September 24, 2019. Although a malfunction MDR corresponding to the referenced event was submitted to FDA, the report was received on March 12, 2024, which is beyond the required 30 calendar day time frame, and it incorrectly identifies the MDR reportable event as a malfunction. A supplement report that correctly identifies referenced MDR reportable event as a Report Type, Serious Injury, must be submitted to the FDA.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response dated March 28, 2024, and concluded that it is not adequate. Your firm stated that it submitted MDR 3004142400-2019-00106 for Complaint COM-19-2014. Although we confirmed that the report was received on March 12, 2024, it incorrectly identifies the MDR reportable event as a malfunction. A supplement report that correctly identifies referenced MDR reportable event as a Report Type, Serious Injury, has not yet been received.\u003C\u002Fp>\n\n\u003Cp>The response dated May 31, 2024, did not include new information to address this violation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to submit a report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fstrong> For example, the information included for Complaints COM-21-0424, COM-21-0467, COM-21-2838, COM-22-0414 and COM-23-2525 reasonably suggests that your firm’s EGPS spinal robotic system malfunctioned (i.e., misplaced screws) while in use. We believe that the referenced malfunction would be likely to cause or contribute to a death or serious injury if it were to recur. There is no information included for the referenced complaints that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Therefore, the information included for each referenced complaint represents a reportable malfunction. Your firm became aware of the event referenced in Complaint COM-21-0424 on January 28, 2021, Complaint COM-21-0467 on February 5, 2021, Complaint COM-21-2838 on September 15, 2021, Complaint COM-22-0414 on February 10, 2022, and Complaint COM-23-2525 on May 25, 2023. However, the corresponding MDRs 3004142400-2020-00028, 3004142400-2023-00098, and 3004142400-2023-00123 were received by the FDA on February 9, 2024, which is beyond the required 30 calendar day timeframe. Additionally, the MDRs 3004142400-2020-00023 and 3004142400-2020-00029 have not yet been received by the FDA.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated March 28, 2024, cannot be determined at this time. The response noted that your firm conducted a retrospective review of complaints received for misplaced screws since the device launched in 2017 and identified 77 complaints that represent MDR reportable events. However, your firm stated it cannot submit all of the MDRs due to duplication issues and is working with the FDA Electronic Submissions Gateway (ESG) helpdesk for resolution.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated May 31, 2024, cannot be determined at this time. Your firm provided an update to its action plans, including continuing to resolve the eMDR acknowledge process.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to maintain copies of all electronic acknowledgments FDA sends you in response to electronic MDR submissions in your MDR event file, as required by 21 CFR 803.18(b)(1)(iii).\u003C\u002Fstrong> For example, during the inspection, your firm was unable to provide the electronic acknowledgments for the following MDRs # 3004142400-2020-00018 (dated January 13, 2020), 3004142400-2020-00030 (dated February 14, 2020, yet not received by FDA), 3004142400-2020-00045 (dated April 29, 2020), 3004142400-2020-00048 (dated May 11, 2020), 3004142400-2020-00049 (dated May 11, 2020), 3004142400-2023-00088 (dated May 11, 2020), and 3004142400-2023-00093 (dated May 23, 2020).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated March 28, 2024, cannot be determined at this time. The response noted that your firm is conducting systemic corrective actions, including procedure updates to verify MDR submissions. However, your firm did not provide any documentation or evidence to demonstrate the completion of these corrective actions, as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated May 31, 2024, cannot be determined at this time. The response included a red-lined copy of its revised Product Complaint Procedure SOP 8.3.1, Rev. Y, which incorporates the submission verification process, as well as staff training records. However, your firm did not provide any documentation or evidence to demonstrate the completion of all corrective actions, including the planned effectiveness checks.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 685606 when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan at 313.393.8253 or sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision I\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>RDML Raquel Peat, Ph.D., MPH, USPHS\u003Cbr>\nDirector\u003Cbr>\nOHT 6: Office of Orthopedic Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC: Daniel Paul, Senior VP of Quality Assurance, &amp; IT, dspaul@globusmedical.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDaniel T. Scavilla\n\nRecipient Title\n\nPresident & CEO\n\nGlobus Medical, Inc.\n\nValley Forge Business Center\n\n2560 General Armistead Avenue\n\nAudubon, PA 19403\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Division I\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 685606\n\nJuly 15, 2024\n\nDear Mr. Scavilla:\n\nDuring an inspection of your firm located at 2560 General Armistead Avenue, Audubon, Pennsylvania 19403 on February 15, 2024, through March 7, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the Class II Excelsius GPS (EGPS) surgical robot and associated interbody spine and cranial modules intended for use as an aid for precisely locating anatomical structures and for the spatial positioning and orientation of an instrument holder or guide tube to be used by surgeons for navigating and\u002For guiding compatible surgical instruments in open or percutaneous procedures provided that the required fiducial markers and rigid patient anatomy can be identified on CT scans or fluoroscopy. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nQuality System Regulation\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Daniel S. Paul, Senior Vice President of Quality Assurance, and Information Technology, dated March 28, 2024, and May 31, 2024, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology, as required by 21 CFR 820.100(a)(1). The specifically section of Observation 5 states that you did not follow your Corrective and Preventative Action Procedure (SOP 8.5.2; Rev.K: Eff: 10\u002F18\u002F19) to conduct a CAPA investigation upon receipt of (b)(4). Two examples were provided to highlight that you did not initiate CAPAs despite documentation in complaints COM-20-2011 (10\u002F6\u002F20) and COM-22-0414 (2\u002F1\u002F22) that there were 55 and 76, previous complaints of misplaced screws, respectively. You explained that the subsequent revision of SOP 8.5.2 was changed to require a trend analysis and risk reconciliation before determination of whether a CAPA is warranted.\n\nWe reviewed your firm’s responses dated March 28, 2024 and May 31, 2024 and concluded that they are not adequate. In your responses, you provided data showing counts of misplaced screws per 10,000 screws implanted from 2017 to 2024. However, there was no additional level of data analyses, using appropriate statistical methodology, to determine whether there are any trends associated with part numbers, including the spine and cranial modules; lot numbers; patient symptoms; confirmed and alleged defects; causes determined by complaint investigations (e.g., software, components, user error); etc. for complaints specifically related to misplaced screws navigated by the EGPS surgical robot. Therefore, the overarching concern is that the trend analysis you rely on to determine whether CAPAs should be initiated does not employ appropriate statistical methodology to detect recurring quality problems. Furthermore, there was no information provided on how your firm evaluated risk as a factor in determining whether to initiate a CAPA for this issue.\n\nYou also provided a revised complaint procedure which includes more details on how to conduct investigations, perform risk reconciliation, and determine when CAPAs should be initiated. Additional corrective actions included restructuring the complaint database to add additional fields for complaint investigations and risk reconciliation and developing a trend analysis procedure. No timelines were provided for corrective actions except to state that the next update will be provided by July 31, 2024. Overall, it is not clear if the identified corrective actions will follow all the requirements of 21 CFR 820.100(a)(2) to (a)(4), including verification that corrective actions are effective.\n\n2. Failure to review, evaluate, and investigate complaints involving the possible failure of a device to meet any of its specifications, as required by 21 CFR 820.198(c). Specifically, you did not follow your Product Complaint Procedure (SOP 8.3.1; Rev.T, U; Eff: 4\u002F22\u002F20, 1\u002F19\u002F22), which requires comprehensive complaint investigations. Moreover, this procedure did not include details on what constitutes a “comprehensive” investigation. For example, your complaint record lacked details on how you concluded that there was no device malfunction or user error for complaint COM-21-3115 (10\u002F5\u002F21) where the EGPS surgical robot was in use when a patient experienced adverse health effects and passed away. In addition, the complaint record for COM-22-0414 (2\u002F10\u002F22), received for “screw missed pedicle which then went superior into the disc space and the screw was removed,” lacked evidence that you made multiple attempts to verify whether a malfunction occurred.\n\nWe reviewed your firm’s responses dated March 28, 2024 and May 31, 2024 and concluded that they are not adequate. In your responses, you acknowledge that autopsy results or a physician statement would have been beneficial in supporting the conclusion that the cause of death was not device-related. You further stated that COM-21-3115 was submitted as an MDR out of abundance of caution after discussion with investigators. You also provided a revised complaint procedure which includes more details on how to conduct investigations, perform risk reconciliation, and determine when CAPAs should be initiated. Additional corrective actions included restructuring the complaint database to add additional fields for complaint investigations and risk reconciliation and developing a trend analysis procedure. No timelines were provided for corrective actions except to state that the next update will be provided by July 31, 2024.\n\nOverall, it is not clear if identified corrective actions will follow the requirements of 21 CFR 820.100(a)(2) to (a)(4), including verification that corrective actions are effective. Also, there was no action identified to retrospectively review complaints for all of your products, for a reasonable period of time, to determine whether there are other examples of inadequate complaint investigations, which require corrections. Lastly, there was no correction identified to obtain information and update COM-21-3115 and COM-22-0414 with additional investigation details.\n\nMedical Device Reporting (MDR)\n\nOur inspection (also) revealed that your firm’s EGPS devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example, the information included for Complaint COM-19-2014 (Exhibit 15) describes an event where a patient’s dural lining of the spinal cord was damaged during a procedure with your firm’s EGPS spinal robotic system, necessitating surgical intervention and repair. There is no information reasonably suggesting that the device might not be a contributing factor to the patient’s serious injury. As such, the referenced event meets the criteria for an MDR reportable serious injury, as defined in 21 CFR 803.3. Your firm became aware of this event on September 24, 2019. Although a malfunction MDR corresponding to the referenced event was submitted to FDA, the report was received on March 12, 2024, which is beyond the required 30 calendar day time frame, and it incorrectly identifies the MDR reportable event as a malfunction. A supplement report that correctly identifies referenced MDR reportable event as a Report Type, Serious Injury, must be submitted to the FDA.\n\nWe have reviewed your firm’s response dated March 28, 2024, and concluded that it is not adequate. Your firm stated that it submitted MDR 3004142400-2019-00106 for Complaint COM-19-2014. Although we confirmed that the report was received on March 12, 2024, it incorrectly identifies the MDR reportable event as a malfunction. A supplement report that correctly identifies referenced MDR reportable event as a Report Type, Serious Injury, has not yet been received.\n\nThe response dated May 31, 2024, did not include new information to address this violation.\n\n2. Failure to submit a report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example, the information included for Complaints COM-21-0424, COM-21-0467, COM-21-2838, COM-22-0414 and COM-23-2525 reasonably suggests that your firm’s EGPS spinal robotic system malfunctioned (i.e., misplaced screws) while in use. We believe that the referenced malfunction would be likely to cause or contribute to a death or serious injury if it were to recur. There is no information included for the referenced complaints that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Therefore, the information included for each referenced complaint represents a reportable malfunction. Your firm became aware of the event referenced in Complaint COM-21-0424 on January 28, 2021, Complaint COM-21-0467 on February 5, 2021, Complaint COM-21-2838 on September 15, 2021, Complaint COM-22-0414 on February 10, 2022, and Complaint COM-23-2525 on May 25, 2023. However, the corresponding MDRs 3004142400-2020-00028, 3004142400-2023-00098, and 3004142400-2023-00123 were received by the FDA on February 9, 2024, which is beyond the required 30 calendar day timeframe. Additionally, the MDRs 3004142400-2020-00023 and 3004142400-2020-00029 have not yet been received by the FDA.\n\nThe adequacy of your firm’s response dated March 28, 2024, cannot be determined at this time. The response noted that your firm conducted a retrospective review of complaints received for misplaced screws since the device launched in 2017 and identified 77 complaints that represent MDR reportable events. However, your firm stated it cannot submit all of the MDRs due to duplication issues and is working with the FDA Electronic Submissions Gateway (ESG) helpdesk for resolution.\n\nThe adequacy of your firm’s response dated May 31, 2024, cannot be determined at this time. Your firm provided an update to its action plans, including continuing to resolve the eMDR acknowledge process.\n\n3. Failure to maintain copies of all electronic acknowledgments FDA sends you in response to electronic MDR submissions in your MDR event file, as required by 21 CFR 803.18(b)(1)(iii). For example, during the inspection, your firm was unable to provide the electronic acknowledgments for the following MDRs # 3004142400-2020-00018 (dated January 13, 2020), 3004142400-2020-00030 (dated February 14, 2020, yet not received by FDA), 3004142400-2020-00045 (dated April 29, 2020), 3004142400-2020-00048 (dated May 11, 2020), 3004142400-2020-00049 (dated May 11, 2020), 3004142400-2023-00088 (dated May 11, 2020), and 3004142400-2023-00093 (dated May 23, 2020).\n\nThe adequacy of your firm’s response dated March 28, 2024, cannot be determined at this time. The response noted that your firm is conducting systemic corrective actions, including procedure updates to verify MDR submissions. However, your firm did not provide any documentation or evidence to demonstrate the completion of these corrective actions, as they are still ongoing.\n\nThe adequacy of your firm’s response dated May 31, 2024, cannot be determined at this time. The response included a red-lined copy of its revised Product Complaint Procedure SOP 8.3.1, Rev. Y, which incorporates the submission verification process, as well as staff training records. However, your firm did not provide any documentation or evidence to demonstrate the completion of all corrective actions, including the planned effectiveness checks.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 685606 when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan at 313.393.8253 or sargum.morgan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision I\n\n\u002FS\u002F\n\nRDML Raquel Peat, Ph.D., MPH, USPHS\n\nDirector\n\nOHT 6: Office of Orthopedic Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC: Daniel Paul, Senior VP of Quality Assurance, & IT, dspaul@globusmedical.com","Globus Medical, Inc.","globus-medical-inc-685606-07152024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobus-medical-inc-685606-07152024","2026-10-26T08:08:47.039644+00:00","2024-08-13","685606","Daniel T. Scavilla","2026-08-19T23:53:45.215+00:00","United Parcel Service","2024-07-15",{"id":187,"raw":188,"subject":192,"body_html":193,"body_text":194,"firm_name":195,"letter_id":196,"created_at":137,"fei_number":19,"letter_url":197,"updated_at":198,"action_type":22,"case_status":23,"posted_date":199,"marcs_cms_no":200,"product_type":142,"closeout_date":19,"issuing_office":131,"recipient_name":19,"body_fetched_at":201,"delivery_method":202,"recipient_title":19,"reference_number":19,"action_taken_date":203,"medical_device_id":19,"response_letter_date":19},472,[189,190,191,131,192,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","2026-08-19T14:27:25.954+00:00","Via Email","2025-11-13",{"id":205,"raw":206,"subject":210,"body_html":211,"body_text":212,"firm_name":213,"letter_id":214,"created_at":18,"fei_number":19,"letter_url":215,"updated_at":216,"action_type":22,"case_status":23,"posted_date":217,"marcs_cms_no":218,"product_type":142,"closeout_date":19,"issuing_office":131,"recipient_name":19,"body_fetched_at":219,"delivery_method":220,"recipient_title":19,"reference_number":19,"action_taken_date":221,"medical_device_id":19,"response_letter_date":19},591,[207,208,209,131,210,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025\">Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:https:\u002F\u002Fwww.getfitmedical.com\"> https:\u002F\u002Fwww.getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:drewcromer@getfitmedical.com\"> drewcromer@getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Get.Fit.Medical:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.\u003Ca id=\"footnoteref1_9e35aee\" href=\"#footnote1_9e35aee\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\u003Cbr>• “SILDENAFIL (GENERIC VIAGRA)”\u003Cbr>• “TADALAFIL (GENERIC CIALIS)”\u003Cbr>• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\u003Cbr>• “TIRZEPATIDE (GENERIC MOUNJARO)”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_gm2b1es\" href=\"#footnote2_gm2b1es\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_9e35aee\">\u003Ca href=\"#footnoteref1_9e35aee\">1\u003C\u002Fa>The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_gm2b1es\">\u003Ca href=\"#footnoteref2_gm2b1es\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nGet.Fit.Medical, LLC dba Get.Fit.Medical\n\nUnited States\n\nhttps:\u002F\u002Fwww.getfitmedical.com\n\ndrewcromer@getfitmedical.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nGet.Fit.Medical:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.1 As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\n• “SILDENAFIL (GENERIC VIAGRA)”\n• “TADALAFIL (GENERIC CIALIS)”\n• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\n• “TIRZEPATIDE (GENERIC MOUNJARO)”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Get.Fit.Medical, LLC dba Get.Fit.Medical","getfitmedical-llc-dba-getfitmedical-715801-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025","2026-10-26T08:08:45.732183+00:00","2025-09-16","715801","2026-08-19T16:21:40.471+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":223,"raw":224,"subject":229,"body_html":230,"body_text":231,"firm_name":232,"letter_id":233,"created_at":137,"fei_number":19,"letter_url":234,"updated_at":235,"action_type":22,"case_status":23,"posted_date":236,"marcs_cms_no":237,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":238,"body_fetched_at":239,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":240,"medical_device_id":19,"response_letter_date":19},63,[225,226,227,11,228,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","2026-05-20",{"id":242,"raw":243,"subject":229,"body_html":247,"body_text":248,"firm_name":249,"letter_id":250,"created_at":18,"fei_number":19,"letter_url":251,"updated_at":252,"action_type":22,"case_status":23,"posted_date":253,"marcs_cms_no":254,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":255,"body_fetched_at":256,"delivery_method":123,"recipient_title":19,"reference_number":19,"action_taken_date":257,"medical_device_id":19,"response_letter_date":19},954,[244,245,246,11,229,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","2025-04-22","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","2025-04-04",{"id":259,"raw":260,"subject":264,"body_html":266,"body_text":267,"firm_name":268,"letter_id":269,"created_at":59,"fei_number":19,"letter_url":270,"updated_at":271,"action_type":22,"case_status":117,"posted_date":272,"marcs_cms_no":273,"product_type":26,"closeout_date":274,"issuing_office":11,"recipient_name":275,"body_fetched_at":276,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":277,"medical_device_id":19,"response_letter_date":19},2483,[261,262,263,11,264,13,265,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":279,"raw":280,"subject":12,"body_html":285,"body_text":286,"firm_name":287,"letter_id":288,"created_at":157,"fei_number":19,"letter_url":289,"updated_at":290,"action_type":22,"case_status":23,"posted_date":291,"marcs_cms_no":292,"product_type":26,"closeout_date":19,"issuing_office":293,"recipient_name":294,"body_fetched_at":295,"delivery_method":202,"recipient_title":19,"reference_number":19,"action_taken_date":296,"medical_device_id":19,"response_letter_date":19},1506,[281,282,283,284,12,13,13,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-29T04:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectrum-medical-ltd-666543-09292023\">Spectrum Medical Ltd\u003C\u002Fa>","&quot;OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality&quot;","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steve Turner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Spectrum Medical Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Harrier 4, Meteor Business Park, Cheltenham Road East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gloucester, Gloucestershire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>GL2 9QL\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 29, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Turner:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at Harrier 4, Meteor Business Park, Cheltenham Road East, Gloucester, Gloucestershire, GL2 9QL United Kingdom on April 24, 2023 through April 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Quantum Perfusion Systems family of devices, which include, but are not limited to, Quantum Oxygenators, Quantum SuperPAC tubing sets and cannulas, Quantum Perfusion Roller Pumps, Quantum Pump Frames, Quantum Power Supplies, Quantum Ventilation Modules, Quantum Smart Occluders, Quantum PureFlow Centrifugal Drives, and Quantum Heater Cooler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you, dated May 5, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved-Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has reviewed your firm’s U.S. promotional material and user manuals for your Quantum Perfusion devices that were collected during the inspection and determined that, based on the labeling changes in the promotional material and user manuals, your firm markets several devices with indications beyond what FDA has cleared in your premarket notifications for these devices. As explained in Section V.A1 of the guidance document “\u003Cu>Deciding When to Submit a 510(k) for a Change to an Existing Device\u003C\u002Fu>” (“510(k) Modifications Guidance”) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device), “most labeling changes that affect the substance, meaning, or scope of the indications for use could significantly affect safety or effectiveness and will require submission of a new 510(k).” As discussed below, your firm’s marketing of the above devices for use beyond the cleared 6 hours in cardiopulmonary bypass procedures and for use in the Intensive Care Unit (ICU) as well as patient transport constitute major changes to the scope of the indications for use that impact the intended use and significantly affect the safety or effectiveness of the devices. Therefore, per 21 CFR 807.81(a)(3)(ii), these changes required the submission of a new 510(k).\u003C\u002Fp>\n\n\u003Cp>We discuss below the specific instances where you market indications that go beyond what FDA has cleared in your premarket submissions for these products.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quantum Pureflow Centrifugal Pumps:\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your Quantum Pureflow Centrifugal Pumps are cleared under marketing submissions K220842, K201320, K202169, and K192850. All cleared indications are similar and are for cardiopulmonary bypass (CPB) surgery, and following is an example of the cleared indications from K201320:\u003C\u002Fp>\n\n\u003Cp>The Quantum Perfusion Centrifugal Blood Pump CP22 with Integrated Sensors indicated for use exclusively with the Quantum Centrifugal Drive of Spectrum Medical is intended to pump the blood through an extracorporeal circuit and to monitor pressure for periods lasting less than 6 hours for the purpose of providing either: (i) Full or partial cardiopulmonary bypass (i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or (ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.\u003C\u002Fp>\n\n\u003Cp>All cleared indications for your Quantum Centrifugal Pumps specify that the pumps are indicated for open surgical procedures lasting 6 hours or less.\u003C\u002Fp>\n\n\u003Cp>However, on page 22, Section 3.1.1 Intended Use, of your “Quantum Perfusions Systems Hardware Manual, ECLS” which is distributed in the U.S., you state that “Quantum PureFlow Centrifugal Blood Pumps are indicated for use for 29 days. Refer to the Instructions for Use provided with Quantum PureFlow products.” The PureFlow Centrifugal Blood Pumps are not indicated for use for 29 days in the United States. They are indicated for use for up to 6 hours. Further, in your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” which is material that is distributed in the U.S., you state on page 13 that the CP22 Centrifugal Drive System “can be used to support ECLS circuits” and “can be integrated with either the Charlotte and Toronto Perfusion Systems or directly connected to the new Quantum Workstation Elite during transport.” Your pump is cleared with an indication for open cardiac procedures. These procedures are not performed in the Intensive Care Unit (ICU) nor are they performed during transportation. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum Roller Pumps and Quantum Power Supply Lite\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The Quantum Roller Pumps and Quantum Power Supply Lite are cleared under premarket submission K173834 with the following indication:\u003C\u002Fp>\n\n\u003Cp>&nbsp; The Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\u003C\u002Fp>\n\n\u003Cp>However, you have listed both the pumps and the power supply lite as part of the ECLS system on page 21 of your “Quantum Perfusion Systems for ECLS Hardware Manual” which is distributed in the U.S.. Neither of these devices have been cleared with indications for any other form of extracorporeal life support (ECLS), other than CPB. You have a separate manual entitled “Quantum Perfusion Systems for CPB Hardware Manual.” Further, on page 14 of your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” you list your roller pumps as part of your portfolio for ECLS in the ICU and patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum SuperPAC with Side Port Technology and Quantum SuperPAC – Dual Lumen Technology\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The SuperPAC family of cannulas are cleared under K221353 and K203067. All cleared indications for models in this family contain the following phrase:\u003C\u002Fp>\n\n\u003Cp>&nbsp; “intended for use…during extracorporeal life support procedures for periods of maximum 6 hours”\u003C\u002Fp>\n\n\u003Cp>On pages 22 and 23 of “Flexible ECLS Solutions for the ICU and Patient Transport” you state that the devices are used during extracorporeal life support and VA extracorporeal life support. You do not indicate that the device is indicated to be used only up to 6 hours. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum Ventilation Module\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>On pages 10 and 11 of “Flexible ECLS Solutions for the ICU and Patient Transport” you list your Quantum Ventilation Module Lite, which, according to the product list provided to the FDA Inspector, was introduced into the U.S. market via a letter to file for your K202733 submission, which is for the Quantum Ventilation Module. In the premarket submission for K202733, the instructions for use provided for FDA review state that “the Quantum Ventilation Module has been designed to be used by experienced and trained clinicians as part of cardiopulmonary bypass therapy.” It further states that the equipment is “suitable for use in a hospital operating environment.” There is no discussion of use for patient transportation or use in the ICU. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum SuperPAC Tubing Set\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>On page 16 “Flexible ECLS Solutions for the ICU and Patient Transport” you present your Quantum SuperPAC tubing system, which is cleared under K213540 for\u003C\u002Fp>\n\n\u003Cp>&nbsp; “use during cardiopulmonary bypass for a duration of up to 6 hours.”\u003C\u002Fp>\n\n\u003Cp>Cardiopulmonary bypass is not performed in the ICU or during patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Charlotte Frame Configuration\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that there are several Quantum Perfusion Frames sold in the U. S. and several have been introduced via letter to file to the submission K173834. One of these is the Charlotte frame configuration. Because it was introduced via a letter to file, FDA has not reviewed this frame configuration. The cleared indications for K173834 are:\u003C\u002Fp>\n\n\u003Cp>&nbsp; The Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\u003C\u002Fp>\n\n\u003Cp>However, the Charlotte frame is not listed in your “Quantum Perfusion Systems for CPB Hardware Manual” but it is listed in your “Quantum Perfusion Systems for ECLS Hardware Manual.” In addition, the Charlotte Perfusion System is presented on page 5 of “Flexible ECLS Solutions for the ICU and Patient Transport” and states it is “designed to maximize mobility within the ICU.” The Charlotte frame is being marketed with a different indication (i.e., ECLS other than CPB) than the frames cleared under K173834 (i.e., CPB). Specifically, frames that cannot safely and reliably support the configuration of devices needed for ECLS procedures other than CPB, raise serious public health concerns when used for those procedures, because failure of the frame to safely hold the devices during transportation or treatment of patients could result in serious patient harm or death. These devices are considered life sustaining and require a new premarket submission to assess safety and effectiveness.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated May 5, 2023, did not address the violations discussed above and, therefore, is not adequate.\u003Cbr>\n\u003Cbr>\nAccordingly, as discussed above, several of the Quantum Perfusion devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures that include requirements for identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>For example: CAPA number 342, which was opened on January 30, 2023, and closed on March 14, 2023, does not contain an adequate evaluation of actions needed to correct nonconforming product in the field. The CAPA notes that the issue will “be picked up during the general Pre-Install process, through existing checks, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be swapped out if\u002Fwhen required.” While this addresses the detectability and corrective actions once the failure occurs, there is no evidence of consideration given to the potential risks of the slipping\u002F failure to lock occurring during use and preventive actions that may be taken to prevent the issue from occurring. This does not identify the action(s) needed to correct the nonconforming product that is in the field, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate with respect to CAPA 342, because it notes that a plan will be determined to verify and validate the CAPA actions and that the results will be documented once they are identified and completed. Your response does not address the risk of this nonconformity to fielded devices nor does it identify any plans for corrections or corrective actions for fielded devices.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures that include requirements for verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>For example: CAPA number 315, which was opened on April 12, 2022, and closed on November 11, 2022, does not contain a verification or validation plan and results that demonstrate that the corrective and preventive actions put in place to prevent the heat transfer fluid bag from breaking and leaking during shipping were effective. The packaging for the fluid bag was modified but there was no verification or validation that this change was effective in preventing the bag from being damaged in shipping. There is also no verification or validation that the corrective and preventive actions do not adversely affect the finished device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate. In this response, you provided an open CAPA, Number 357, that states effectiveness of the verification\u002Fvalidation plan and results will be documented. Your firm stated that you intended to submit your plans to verify and validate the actions taken in the CAPA by May 31, 2023, and results recorded by August 31, 2023, to FDA. In addition, SOP-018_V16 “Corrective and Preventive Action Procedure” will be reviewed and updated and the “Corrective and Preventative Action Report” will be updated to include an effectiveness of Verification\u002F Validation plan and results within the form.\u003C\u002Fp>\n\n\u003Cp>This response is not adequate because 1) the plans and results have not been provided to FDA as promised to verify that the actions identified in the CAPA have been verified and validated for effectiveness and that the actions do not adversely impact the final finished device and 2) there is no planned retrospective review to identify other CAPAs whose actions have been implemented without verification and validation.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QSR violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. \u003Cstrong>Refer to CMS case #666543\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Kathleen Grunder, Biomedical Engineer, at 301-796-2676 or Kathleen.Grunder@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, MD\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health for\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nColleen Powell, US Agent\u003Cbr>\nSpectrum Medical Inc\u003Cbr>\n481 Munn Road, Suite 180\u003Cbr>\nFort Mills, SC US 29715\u003Cbr>\nVia Email: Colleen.Powell@spectrummedical.com&gt;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteve Turner\n\nRecipient Title\n\nChief Executive Officer\n\nSpectrum Medical Ltd\n\nHarrier 4, Meteor Business Park, Cheltenham Road East\n\nGloucester, Gloucestershire\n\nGL2 9QL\n\nUnited Kingdom\n\nIssuing Office:\n\n\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nWARNING LETTER\n\nSeptember 29, 2023\n\nDear Mr. Turner:\n\nDuring an inspection of your firm located at Harrier 4, Meteor Business Park, Cheltenham Road East, Gloucester, Gloucestershire, GL2 9QL United Kingdom on April 24, 2023 through April 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Quantum Perfusion Systems family of devices, which include, but are not limited to, Quantum Oxygenators, Quantum SuperPAC tubing sets and cannulas, Quantum Perfusion Roller Pumps, Quantum Pump Frames, Quantum Power Supplies, Quantum Ventilation Modules, Quantum Smart Occluders, Quantum PureFlow Centrifugal Drives, and Quantum Heater Cooler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response from you, dated May 5, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nUnapproved-Device Violations\n\nFDA has reviewed your firm’s U.S. promotional material and user manuals for your Quantum Perfusion devices that were collected during the inspection and determined that, based on the labeling changes in the promotional material and user manuals, your firm markets several devices with indications beyond what FDA has cleared in your premarket notifications for these devices. As explained in Section V.A1 of the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device” (“510(k) Modifications Guidance”) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device), “most labeling changes that affect the substance, meaning, or scope of the indications for use could significantly affect safety or effectiveness and will require submission of a new 510(k).” As discussed below, your firm’s marketing of the above devices for use beyond the cleared 6 hours in cardiopulmonary bypass procedures and for use in the Intensive Care Unit (ICU) as well as patient transport constitute major changes to the scope of the indications for use that impact the intended use and significantly affect the safety or effectiveness of the devices. Therefore, per 21 CFR 807.81(a)(3)(ii), these changes required the submission of a new 510(k).\n\nWe discuss below the specific instances where you market indications that go beyond what FDA has cleared in your premarket submissions for these products.\n\nQuantum Pureflow Centrifugal Pumps:\n\nYour Quantum Pureflow Centrifugal Pumps are cleared under marketing submissions K220842, K201320, K202169, and K192850. All cleared indications are similar and are for cardiopulmonary bypass (CPB) surgery, and following is an example of the cleared indications from K201320:\n\nThe Quantum Perfusion Centrifugal Blood Pump CP22 with Integrated Sensors indicated for use exclusively with the Quantum Centrifugal Drive of Spectrum Medical is intended to pump the blood through an extracorporeal circuit and to monitor pressure for periods lasting less than 6 hours for the purpose of providing either: (i) Full or partial cardiopulmonary bypass (i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or (ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.\n\nAll cleared indications for your Quantum Centrifugal Pumps specify that the pumps are indicated for open surgical procedures lasting 6 hours or less.\n\nHowever, on page 22, Section 3.1.1 Intended Use, of your “Quantum Perfusions Systems Hardware Manual, ECLS” which is distributed in the U.S., you state that “Quantum PureFlow Centrifugal Blood Pumps are indicated for use for 29 days. Refer to the Instructions for Use provided with Quantum PureFlow products.” The PureFlow Centrifugal Blood Pumps are not indicated for use for 29 days in the United States. They are indicated for use for up to 6 hours. Further, in your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” which is material that is distributed in the U.S., you state on page 13 that the CP22 Centrifugal Drive System “can be used to support ECLS circuits” and “can be integrated with either the Charlotte and Toronto Perfusion Systems or directly connected to the new Quantum Workstation Elite during transport.” Your pump is cleared with an indication for open cardiac procedures. These procedures are not performed in the Intensive Care Unit (ICU) nor are they performed during transportation. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum Roller Pumps and Quantum Power Supply Lite\n\nThe Quantum Roller Pumps and Quantum Power Supply Lite are cleared under premarket submission K173834 with the following indication:\n\nThe Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\n\nHowever, you have listed both the pumps and the power supply lite as part of the ECLS system on page 21 of your “Quantum Perfusion Systems for ECLS Hardware Manual” which is distributed in the U.S.. Neither of these devices have been cleared with indications for any other form of extracorporeal life support (ECLS), other than CPB. You have a separate manual entitled “Quantum Perfusion Systems for CPB Hardware Manual.” Further, on page 14 of your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” you list your roller pumps as part of your portfolio for ECLS in the ICU and patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum SuperPAC with Side Port Technology and Quantum SuperPAC – Dual Lumen Technology\n\nThe SuperPAC family of cannulas are cleared under K221353 and K203067. All cleared indications for models in this family contain the following phrase:\n\n“intended for use…during extracorporeal life support procedures for periods of maximum 6 hours”\n\nOn pages 22 and 23 of “Flexible ECLS Solutions for the ICU and Patient Transport” you state that the devices are used during extracorporeal life support and VA extracorporeal life support. You do not indicate that the device is indicated to be used only up to 6 hours. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum Ventilation Module\n\nOn pages 10 and 11 of “Flexible ECLS Solutions for the ICU and Patient Transport” you list your Quantum Ventilation Module Lite, which, according to the product list provided to the FDA Inspector, was introduced into the U.S. market via a letter to file for your K202733 submission, which is for the Quantum Ventilation Module. In the premarket submission for K202733, the instructions for use provided for FDA review state that “the Quantum Ventilation Module has been designed to be used by experienced and trained clinicians as part of cardiopulmonary bypass therapy.” It further states that the equipment is “suitable for use in a hospital operating environment.” There is no discussion of use for patient transportation or use in the ICU. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum SuperPAC Tubing Set\n\nOn page 16 “Flexible ECLS Solutions for the ICU and Patient Transport” you present your Quantum SuperPAC tubing system, which is cleared under K213540 for\n\n“use during cardiopulmonary bypass for a duration of up to 6 hours.”\n\nCardiopulmonary bypass is not performed in the ICU or during patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nCharlotte Frame Configuration\n\nOur inspection revealed that there are several Quantum Perfusion Frames sold in the U. S. and several have been introduced via letter to file to the submission K173834. One of these is the Charlotte frame configuration. Because it was introduced via a letter to file, FDA has not reviewed this frame configuration. The cleared indications for K173834 are:\n\nThe Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\n\nHowever, the Charlotte frame is not listed in your “Quantum Perfusion Systems for CPB Hardware Manual” but it is listed in your “Quantum Perfusion Systems for ECLS Hardware Manual.” In addition, the Charlotte Perfusion System is presented on page 5 of “Flexible ECLS Solutions for the ICU and Patient Transport” and states it is “designed to maximize mobility within the ICU.” The Charlotte frame is being marketed with a different indication (i.e., ECLS other than CPB) than the frames cleared under K173834 (i.e., CPB). Specifically, frames that cannot safely and reliably support the configuration of devices needed for ECLS procedures other than CPB, raise serious public health concerns when used for those procedures, because failure of the frame to safely hold the devices during transportation or treatment of patients could result in serious patient harm or death. These devices are considered life sustaining and require a new premarket submission to assess safety and effectiveness.\n\nYour firm’s response dated May 5, 2023, did not address the violations discussed above and, therefore, is not adequate.\n\nAccordingly, as discussed above, several of the Quantum Perfusion devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures that include requirements for identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3).\n\nFor example: CAPA number 342, which was opened on January 30, 2023, and closed on March 14, 2023, does not contain an adequate evaluation of actions needed to correct nonconforming product in the field. The CAPA notes that the issue will “be picked up during the general Pre-Install process, through existing checks, the (b)(4) can be swapped out if\u002Fwhen required.” While this addresses the detectability and corrective actions once the failure occurs, there is no evidence of consideration given to the potential risks of the slipping\u002F failure to lock occurring during use and preventive actions that may be taken to prevent the issue from occurring. This does not identify the action(s) needed to correct the nonconforming product that is in the field, as required by 21 CFR 820.100(a)(3).\n\nWe reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate with respect to CAPA 342, because it notes that a plan will be determined to verify and validate the CAPA actions and that the results will be documented once they are identified and completed. Your response does not address the risk of this nonconformity to fielded devices nor does it identify any plans for corrections or corrective actions for fielded devices.\n\n2. Failure to adequately establish and maintain procedures that include requirements for verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\n\nFor example: CAPA number 315, which was opened on April 12, 2022, and closed on November 11, 2022, does not contain a verification or validation plan and results that demonstrate that the corrective and preventive actions put in place to prevent the heat transfer fluid bag from breaking and leaking during shipping were effective. The packaging for the fluid bag was modified but there was no verification or validation that this change was effective in preventing the bag from being damaged in shipping. There is also no verification or validation that the corrective and preventive actions do not adversely affect the finished device.\n\nWe reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate. In this response, you provided an open CAPA, Number 357, that states effectiveness of the verification\u002Fvalidation plan and results will be documented. Your firm stated that you intended to submit your plans to verify and validate the actions taken in the CAPA by May 31, 2023, and results recorded by August 31, 2023, to FDA. In addition, SOP-018_V16 “Corrective and Preventive Action Procedure” will be reviewed and updated and the “Corrective and Preventative Action Report” will be updated to include an effectiveness of Verification\u002F Validation plan and results within the form.\n\nThis response is not adequate because 1) the plans and results have not been provided to FDA as promised to verify that the actions identified in the CAPA have been verified and validated for effectiveness and that the actions do not adversely impact the final finished device and 2) there is no planned retrospective review to identify other CAPAs whose actions have been implemented without verification and validation.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QSR violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #666543 when replying. If you have any questions about the contents of this letter, please contact: Kathleen Grunder, Biomedical Engineer, at 301-796-2676 or Kathleen.Grunder@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, MD\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health for\n\nCC:\n\nColleen Powell, US Agent\n\nSpectrum Medical Inc\n\n481 Munn Road, Suite 180\n\nFort Mills, SC US 29715\n\nVia Email: Colleen.Powell@spectrummedical.com>","Spectrum Medical Ltd","spectrum-medical-ltd-666543-09292023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectrum-medical-ltd-666543-09292023","2026-10-26T08:10:02.82461+00:00","2024-04-30","666543","\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"","Steve Turner","2026-08-20T00:09:37.797+00:00","2023-09-29",15,{"510k":299,"classification":300,"enforcement":301,"event":302,"event_backfill":303,"pma":304,"warning_letter":305},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]